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Dr. Dilbert Doppler: She has lost her mind!
Jim Hawkins: Well, you can help her!
Dr. Dilbert Doppler: Quit it Jim! I´m an astronomer, not a 
doctor. I mean, I´m a doctor, but not that kind of a doctor. 
I have a doctorate, its not the same thing. You can’t help 
people with a doctorate, you just sit there and you’re useless.
[Dr. Dilbert Doppler holds his hands in front of his face and starts crying.]
Jim Hawkins: It’s ok doc, its allright.
Treasure Planet - Walt Disney Pictures
De Sint is al oud en heeft in zijn leven veel gestudeerd,
maar een aantal zaken krijgt hij maar niet aangeleerd.
Humaan exosoom, een complex van exoribonucleases,
en dat vormt met bepaalde eiwitten associaties.
In de nucleolus vertonen die eiwitten accumulatie,
maar dat is weer afhankelijk van de conformatie.
Daar bij komt dat een exosoom kan coprecipiteren,
terwijl bepaalde deletiemutanten dat niet presteren.
Uit dat alles kan dan worden geconcludeerd,
dat inderdaad het exosoom en eiwit zijn geassocieerd.
...
Sinterklaas, December 2001
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General introduction
Although DNA (deoxyribonucleic acid) and proteins are probably the most gen-
erally known biomolecules (one carrying the genetic code, the other because 
enzymes, which are usually proteins, are nowadays included in a lot of consumer 
products), a third biomolecule called RNA (ribonucleic acid) is at least equally 
important for life on earth. It is generally assumed that RNA was the fi rst bio-
molecule in the evolution of life and many types of RNA still play an important role 
in various cellular processes, particularly as an intermediate in the translation 
of the genetic code into functional proteins. For example, small nucleolar RNAs 
(snoRNAs) are involved in the generation of ribosomal RNA (rRNA), which are mol-
ecules that are part of the ribosome, the machinery that translates messenger 
RNAs (mRNAs), copies of the genetic code in the DNA, into proteins. In addition, 
transfer RNAs (tRNAs) bring the amino acids to the ribosome. The production of 
mRNA involves not only proteins and DNA, but also small nuclear RNAs (snRNAs) 
to obtain the mature messengers. All these processes are carefully regulated 
and cellular levels of these RNAs must therefore be tightly controlled. One of the 
most important protein complexes in human cells involved in maintaining correct 
RNA levels is called the exosome. This chapter summarizes our current knowledge 
on structure and composition of this complex and explains the role of the com-
plex in both the production and degradation of various types of RNA molecules.
Brief history of the human exosome
The human exosome, originally called 
the PM/Scl complex, was fi rst identifi ed as an 
autoantigen in 1977, when specifi c autoantibod-
ies in sera of patients suffering from polymyositis 
(PM) and overlap syndromes precipitated an anti-
gen (‘PM-1’) from calf thymus extract  (1). Later 
it became apparent that especially sera of patients 
with an overlap syndrome of (poly)myositis and 
scleroderma (Scl) contained reactivity with this 
antigen, which was therefore termed the ‘PM/Scl 
antigen’ (2,3). The PM/Scl antigen was shown to 
be a nucleolar complex (4), consisting of 11-16 
proteins ranging from 20-110 kDa (5,6). After the 
identifi cation and cloning of the main autoan-
tigenic proteins, PM/Scl-100 and PM/Scl-75 
(7-9), both these proteins were shown to be ho-
mologous to bacterial exoribonucleases (RNase 
D and RNase PH, respectively)(10).
In recent years, the PM/Scl complex was 
shown to be the human equivalent of the yeast 
exosome, a complex consisting of a large number 
of exoribonucleases, involved in the degradation 
and processing of many different RNA species 
(11).
Composition and structure of the 
exosome
Components of the exosome complex
Originally described in the yeast Saccharo-
myces cerevisiae, the exosome complex was shown 
to consist of nine core components of which six 
are homologous to bacterial RNase PH (Rrp41p, 
Rrp42p, Rrp43p, Rrp45p, Rrp46p and Mtr3p) 
and three contain a putative S1 RNA binding 
domain (RBD) (Rrp4p, Rrp40p and Csl4p)(11-
13). In addition, the RNase D homologue Rrp6p 
was found only in the nuclear exosome complex 
and Rrp44p/Dis3p (homologous to bacterial 
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RNase R) in both nuclear and cytoplasmic exo-
some complexes (13). For all these proteins, hu-
man homologues have been described and with 
the exception of hRrp44p/hDis3p, all of these 
proteins were shown to be present in the human 
exosome (11,14-17). Four yeast exosome proteins 
(Rrp4p, Rrp41p, Rrp44p/Dis3p and Rrp6p) and 
two human exosome proteins (OIP2, the human 
homologue of Rrp43p, and hRrp4p) have been 
shown to display 3’-5’ exoribonuclease activity in 
vitro (12,18,19). However, based on the homol-
ogy between the exosome proteins, the majority 
of the other subunits is predicted to have a similar 
enzymatic activity. An overview of the proteins 
known to be incorporated in the human and 
yeast exosome is given in Table 1. 
Recently, the core components of the 
yeast exosome were shown to assemble in a 
donut-shaped structure, with the six RNase PH 
homologous proteins forming a hexameric ring 
and the three S1 RNA binding proteins on top of 
this ring, a structure similar to that of the bacte-
rial protein polyribonucleotide phosphorylase 
(Figure 1) (20,21). The nature of the association 
of the Rrp6p and Rrp44p/Dis3p proteins with 
the core of the exosome complex has not been 
characterized yet.
The exosome in other organisms
Besides yeast and human, the exosome has 
been characterized in a number of other organ-
isms. In archaebacteria, a similar complex has 
been suggested to exist, consisting of only three 
different proteins, two homologous with RNase 
PH and one containing an S1 RBD (22). The 
Trypanosoma brucei exosome contains six RNase 
PH homologous proteins, three proteins with 
an S1 RNA binding domain and homologues 
of the yeast proteins Rrp6p and Lrp1p (23,24). 
The exosome of Drosophila melanogaster contains 
homologues of all yeast exosome proteins except 
for Rrp43p and Rrp45p (25). Also in Arabidopsis 
thaliana homologues of Rrp4p and Rrp41p have 
been characterized (22,26). The fact that not all 
organisms contain six RNase-PH like proteins 
and three S1 RBD proteins, which in the (yeast) 
exosome assemble into such a well conserved 
structure, suggests that in some organisms multi-
ple copies of specifi c proteins might be present in 
the fully assembled exosome. 
Figure 1. Model of the yeast exosome complex.
A three-dimensional model of the core of the yeast exosome generated based upon the structural homology between the 
exosome and PNPase (21). Panel A: side view; panel B: top view. Panel C shows a schematic model of the arrangement 
of the nine core proteins in the yeast exosome. The six RNase PH-like proteins, forming a hexameric ring, are shown in 
semi-white and light gray, the three proteins with an S1 RNA binding domain, associated with one side of the ring, are 
shown in dark gray.
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Table 1. Components of the exosome complex
human protein1 yeast equivalent1 conserved domains activity (hypothetical or 
experimental) 
comments
core proteins
hCsl4p Csl4p/Ski4p S1 RNA binding
hRrp4p Rrp4p S1 / KH 3’-5’ hydrolytic 
exoribonuclease 
hRrp40p Rrp40p S1 / KH 3’-5’ hydrolytic 
exoribonuclease
hRrp41p Rrp41p/Ski6p RNase PH 3’-5’ phosphorolytic 
exoribonuclease
hRrp42p Rrp42p RNase PH 3’-5’ phosphorolytic 
exoribonuclease
hRrp46p Rrp46p RNase PH 3’-5’ phosphorolytic 
exoribonuclease
hMtr3p Mtr3p RNase PH 3’-5’ phosphorolytic 
exoribonuclease
OIP2 Rrp43p RNase PH 3’-5’ phosphorolytic 
exoribonuclease
PM/Scl-75 Rrp45p RNase PH 3’-5’ phosphorolytic 
exoribonuclease 
binds to AU-rich RNA 
sequences
other common proteins
PM/Scl-100 Rrp6p RNase D 3’-5’ hydrolytic 
exoribonuclease
has been suggested to 
be only in the nuclear 
exosome 
(hDis3p) Rrp44p/Dis3p RNase R 3’-5’ hydrolytic 
exoribonuclease
human protein not 
observed in complex
associated proteins 
hSki2w Ski2p DEAD box RNA helicase Ski2p/Ski3p/Ski8p 
cytoplasmic complex
(KIAA0372) Ski3p TPR repeats unknown Ski2p/Ski3p/Ski8p 
cytoplasmic complex
(REC14) Ski8p WD40 repeats unknown Ski2p/Ski3p/Ski8p 
cytoplasmic complex
(eRFS) Ski7p GTPase unknown associated with the 
cytoplasmic exosome
MPP-6 - - unknown no yeast homologue 
known
ISG20 (Rex4p) ExoI/II/III 3’-5’ exonuclease
(KIAA0052) Mtr4p/Dob1p DEAD box RNA helicase associated with the 
nuclear exosome
(Ran) Gsp1p GTPase GTPase interacts with Dis3p
(CGI-37) Nip7p - unknown interacts with Dis3p
Rpp14 - - 3’-5’ phosphorolytic 
exoribonuclease
interacts with OIP2
1 If the name is between brackets, the association is based on homology only. 
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Specifi city of the exosome
Apart from the proteins homologous to 
known exoribonucleases, a number of other 
proteins have been found to be associated with 
the exosome that might play a role in the specifi -
city of the complex (Table 1). In yeast, the ATP-
dependent RNA helicase Mtr4p/Dob1p has 
been implicated in the specifi city of the nuclear 
exosome complex (27). The cytoplasmic yeast 
exosome associates with the putative GTPase 
Ski7p (28) and a complex of three proteins (Ski2p, 
Ski3p and Ski8p), one of which is also a putative 
RNA helicase (29). The human homologue of 
this RNA helicase, hSki2w, has also been found 
in the human exosome (17), but localizes to both 
the nucleolus and the cytoplasm (30). 
Functions of the exosome
The exosome has in recent years shown 
to be involved in a wide variety of processes. 
It is present in the cytoplasm, nucleoplasm and 
nucleolus of eukaryotic cells and functions in 
both biogenesis and degradation of many RNA 
species. Most of the functions of the exosome 
described below have been identifi ed in yeast, but 
the same multi-functionality is also believed to 
apply on the human exosome.
rRNA processing
The fi rst function attributed to the exosome 
in S. cerevisiae was its role in the maturation of the 
5.8S ribosomal RNA (12,31). Of the four RNA 
molecules present in fully assembled eukaryotic 
ribosomes (5S, 5.8S, 18S and 28S in human), three 
are transcribed by RNA polymerase I as a single 
precursor RNA which is subsequently processed 
to the mature ribosomal RNAs (Figure 2). Yeast 
strains lacking exosome core subunits or proteins 
associated with the nuclear exosome (Rrp6p, 
Dis3p, Gsp1p or Mtr4p) tend to accumulate 5.8S 
rRNA molecules that are extended at the 3’ end 
(the 12S RNA in human and the 7S RNA in 
yeast) (27,32-35). In the absence of these proteins, 
also other incomplete or incorrectly processed 
rRNA precursors, that normally are rapidly 
degraded by the exosome complex, tend to ac-
cumulate as well (23,27,34-36). 
Small RNA processing
The processing of the pre-rRNA is also me-
diated by a signifi cant number of small nucleolar 
RNAs (snoRNAs) and their associated proteins. 
These complexes function in endonucleolytic 
cleavage of the RNA at specifi c sites and the 
2’O-methylation and pseudouridinylation of 
specifi c residues. In the nucleoplasm, a number of 
small RNAs (snRNAs) is involved in the splicing 
of pre-mRNA. Usually, these small RNA mol-
ecules are transcribed by RNA polymerase II or 
III and most of them require post-transcriptional 
modifi cation (37). In many cases, like the U1, U4 
and U5 snRNAs and a wide variety of snoRNAs 
(including the U3 snoRNA), the nuclear exo-
some is involved in the maturation of the 3’ end 
of these RNA molecules (33,38,39), although 
also other exoribonucleases may participate in 
these processes (40). One of the human exosome 
subunits, OIP2, has been reported to interact with 
Rpp14, a protein associated with the RNase P 
and RNase MRP complexes, which are involved 
in the maturation of tRNA and rRNA, respec-
tively(19,41). Finally, the exosome and especially 
the Rrp44p/Dis3p subunit might play a role in 
the biogenesis of the small RNA component of 
the cytoplasmic signal recognition particle (SRP), 
which is assembled in the nucleolus of eukaryotic 
cells (42,43).
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Quality control of pre-mRNA
Upon transcription of a precursor mRNA 
molecule by RNA polymerase II, the pre-
mRNA has to be capped, spliced and generally 
poly-adenylated before it can be transported to 
the cytoplasm to be translated. Many of these 
maturation steps are subjected to quality control 
of the pre-mRNA and if a problem is encoun-
tered, the RNA will be degraded. An overview of 
the steps of this quality control process involving 
the exosome in yeast is shown in Figure 3. Imme-
diately following transcription, pre-mRNAs with 
an extended 3’ UTR (in cases where the RNA 
polymerase failed to stop at the correct position) 
are recognized by the nuclear exosome complex. 
The core of the exosome degrades the additional 
3’ sequence to approximately the correct end of 
the pre-mRNA. These RNAs can then be further 
processed to functional pre-mRNA molecules, or 
they are handed-over to the exosome subunit 
Rrp6p, which degrades the rest of the RNA (44). 
After the splicing and polyadenylation, a second 
checkpoint involving both Rrp6p and the core of 
the exosome is used to prevent hyperadenylated 
Figure 2. Pre-rRNA processing pathway in human.
A schematic representation of the processing of the human pre-ribosomal RNA into three mature rRNAs, 5.8S, 18S and 
28S. The pre-rRNA is transcribed as a single precursor, the 47S pre-rRNA. Endonucleolytic cleavages at the primary 
processing site (PPS) and secondary processing site (SPS) initiate the processing. Subsequently, cleavage at sites 1 and 2 
separates the 21S precursor, which matures into the 18S rRNA, from the 30S precursor. The latter is fi nally converted into 
the 28S rRNA and the 5.8S rRNA. Based on yeast experiments, the exosome complex is predicted to be involved in the 
fi nal maturation step of the 5.8S rRNA and in the degradation of the 5’ ETS sequence.
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mRNAs or mRNAs without any poly(A) tail 
from leaving the site of transcription, possibly 
by removing (part of) the 3’ UTR of the mR-
NAs (18,45,46). If the poly(A) tail is correct, a 
complex of Rrp6p, poly(A) polymerase and the 
hnRNP protein Npl3p hands the mRNA over 
to a number of proteins (Hpr1p, Sub2p, Yra1p), 
capable of binding the 3’ UTR of the mRNA, 
which are involved in the export of the mRNA 
to the cytoplasm (18,47). The mRNA is recruited 
to the cytoplasmic ribosomes to be translated for 
the fi rst time, although recent evidence suggests 
that also a nuclear translation machinery might 
be involved in this quality control step (48). If the 
mRNA contains premature stop codons (e.g. due 
to incorrect splicing), it is rapidly shifted into the 
normal turnover pathway for mRNA, prevent-
ing further translation (a process called nonsense 
mediated decay, NMD) (49). If, however, the 
mRNA somehow lacks a normal stop codon, a 
different pathway is used to degrade the mRNA, 
called non-stop decay (50,51). In this pathway, the 
cytoplasmic exosome and its associated proteins 
degrade both the poly(A) tail and the rest of the 
mRNA. Messenger RNAs that can be translated 
correctly the fi rst time are often translated mul-
tiple times, before also they are degraded by the 
normal mRNA turnover mechanism.
With regard to mRNA quality control in 
other organisms, a physical link between the exo-
some and the RNA polymerase II transcription 
machinery was recently shown in D. melanogaster
(25). In addition, the human exosome subunit 
PM/Scl-75 has been shown to interact directly 
with two transcription co-factors, E12 and E37 
(52). 
mRNA turnover
The normal pathway for mRNAs to be 
degraded starts with the removal of the poly(A) 
tail, followed by decapping and degradation in 
either a 5’-3’ or a 3’-5’ direction (53,54). These 
processes are mediated by the exosome and pos-
sibly regulated by the cytoplasmic Lsm complex 
(55). Whereas in yeast the main turnover pathway 
starts at the 5’ end of the mRNA and only a 
minority of the mRNAs are degraded by the 
exosome, in mammalian cells most of the mRNA 
is degraded by the 3’-5’ exoribonucleases of the 
exosome (56,57). Following deadenylation, the 
mRNA is rapidly degraded by the exosome 
complex, fi nally resulting in the hydrolysis of the 
5’ cap structure (56,58). The recruitment of the 
exosome to mRNAs that have to be degraded in 
yeast is most likely mediated by sequence specifi c 
RNA binding proteins, possibly via Ski7p and the 
Ski2p/Ski3p/Ski8p complex (53). In human cells, 
the degradation of inherently instable mRNAs 
that contain AU-rich elements (AREs) requires 
only the exosome (containing hSki2w) and one 
or more AU binding proteins (17). In addition, it 
has been shown that the exosome subunit PM/
Scl-75 is capable of binding directly to mRNAs 
containing AU rich sequences (57).
Anti-viral protection
A number of the subunits of the yeast exo-
some and its associated proteins were originally 
described as one of eight so-called SKI genes 
(SKI1-SKI8) in yeast. Loss of any SKI gene 
function gives rise to the super killer phenotype, 
which is characterized by an enhanced replication 
of dsRNA viruses in infected ski- strains com-
pared to infected wild-type strains (59). It is now 
known that all of these proteins, except Ski1p, are 
somehow associated with the exosome complex 
15
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(Ski5p proved to be identical to Ski3p (60)). A 
model has been proposed, in which the Ski2p/
Ski3p/Ski8p complex, together with Ski7p, 
recruits the viral RNA to the exosome complex 
(which contains Csl4p/Ski4p and Rrp41p/
Ski6p), where it is degraded (61). In ski- mutants 
this degradation process is less effi cient, leading 
to the super killer phenotype. Recently, an inter-
feron stimulated gene (ISG20, homologous to the 
yeast 3’-5’ exoribonuclease Rex4p), capable of 
protecting cells from infection with RNA viruses 
(62), has been found to associate with the human 
exosome (dr. N. Mechti, personal communica-
tion). Taken together, these data suggest that the 
exosome complex plays an important role in the 
anti-viral response in eukaryotic cells.
Regulation of exosome function
The variety of cellular functions in which 
the exosome is involved, raises the question how 
the complex is recruited and guided to perform 
a specifi c function. Most likely, many proteins are 
capable of interacting with the exosome, most of 
them directing a specifi c function or specifi city 
for the exosome. The proteins Rrp6p and Mtr4p, 
for example, are only associated with the nuclear 
and not with the cytoplasmic complex and have 
very specifi c functions in the processing and deg-
radation of rRNA and pre-mRNA, but not in 
cytoplasmic mRNA decay (13,63). The recruit-
ment of the nuclear exosome to the site of rRNA 
processing might involve the protein Nip7p, 
which is essential for correct ribosome assembly 
Figure 3. Quality control of eukaryotic (pre-)mRNA.
An overview of the steps in the quality control pathway of (pre-)mRNA in the nucleoplasm and the cytoplasm in which 
the exosome complex or its associated proteins are involved. The main processes involved are the degradation of mRNAs 
containing extended 3’ termini or aberrant poly(A) tails in the nucleus, and the removal of mRNAs containing none or 
aberrant stopcodons in the cytoplasm by either non-stop decay or nonsense mediated decay (NMD). See text for details. 
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and has been shown to interact with the exosome 
subunit Rrp43p (64).  As mentioned above, the 
Ski2p/Ski3p/Ski8p complex and Ski7p might 
play a similar role in recruiting the exosome to 
cytoplasmic mRNAs, since these proteins are 
required for correct mRNA degradation, but not 
for rRNA processing (28,53).
A special role might be reserved for the (pu-
tative RNA binding) core exosome component 
Csl4p, since mutants of this protein have been 
identifi ed that are either defective in mRNA or 
rRNA processing, but not in both (53). Although 
many yeast proteins have been found to be associ-
ated with the exosome, only limited information 
is available on such proteins in human cells. The 
human homologue of Ski2p has been found in 
association with the human exosome, as well as 
a protein (MPP-6) of unknown function and 
without an obvious homologue in yeast, which is 
phosphorylated during mitosis (17,65). Strikingly, 
the yeast exosome component Rrp44p/Dis3p, of 
which the human homologue has not yet been 
linked to the exosome, is implicated to function 
in mitotic control and is known to interact with 
Gsp1p/Ran, a GTPase involved in cell cycle con-
trol (66,67). Finally, as already mentioned above, 
recent evidence suggests that the exosome might 
also be regulated by interferons, since a known 
interferon  stimulated gene (ISG20, homologous 
to the yeast exoribonuclease Rex4p) has been 
shown to associate with the exosome complex 
(dr. N. Mechti, personal communication).
Autoantigenicity of the exosome
Antigenicity of the complex
Autoantibodies reactive with the human 
exosome are predominantly found in patients 
with the overlap syndrome of polymyositis 
and scleroderma (PM/Scl). The percentage of 
PM/Scl patients reported to contain antibodies 
capable of precipitating the PM/Scl antigen from 
calf thymus extract varies considerably, depend-
ing on the cohort of patients studied (12% (2), 
24% (68), 76% (69)). Of the patients suffering 
from either scleroderma or myositis alone, only 
2% and 5-9%, respectively, are reactive with the 
PM/Scl complex in immunodiffusion or im-
munoprecipitation experiments (2,68,70,71). The 
presence of anti-PM/Scl antibodies in the serum 
of patients correlates in 43-88% of the cases with 
the diagnosis of the polymyositis/scleroderma 
overlap syndrome (68,72,73).
Antigenicity of exosome subunits
After the identifi cation of the PM/Scl 
antigen as a multi-protein complex (5,6), two of 
the proteins in the complex, termed PM/Scl-100 
and PM/Scl-75, were shown to contain the main 
autoantigenic epitopes. Anti-PM/Scl-100 and 
anti-PM/Scl-75 antibodies are found in 98% 
and 63% of the sera reactive with the PM/Scl 
antigen, respectively (74). The cloning of the 
cDNAs encoding these proteins (7-9) and the 
use of recombinant proteins to detect these 
antibodies allowed and initiated further charac-
terization of the B-cell epitopes recognized. The 
main epitope on the PM/Scl-100 protein was 
shown to be contained in a stretch of 21 amino 
acids (226-246) and is recognized by 95% of all 
PM/Scl-100 reactive sera (75,76). Using ELISA 
based assays, anti-PM/Scl-100 antibodies were 
detected in approximately 6% of all patients with 
myositis, whereas anti-PM/Scl-75 reactivity was 
exclusively detected in sera also reactive with 
PM/Scl-100 (77). Most of the other human exo-
some subunits identifi ed in recent years (reviewed 
in (78)) were shown to be autoantigenic, although 
17
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only anti-hRrp4p and anti-hRrp42p antibodies 
were found in a signifi cant number of the anti-
PM/Scl-100 positive myositis patients (52% and 
23%, respectively) (79). Finally, anti-hRrp46p 
antibodies have been reported to occur in several 
patients with lung or prostate cancer and malig-
nant melanoma (80).
Outline of this thesis
Original goals
When the project started in 1999, the 
main goals of the project were to (1) identify 
components of the exosome, (2) to fi nd pro-
tein-protein interactions between exosome 
proteins, (3) to study how and where the exo-
some complex is assembled and (4) to study 
the function of individual exosome subunits. 
The fi rst goal was met in 2001, when all the 
proteins present in the human exosome where 
published in a collaborative effort of a number of 
laboratories, including ours (81). Knowing all the 
components of the complex, a mammalian 2-hy-
brid system was used to identify protein-protein 
interactions between these protein, the second 
goal of the project. In Chapter 2 the interaction 
of one of the exosome subunits, hCsl4p, with two 
other subunits is described, as well as the role of 
different domains of the hCsl4p protein in these 
interactions. The elucidation of a large number of 
other interactions between subunits in Chapter 
3 allowed the construction of a structural model 
for the exosome, which is also based on the ho-
mology between the exosome and a bacterial 
protein called polyribonucleotide phosphorylase 
(PNPase). In addition, the human homologue of 
this PNPase is described. In Chapter 5 a partially 
new sequence for one of the exosome subunits, 
PM/Scl-75, is described and compared with the 
originally published sequence. In contrast to the 
original form, this longer form of PM/Scl-75 
associates readily with the exosome complex. The 
third and the fourth of the original goals are not 
extensively addressed in this thesis, although both 
of them are discussed in the fi nal Chapter 8.
Additional goals
During the course of any scientifi c project, 
one can encounter fi ndings leading to new 
questions and consequently to new research 
goals. In our case, two new perspectives could 
be added to the project, (1) the characteriza-
tion of human PNPase, a protein related to the 
exosome and (2) the role of the longer form 
of the exosome subunit PM/Scl-75 in the 
autoantigenicity of the human exosome.
The fi rst of these goals started with the unex-
pected discovery of a human equivalent of the 
bacterial protein PNPase. This latter protein has 
a structure closely related to that of the exosome 
complex (Chapter 3). The functional and evo-
lutionary relationship between PNPase and the 
exosome is addressed in Chapter 4. The second 
additional goal was to determine the role of PM/
Scl-75 in the autoantigenicity of the complex. In 
Chapter 6 the protein is shown to be cleaved dur-
ing apoptosis, a process believed to play a role in 
the generation of autoimmunity. Finally, in Chap-
ter 7 the new PM/Scl-75 polypeptide, which was 
identifi ed in Chapter 5, is shown to be a much 
more important autoantigen in patients with the 
PM/Scl overlap syndrome, than the originally de-
fi ned polypeptide. All results obtained with regard 
to these new goals are discussed in relation to the 
structure and function of the exosome complex 
in Chapter 8. 
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Introduction
The exosome was originally described 
as a complex of exoribonucleases in the yeast 
S. cerevisiae involved in the maturation of the 3′
end of 5.8S ribosomal RNA (rRNA) (12,31,34) 
(32). Additional functions for the exosome were 
found in the processing of small nuclear RNAs 
(snRNAs), small nucleolar RNAs (snoRNAs) 
(33,38) and the SRP RNA (scR1) (42), the 
degradation of aberrant rRNA and its precursors 
(36) and the 3′→ 5′ turnover of (pre-) messenger 
RNA (mRNA) in the cytoplasm (82) and the 
nucleus (83). The yeast exosome contains at 
least 11 proteins, which all have been shown or 
predicted to be 3′→ 5′ exoribonucleases (11,12). 
In addition, several proteins have been identifi ed 
that are believed to interact transiently with the 
exosome. A complex of Ski2p, Ski3p and Ski8p 
probably regulates the cytoplasmic pool of the 
exosome (29), whereas the nuclear exosome is 
controlled by Dob1p/Mtr4p (27). Some of the 
exoribonucleases associated with the exosome 
seem to have specifi city for certain substrates 
and/or to be localized in different subcellular 
compartments. In yeast, the Rrp6p protein is ex-
clusively present in the nuclear exosome complex 
(11) and certain mutations in the CSL4 gene can 
affect the turnover of mRNA in the cytoplasm, 
but not the nuclear processing of rRNA and 
snRNA (53).
By sequence homology, 11 human proteins 
have been identifi ed as (putative) components 
of a similar complex in human cells (11,14,17). 
Among these homologues are the human 
proteins PM/Scl-100 and PM/Scl-75, which 
are well-known autoantigens in patients with 
the polymyositis/scleroderma overlap syndrome 
(7-9,32). It has been shown that antibodies 
reactive with the PM/Scl autoantigens are able 
to precipitate a complex of 11-16 proteins, rang-
ing from 20-110 kDa, designated the PM/Scl 
complex (5,6). Recent evidence confi rmed that 
the PM/Scl complex is in fact the human exo-
some (11,78). The cDNAs encoding 10 protein 
components have been cloned and fi ve of them 
(hRrp4p, hRrp40p, hRrp41p, hRrp46p and PM/
Scl-100) have been shown to be components of 
the human exosome (14). Functional conserva-
tion from yeast to human has been shown for four 
exosome proteins (hRrp4p, hRrp41p, hRrp44p/
hDis3p and hCsl4p) (12,14,16,84).
No data are available yet on the architecture 
and structure of the exosome, neither in yeast 
The exosome is a complex of 3′ → 5′ exoribonucleases, which functions in a va-
riety of cellular processes, all requiring the processing or degradation of RNA. 
We demonstrate that the two human proteins hCsl4p and hRrp42p, which have 
been identifi ed based on their sequence homology with Saccharomyces cerevisiae
proteins, are associated with the human exosome. By mammalian two-hybrid and 
GST pull-down assays we show that the hCsl4p protein interacts directly with 
two other exosome proteins, hRrp42p and hRrp46p. Mutants of hCsl4p that 
fail to interact with either hRrp42p or hRrp46p are also not able to associate 
with exosome complexes in vivo. These results indicate that the association 
of hCsl4p with the exosome is mediated by protein-protein interactions with 
hRrp42p and hRrp46p.
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nor in higher eukaryotes. Here we demonstrate 
that hCsl4p directly interacts with both hRrp42p 
(which is identical to KIAA0116 (11)) and 
hRrp46p and that abrogation of either of these 
interactions prevents incorporation of hCsl4p 
in the exosome and also its accumulation in the 
nucleolus. 
Results
hCsl4p interacts with hRrp42p and hRrp46p
To analyze protein-protein interactions 
in the human exosome, the full-length cDNAs 
encoding 10 (putative) human exosome com-
ponents (hRrp4p, hRrp40p, hRrp41p, hRrp42p, 
hRrp46p, PM/Scl-75, PM/Scl-100, hCsl4p, 
hRrp44p/hDis3p and OIP2) were cloned into 
both the pACT and pBIND vectors of the 
Checkmate Mammalian Two-Hybrid system by 
fusing their open reading frames to the VP16 
transcription activation domain and the GAL4 
DNA binding domain, respectively. COS-1 cells 
were co-transfected with pairs of these cDNA 
constructs, followed by determination of the 
potentially induced luciferase activity 40-48 
hours after transfection. These analyses revealed 
that hCsl4p interacted with two other human 
exosome proteins, hRrp42p and hRrp46p. Im-
portantly, these interactions were observed both 
when hCsl4p was fused to the GAL4 DNA bind-
ing domain and hRrp42p and hRrp46p to the 
VP16 activation domain and vice versa (Fig. 1). 
The expression levels of the fusion proteins were 
monitored by western blot analysis using antibod-
ies specifi c for the VP16 or GAL4 domains, which 
showed that all proteins were expressed at compa-
rable levels (data not shown). To check the validity 
of these interactions, GST pull-down assays were 
performed using recombinant GST-hCsl4p fu-
sion protein and in vitro translated hRrp42p and 
hRrp46p. As is shown in Fig. 2B, precipitation 
of GST-hCsl4p by glutathione-Sepharose beads 
resulted in effi cient co-precipitation of hRrp46p 
and, albeit less effectively, hRrp42p, whereas in 
control experiments neither of these proteins 
was detectably precipitated by beads containing 
GST alone. In addition, other in vitro translated 
human exosome components were tested in this 
assay, but none of these proteins were specifi cally 
co-precipitated by GST-hCsl4p.
Figure 1. Two-hybrid interactions 
between hCsl4p, hRrp42p and 
hRrp46p. 
COS-1 cells were cotransfected with 
constructs encoding fusion proteins 
of hCsl4p, hRrp42p and hRrp46p 
and either the VP16 transcription 
activation domain (pACT constructs) 
or the GAL4 DNA binding domain 
(pBIND constructs), simultaneously 
with a reporter plasmid. The resulting 
luciferase activity is depicted in relative 
luminescence units (RLU). The 
activity observed for the combination 
of hRrp42p in pBIND and hCsl4p in 
pACT was defi ned as 100 RLU.
23
2
hCsl4p and the human exosome
hCsl4p, hRrp42p and hRrp46p are associated 
with the human exosome
The yeast proteins Csl4p, Rrp42p and 
Rrp46p all have been shown to be part of the sta-
ble ‘core’ complex of the yeast exosome (11,13), 
whereas exosome association of the correspond-
ing human proteins has only been demonstrated 
for hRrp46p (14).
To investigate whether hCsl4p and hRrp42p 
are also part of the human exosome, which would 
be consistent with the observed protein-protein 
interactions described above, we generated 
transfection constructs encoding fusion proteins 
of each of these proteins with the enhanced green 
fl uorescent protein (EGFP).
After expression of these fusion proteins in 
transiently transfected HEp-2 cells, lysates were 
prepared and used for immunoprecipitation 
experiments with a rabbit anti-EGFP antiserum. 
The immunoprecipitated material was analyzed 
by western blotting using a serum (Ven96) from 
an autoimmune patient strongly reactive with 
Figure 2. GST pull-down analysis of interactions of hCsl4p with hRrp42p and hRrp46p.
A. A fusion protein of hCsl4p and GST was expressed and purifi ed by glutathione affi nity chromatography. Approx. 1 µg 
purifi ed fusion protein (GST-hCsl4p, lane 2) and GST alone as a control (lane 1) were analyzed by SDS-PAGE followed by 
Coomassie Brilliant Blue staining. On the left the positions of molecular weight markers are indicated.
B. The GST-hCsl4p and GST proteins were incubated with 35S-labeled, in vitro translated hRrp42p (lane 1) or hRrp46p 
(lane 4). After precipitation with glutathione-Sepharose beads co-precipitated proteins were analyzed by SDS-PAGE and 
autoradiography. Lanes 3 and 6 show hRrp46p and hRrp42p, respectively, co-precipitated with GST-hCsl4p. Lanes 2 and 5 
show the corresponding controls for GST alone. The faster migrating bands observed in the in vitro translates are most likely 
caused by alternative translation initiation. In lanes 1 and 4 5% of the amount of labeled protein used for co-precipitation 
was loaded.
Figure 3. Association of hRr42p, hRrp46p and 
hCsl4p with the human exosome.
Co-immunoprecipitations were performed using anti-
EGFP antibodies and extracts of transfected HEp-2 cells 
expressing either EGFP alone (lane 2) or hCsl4p, hRrp42p 
and hRrp46p fused to the C-terminus of EGFP (lanes 3-
5). In lane 1 a nuclear extract from non-transfected HEp-2 
cells was loaded. The immunoprecipitates were analyzed 
by western blotting using a PM/Scl positive patient serum 
(Ven96). Arrows indicate the positions of PM/Scl-100 and 
other co-precipitated autoantigenic exosomal proteins. 
The positions of molecular weight markers are indicated 
on the left.
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the PM/Scl-100 protein and to different extends 
with other exosome components (including PM/
Scl-75, hRrp4p, hRrp40p, hRrp41p, hRrp42p, 
hRrp46p, and hCsl4p). The results show that the 
PM/Scl-100 protein was co-precipitated with 
all three fusion proteins, but not with EGFP 
alone, indicating that in addition to hRrp46p 
also hCsl4p and hRrp42p are associated with 
the human exosome (Fig. 3). The serum reacted 
also strongly with 3 other specifi cally precipitated 
autoantigenic proteins. Since these proteins co-
precipitate and are recognized by this serum, they 
are most likely other exosome components. Based 
on their molecular weight (approximately 28, 32 
and 75 kDa) and the specifi city of the serum used 
these proteins presumably represent hRrp41p, 
hRrp4p and PM/Scl-75, respectively.
The analysis of the transiently transfected 
HEp-2 cells expressing these EGFP-fusion pro-
teins by fl uorescence microscopy revealed a nu-
cleolar localization for all three proteins (Fig. 4), 
consistent with similar analyses of other exosome 
components including the endogenous hRrp46p 
protein (14).
hRrp46p interacts with the N- and C-terminal 
regions of hCsl4p
Very little is known about the structural 
elements of the different exosome proteins. The 
hCsl4p (195 aa, 21 kDa) protein contains a region 
that is homologous to the E. coli S1 RNA bind-
ing domain (amino acids 68-147) indicating that 
this protein may contain RNA-binding activity. 
The presence of domains that could be involved 
in protein-protein interactions is not evident in 
the primary structure. To identify the regions of 
hCsl4p that mediate the binding to hRrp42p 
and hRrp46p, a set of deletion mutants was 
constructed as shown in Fig 5A. These mutants 
were created using the restriction sites BalI 
(hCsl4p ∆C130), PvuII (hCsl4p ∆C168), EcoRI 
(hCsl4p ∆C182), SmaI (hCsl4p ∆N22) and HinfI 
(hCsl4p ∆61-159) and were subsequently cloned 
into the pBind vector of the mammalian two-
hybrid system, fusing them to the C-terminus 
of the GAL4 binding domain. The capacity of all 
hCsl4p mutants to interact with either hRrp42p 
or hRrp46p was determined by monitoring the 
expression of the two-hybrid reporter protein 
Figure 4. Nucleolar accumulation of hCsl4p, hRrp42p and hRrp46p.
HEp-2 cells were transfected with constructs encoding hCsl4p (panel A), hRrp42p (panel B) or hRrp46p (panel C) fused 
to the C-terminus of EGFP. After overnight culturing cells were fi xed and the expressed fusion proteins were visualized by 
fl uorescence microscopy. The corresponding phase-contrast images are shown in panels D-F. Each bar represents 10 µm.
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luciferase. As is shown in Fig. 5B, deletion of 
either the N-terminal 22 or the C-terminal 
14 amino acids of hCsl4p strongly reduced or 
abolished its binding to both exosome proteins. 
In contrast, a large deletion of the central part 
of the protein, comprising the putative S1 RNA 
binding domain, did not inhibit the interaction 
of hCsl4p with hRrp46p (in fact, this deletion 
seemed to increase the affi nity for hRrp46), 
whereas the binding to hRrp42p was markedly 
reduced. Equivalent results were obtained in the 
reverse experiment, in which the hCsl4p mutants 
were cloned in the pAct vector and hRrp42p and 
hRrp46p in the pBind vector (data not shown).
Deletion mutants of hCsl4p do not associate 
with the exosome
To investigate whether the amino acids de-
leted in the mutants of hCsl4p not only affected 
its interaction with hRrp42p and hRrp46p, but 
also its association with (functional) exosome 
complexes, the wild-type and mutant hCsl4p 
encoding sequences were cloned in transfec-
tion vectors in frame with the EGFP protein 
encoding sequence. After transient transfection of 
HEp-2 cells with these constructs, the expression 
of the EGFP-(mutant)hCsl4p fusion proteins was 
analyzed by fl uorescence microscopy and western 
blotting. In contrast to the wild-type EGFP-
hCsl4p, which accumulated in the nucleolus, all 
mutants showed cytoplasmic and nucleoplasmic 
staining with no or only weak staining of the nu-
cleoli (Fig. 6 and results not shown). Western blot-
ting analysis using anti-EGFP antibodies revealed 
that the wild-type and mutant hCsl4p proteins 
(fused to EGFP) were expressed to similar levels 
in these transfected cells (Fig. 7A). To analyze their 
association with exosome complexes, co-im-
Figure 5. Interactions of hCsl4p 
mutants with hRrp42p and 
hRrp46p.
A. Schematic overview of the 
deletion mutants of hCsl4p. The 
position of the putative S1 RNA 
binding domain is indicated above 
the wild-type hCsl4p.
B. Two-hybrid interactions between 
hCsl4p mutants fused to the GAL4 
DNA binding domain (pBIND 
constructs) and hRr46p and hRrp42p 
fused to the VP16 transcription 
activation domain (pACT constructs). 
The ‘empty’ pACT vector was 
included as a negative control. The 
luciferase activity resulting from the 
co-transfected reporter plasmid is 
depicted in relative luminescence 
units (RLU). The activity observed 
for the interaction between GAL4-
hRrp42p and VP16-hCsl4p (not 
shown) was defi ned as 100 RLU.
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munoprecipitation experiments were performed 
using extracts from these cells and an anti-EGFP 
antiserum. Co-immunoprecipitation of exosome 
components was monitored by western blotting 
with a serum (Ven96) from an autoimmune 
patient, known to be reactive with several human 
exosome components (see above). These experi-
ments (Fig. 7B) revealed that all hCsl4p mutants 
analyzed did not detectably associate with other 
autoantigenic exosome proteins, including PM/
Figure 6. Subcellular localization of hCsl4p mutants. 
HEp-2 cells were transfected with constructs encoding hCsl4p wt (panel A), hCsl4p ∆C168 (panel B), hCsl4p ∆N22 (panel 
C) or hCsl4p ∆61-159 (panel D) fused to the C-terminus of EGFP and the expression was visualized by fl uorescence 
microscopy. The corresponding phase-contrast images are shown in panels E-H.
Figure 7. Mutants of hCsl4p do not co-precipitate autoantigenic exosome components.
A. Total extracts of HEp-2 cells transfected with constructs encoding hCsl4p mutants fused to EGFP were analyzed by 
western blotting using an anti-EGFP antiserum. 
B. Immunoprecipitates of EGFP-tagged hCsl4p mutants from transfected cell extracts were analyzed by western blotting 
using a patient serum reactive with multiple exosome components. Lane 1 contains nuclear extract from non-transfected 
cells. Arrows indicate proteins that are co-precipitated with the wild-type hCsl4p fusion protein (lane 3) but not by any of 
the mutants (lanes 4-7) nor by EGFP alone (lane 2). On the left the positions of molecular weight markers are indicated.
27
2
hCsl4p and the human exosome
Scl-100. The weak bands visible in the lanes 4-7 
of Fig. 7B correspond to the expressed mutants of 
hCsl4p, that are recognized by the patient serum.
Previously it has been shown that rabbit 
antibodies raised against hRrp40p and hRrp46p 
were able to immunopurify exoribonuclease 
activity, most likely associated with exosome 
complexes (14). To investigate whether the 
EGFP-hCsl4p fusion protein also contained 
or associated with exoribonuclease activity an 
extract of transfected HEp-2 cells was subjected 
to immunoprecipitation by anti-EGFP antibodies 
and the immunoprecipitated material was assayed 
for exonuclease activity in vitro. The results in 
Fig. 8 demonstrate that the fusion protein either 
acts as an exonuclease or associates with other 
proteins displaying this activity (lanes 1-7). It 
should be noted that material precipitated from 
cells expressing EGFP alone did not display this 
activity, suggesting that this is due to the hCsl4p 
moiety of the fusion protein. When the same 
analysis was performed with material from cells 
expressing the mutant hCsl4p fusion proteins no 
or hardly any exonuclease activity was observed, 
indicating that either the association of hCsl4p 
with the exosome is a prerequisite for the co-
precipitation of exonuclease activity or that the 
exonuclease activity of hCsl4p is abolished by all 
mutations analyzed. 
Discussion
In this paper we have identifi ed direct 
interactions between three components of the 
human exosome, hCsl4p, hRrp42p and hRrp46p, 
by means of mammalian two-hybrid and GST 
pull-down assays. hCsl4p appeared to interact 
with both hRrp42p and hRrp46p, whereas no 
interactions between hRrp42p and hRrp46p 
could be detected. Deletions of different parts 
of hCsl4p were found to affect not only its as-
sociation with hRrp42p and hRrp46p, but also 
Figure 8. hCsl4p mutants are not 
associated with ribonuclease ac-
tivity in HEp-2 cell extracts.
Extracts were prepared from transfected 
HEp-2 cells expressing EGFP or the 
EGFP-(mutant)hCsl4p fusion proteins. 
Material (co-)precipitated with anti-
EGFP antibodies from these extracts 
was analyzed for ribonuclease activity 
by incubating the precipitates at 37 °C 
with a uniformly 32P-labeled substrate 
RNA. Samples were taken after 1 
hour and 4 hours of incubation and 
analyzed by denaturing polyacrylamide 
gel electrophoresis followed by 
autoradiography. The untreated RNA 
substrate (input) was loaded in lane 
1 and as a positive control an anti-
hRrp40p immunoprecipitate from 
a HeLa S100 extract was included 
(lanes 2 and 3). Arrows mark the 
positions of the substrate RNA and 
its major degradation product obtained 
after incubation with material co-
precipitating with wild-type hCsl4p.
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its association with exosome complexes and 
exonuclease activity.
The association of hCsl4p, hRrp42p and hRrp46p 
with the human exosome
Consistent with previous observations 
for human exosome components (hRrp40p, 
hRrp41p, hRrp46p, PM/Scl-75 and PM/Scl-
100) (4,7-9,14), hCsl4p, hRrp42p and hRrp46p 
show a mainly nucleolar localization in fl uo-
rescence microscopy. For hRrp46p it has been 
shown before that, despite the apparent nucleolar 
accumulation, the protein is also present in the 
cytoplasm and nucleoplasm of human cells (14). 
Since we provide evidence for direct protein-pro-
tein interactions between hRrp46p and hCsl4p 
on the one hand and hCsl4p and hRrp42p on the 
other, the localization of the latter two proteins 
may also not be restricted to the nucleolus. More-
over, the S. cerevisiae homologues of these three 
proteins are all part of the exosome complex and 
are located in both the cytoplasm and the nucleus 
of yeast cells (11). Also in Trypanosoma brucei both 
cytosolic and nuclear forms of the exosome have 
been reported recently, although only for hCsl4p 
(and not for hRrp42p and hRrp46p) a T. brucei
homologue has been identifi ed (23). The inability 
to detect hCsl4p in the cytoplasm and nucleo-
plasm by fl uorescence microscopy is most likely 
due to the local concentration of hCsl4p, which 
is signifi cantly higher in the nucleolus compared 
to other cellular compartments.
Using yeast two-hybrid systems several ex-
tensive protein-protein interaction screenings, in 
which all S. cerevisiae proteins were assayed, have 
been performed (67,85). In these studies a number 
of interactions between S. cerevisiae exosome pro-
teins have been identifi ed, which however do not 
include interactions of Csl4p with other proteins. 
Also no protein partners were found for Rrp46p, 
whereas in both studies Rrp42p was found to 
interact with Mtr3p, another protein subunit of 
the yeast exosome. It should, however, be noted 
that the functional conservation of the exosome is 
not necessarily associated with a conservation of 
the composition of this complex. This is substan-
tiated by recent data obtained for the exosome 
complexes from Caenorhabditis elegans, T. brucei
and archaea(23,63,86). For the Arabidopsis thaliana
exosome subunit AtRrp41p interactions with the 
yeast exosome components Rrp4p and Rrp44p 
have recently been reported (22).
Several regions of hCsl4p are required for its 
association with the exosome and exonuclease 
activity
The human hCsl4p protein is a relatively 
small protein of only 21 kDa, which contains a 
putative RNA binding domain (11,84) and at 
least two binding sites for other exosome pro-
teins, hRrp42p and hRrp46p. The formation of a 
functional binding site for hRrp46p requires both 
the N-terminal and the C-terminal region of the 
hCsl4p protein and this interaction is apparently 
not disrupted  by the fusion of a reporter protein 
(EGFP) to its N-terminus. The binding site for 
hRrp42p seems to be more critically dependent 
on the overall conformation of hCsl4p, because 
the binding is disrupted by non-overlapping N-
terminal, C-terminal as well as internal deletions. 
These data also indicate that the binding sites for 
hRrp42p and hRrp46p on hCsl4p are at least 
partially distinct and that both interactions may 
occur simultaneously during the assembly of the 
exosome. Therefore it is tempting to speculate 
that the interactions with both hRrp42p and 
hRrp46p are required for hCsl4p to be incor-
porated into exosome complexes. The presence 
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of only the binding site for hRrp46p (hCsl4p 
∆61-159) did not appear to be suffi cient for the 
association with other exosome proteins. 
Wild-type hCsl4p effi ciently co-precipitat-
ed exoribonuclease activity. This activity appeared 
to be mainly processive, since the degradation 
products contain very few RNA fragments of 
intermediate size indicative of a distributive 
mode of action. In contrast, exosome proteins 
hRrp40p and hRrp46p have been shown to 
co-precipitate a mixture of distributive and 
processive exoribonuclease activities from HeLa 
extracts (14). A processive exonuclease remains 
on the RNA substrate until it is degraded to its 
minimal length, whereas distributive exonuclease 
activity involves the repetitive binding and dis-
sociation of the protein, removing one nucleotide 
at a time, leading to a simultaneous degradation of 
the entire substrate pool. The results in Figure 8 
illustrate the different patterns of degradation in-
termediates obtained by the hRrp40p and hCsl4p 
associated activities. These differences might 
indicate that either hCsl4p itself has (processive) 
exonuclease activity, or that at least two differ-
ent exosome complexes exist, one enriched in 
hRrp40p and another enriched in hCsl4p, that 
display (partially) different activities. Most likely, 
the observed exoribonuclease activity associated 
with hCsl4p can not be ascribed to the hCsl4p 
protein itself, but instead is a function of one of 
the associated exosome proteins. This assumption 
is based on the fact that hCsl4p (as well as its yeast 
counterpart) does not share any homology with 
known exoribonucleases and that the S. cerevisiae
Csl4p protein is the only exosome component 
for which no exonuclease activity has been 
demonstrated (13). Moreover, the recombinant 
GST-hCsl4p protein used in this study was unable 
to degrade the RNA substrate even when high 
amounts of protein were used (data not shown). 
Nevertheless, we can not rule out the possibility 
that lack of enzymatic activity of the recombinant 
bacterially expressed protein is due to the absence 
of essential post-translational modifi cations. It is 
tempting to speculate that the S1 RNA binding 
domain of hCsl4p is involved in the recruitment 
of substrate RNAs to the exosome, whereas 
the remaining parts of this protein are required 
for the binding of other exosome components, 
i.e. hRrp42p and hRrp46p, which do contain 
exoribonuclease activity and play a role in the 
degradation of substrate RNA. A similar function 
has been suggested for yeast Csl4p, for which it 
has been shown that a point mutation in its RNA 
binding domain does not affect rRNA processing 
by the exosome, in contrast to mRNA degrada-
tion. This may indicate that (h)Csl4p is somehow 
mediating substrate specifi city of (part of) the 
exosome. Importantly, a mutation in the promo-
tor region of  yeast Csl4p does lead to defects in 
rRNA processing, indicating that the protein is 
required for correct assembly and/or subcellular 
transport of the exosome (53,84). This might be 
in accordance with our observation that mutants 
of hCsl4p lacking the binding sites for hRrp42p 
and hRrp46p are no longer associated with the 
human exosome. 
These results provide the fi rst information 
on direct interactions between components of the 
human exosome. When more of such interactions 
are identifi ed, this will lead to more insight into 
the way the exosome is assembled, which is im-
portant for our understanding of the mechanism 
by which the exosome operates in the RNA 
degrading machinery.
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Materials and Methods
cDNA cloning and construction of deletion mutants
All cDNAs used were cloned into the pAct and 
pBind vectors (Promega) by PCR or the use of available 
restriction sites. The database accession numbers for the 
cDNAs of hCsl4p, hRrp42p and hRrp46p are AF151866, 
D29958 and AF281134, respectively. Deletion mutants of 
hCsl4p were constructed by using suitable internal restric-
tion sites. 
Western blot analysis
For western blot analysis, autoimmune patient and 
rabbit antisera were diluted 5000- and 500-fold, respec-
tively, in blocking buffer (4% skimmed milk, phosphate-
buffered saline (PBS), 0.1% NP-40). As secondary antibody, 
horseradish peroxidase-conjugated rabbit-anti human IgG 
or swine anti-rabbit IgG (Dako Immunoglobulins) were 
used after 5000-fold dilution in blocking buffer. Visualiza-
tion was performed by chemiluminescence.
Transient transfection of HEp-2 cells and direct 
immunofl uoresence
For transfection, hCsl4p, hRrp42p and hRrp46p 
cDNAs were cloned into suitable pEGFP vectors 
(Clontech), allowing expression of the proteins fused to 
the C-terminus of the EGFP protein. HEp-2 cells were 
grown to 80% confl uent monolayers by standard tissue 
culture techniques in Dulbecco’s modifi ed Eagle’s medium 
(DMEM, Life Technologies Inc.) containing 10% fetal calf 
serum (FCS). For immunoprecipitation, approximately 10 
x 106 cells  were transfected with 20-30 µg of DNA in 
1600 µl of DMEM containing 10% FCS by electropora-
tion, which was performed at 270V and 950 µF using a 
Gene-Pulser II (Bio-Rad). After transfection, cells were 
seeded in 75-cm2 culture fl asks and cultured overnight. 
After washing twice with PBS, the cells were resuspended 
in 500 µl of lysis buffer (25 mM Tris-HCl pH 7.5, 100 mM 
KCl, 2 mM EDTA, 1 mM DTE, 0.5 mM PMSF and 
0.05% NP-40) and homogenized by sonifi cation. For 
fl uorescence microscopy, approximately 2 x 106 cells  were 
transfected with 10-20 µg of DNA in 800 µl of DMEM 
containing 10% FCS by electroporation, as described 
above. After transfection, cells were seeded onto coverslips 
and cultured overnight. Cells were washed twice with PBS, 
fi xed with 4% paraformaldehyde in PBS for 20 minutes, 
washed in PBS twice and fi nally cells were mounted with 
PBS/glycerol, and expressed proteins were visualized by 
fl uorescence microscopy.
Immunoprecipitation
Polyclonal antibodies from rabbits and patients 
were coupled to protein A-agarose beads (Biozym) in 
IPP500 (500 mM NaCl, 10 mM Tris-HCl, pH 8.0, 0.05% 
NP-40) by incubation for 2 h at room temperature. Beads 
were washed twice with IPP500 and once with IPP150 
(150 mM NaCl, 10 mM Tris-HCl, pH 8.0, 0.05% NP-40). 
For each immunoprecipitation, cell extract was incubated 
with the antibody-coupled beads for 1 h at 4°C. Subse-
quently, beads were washed three times with IPP150.
Mammalian two-hybrid analysis
All interactions were analyzed using the CheckMate 
Mammalian Two-Hybrid System (Promega) essentially 
according to the manufacturer’s protocol. Briefl y, 3-4 x 
105 COS-1 cells seeded in one well of a 6-wells plate were 
transfected with 3 vectors (1 µg each), pACT and pBIND, 
either with or without insert, and the pG5luc reporter vec-
tor using 5 µl Fugene Transfection Reagent (Roche), as de-
scribed by the manufacturer. After 40-48 hours of growth, 
cells were harvested using 500 µl Passive Lysis Buffer (PLB; 
Promega) and the activity of both the fi refl y luciferase and 
the control renilla luciferase were determined using the 
Dual Luciferase Reporter Assay System (Promega) on a 
Berthold Lumat LB 9507 Luminometer. In brief, 100 µl 
of fi refl y luciferase substrate solution was added to 20 µl 
of cell extract and the luminescence was measured to 
determine the effi ciency of the interaction. Next, 100 µl of 
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renilla luciferase substrate solution (containing a quencher 
for the fi refl y luciferase activity) was added and again the 
luminescence was determined to monitor the transfection 
effi ciency.
Expression of recombinant proteins
The GST (fusion) proteins were expressed in bacteria 
and purifi ed as described previously (87). After induction 
with IPTG the bacteria expressing the GST-hCsl4p fusion 
protein were grown at room temperature to enhance the 
production of soluble protein, whereas the cells producing 
GST were grown at 37°C.
In vitro translation
Radioactively labeled proteins were produced using 
the TnT Coupled Reticulocyte Lysate System (Promega) 
according to the manufacturer’s protocol, in a total volume 
of 25 µl, containing approximately 1 µg of circular plasmid 
(pCDNA3, Invitrogen) containing the coding sequence of 
hRrp42p or hRrp46p or another protein and in the pres-
ence of  [35S]methionine.
GST pull-down assay
Recombinant GST or GST-hCsl4p fusion protein 
(approx. 1 µg) immobilized on glutathione-Sepharose 
beads (Amersham Pharmacia Biotech) was incubated with 
[35S]methionine-labeled in vitro translation product in 
200 µl of binding buffer (20 mM HEPES-KOH pH 7.9, 
100 mM KCl, 5 mM MgCl
2
, 1 mM DTE, 0.5 mM EDTA, 
0.05% NP-40, 0.02% BSA, Complete Protease Inhibitor 
Cocktail (Roche)). The mixture was incubated for 2 hours 
at 4°C on a rotator, after which the beads were washed 
three times with wash buffer (20 mM HEPES-KOH pH 
7.9, 150 mM KCl, 5 mM MgCl
2
, 1 mM DTE, 0.5 mM 
EDTA, 0.05% NP-40, 0.02% BSA, Complete Protease In-
hibitor Cocktail (Roche)). After removing the supernatant 
in the fi nal wash, samples were resuspended in 20 µl of 
2× SDS sample buffer and boiled for 5 minutes. Finally, 
samples were resolved by 10% SDS-PAGE and visualized 
by autoradiography. 
Exoribonuclease activity assay
Immunoprecipitations were performed as described 
above. After removal of non-bound material, immune 
complexes bound to the protein A-agarose beads were 
washed twice with buffer A (10 mM Tris-HCl, pH 7.5, 
50 mM KCl, 5 mM MgCl
2
 ,1 mM Na
2
HPO
4
 ). Substrate 
solution (approx. 100 ng 32P-labeled substrate in 40 µl buff-
er A) was added to the protein A beads, and the suspension 
was incubated at 37 °C with gentle agitation. Formamide 
loading buffer was added to 10 µl samples taken at regular 
intervals and these were immediately frozen until analysis. 
Samples were analyzed by denaturing polyacrylamide gel 
electrophoresis followed by autoradiography. Substrates, 
transcribed in vitro by T3 RNA polymerase from XbaI-
linearized pBS(-) template (Stratagene), were labeled ran-
domly using [32P]UTP (Amersham Pharmacia Biotech).
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Introduction
Many cellular events in eukaryotic cells 
that include 3’→5’  processing or degradation 
of RNA require the activity of a multi-protein 
complex called the exosome. Among these proc-
esses are the maturation of 5.8S rRNA(12,31,32), 
the processing of many small RNAs (33,38,42) 
and the turnover of different types of mRNAs 
(17,57,82,83). The exosome consists of at least 
11 proteins, all of which have been either shown 
to possess 3’→5’ exoribonuclease activity or are 
predicted to contain exoribonuclease or RNA 
binding activity based on their homology with 
prokaryotic proteins(10-12). These prokaryotic 
proteins include RNase PH, RNase R, RNase 
D and the RNA binding domain of the S1 
ribosomal protein. 
Ten of the eleven human proteins that were 
identifi ed as putative exosome subunits have been 
shown to be associated with the human exosome 
complex (14,17). These include the polymyositis/
scleroderma overlap syndrome autoantigens PM/
Scl-75, PM/Scl-100 and hRrp4p (78,79).
Our current knowledge on the interactions 
between different exosome subunits and on 
the overall structure of the exosome is limited. 
Recently, we have demonstrated that the hCsl4p 
protein binds to two other human exosome 
subunits, hRrp42p and hRrp46p (88). In ge-
nome-wide yeast two-hybrid screens interactions 
between the S. cerevisiae Mtr3p and Rrp42p and 
between Rrp41p and Rrp45p proteins have been 
identifi ed (67,85). Finally, in Arabidopsis thaliana
AtRrp4p and AtRrp41p display a direct interac-
tion (26), whereas AtRrp41p is able to interact 
with the yeast Rrp45p and Rrp44p proteins 
(22).
In eubacteria and chloroplasts, 3’→5’  RNA 
decay is carried out by a multiprotein complex 
called the degradosome (89,90). The bacterial 
degradosome contains several proteins, including 
the endoribonuclease RNase E, the exoribo-
nuclease polynucleotide phosphorylase (PNPase), 
enolase (a glycolytic enzyme) and an RNA 
The exosome is a complex of 3′ → 5′ exoribonucleases, which functions in a vari-
ety of cellular processes, all requiring the processing or degradation of RNA. Here 
we present a model for the assembly of the six human RNase PH-like exosome 
subunits into a hexameric ring structure. In part this structure is based upon 
the evolutionarily related bacterial degradosome, the core of which consists of 
three copies of the PNPase protein, each containing two RNase PH domains. 
In our model three additional exosome subunits, which contain S1 RNA bind-
ing domains, are positioned on the outer surface of this ring. Evidence for this 
model was obtained by the identifi cation of protein-protein interactions between 
individual exosome subunits in a mammalian two-hybrid system. In addition, the 
results of co-immunoprecipitation assays indicate that at least two copies of 
hRrp4p and hRrp41p are associated with a single exosome, strongly suggesting 
that at least two of these ring structures are stacked in this complex. Finally, 
the identifi cation of a human gene encoding the putative human counterpart of 
the bacterial PNPase protein is described, which suggests that the exosome is 
not the eukaryotic equivalent of the bacterial degradosome, although they do 
share similar functional activities.
36
helicase, termed RhlB (91,92). The chloroplast 
degradosome contains only PNPase and no other 
proteins (90).
The structure and assembly of the bacte-
rial degradosome has been studied in detail and 
RNase E was found to play a key role in the 
structural organization of this complex (93). In 
addition, the crystal structures of the degrado-
some components PNPase and enolase have been 
resolved (94,95). Interestingly, PNPase is a tightly 
associated trimeric enzyme (20), with the six 
RNase PH domains (RPDs) arranged in a ring-
like structure. Very recently, the EM-structure of 
the yeast exosome has been determined and ap-
peared to be consistent with six RPD containing 
exosome proteins arranged in a hexameric ring 
and three S1/KH proteins associated with the 
outer surface of the ring (21).
In this study we systematically analysed 
mutual interactions between all known subunits 
of the human exosome in a mammalian two-hy-
brid system. In combination with protein module 
similarities between human exosome subunits 
and the bacterial PNPase, our data were used to 
generate a model for the human exosome, the 
main feature of which is a ring composed by the 
six RNase PH type subunits, which is consistent 
with the EM-structure of the yeast exosome.
Results
Interactions between human exosome subunits
To identify protein-protein interactions in 
the human exosome, the full-length cDNAs en-
coding 11 (putative) human exosome components 
(hRrp4p, hRrp40p, hRrp41p, hRrp42p, hRrp46p, 
PM/Scl-75, PM/Scl-100, hCsl4p, hRrp44p/
hDis3p, OIP2 and hMtr3p) were cloned in both 
the pACT (in-frame with the sequence encoding 
the VP16 transcription activation domain) and 
pBIND (in-frame with the sequence encoding 
the GAL4 DNA binding domain) vectors of the 
Checkmate Mammalian Two-Hybrid system. 
COS-1 cells were co-transfected with each pair 
of these constructs and after 40-48 hours the 
luciferase activity of extracts prepared from these 
cells was determined. The expression levels of the 
fusion proteins were monitored by western blot 
analysis using antibodies specifi c for the VP16 or 
GAL4 (Santa Cruz) domains. This showed that all 
Figure 1. Summary of protein-protein interaction 
data for human exosome components as deter-
mined in a mammalian two-hybrid system.
COS-1 cells were cotransfected in a pairwise manner with 
constructs encoding the human exosome subunits fused to 
either the VP16 transcription activation domain (pACT 
constructs) or the GAL4 DNA binding domain (pBIND 
constructs), in combination with a luciferase encoding 
reporter plasmid. The activation of luciferase expression 
resulting from two-hybrid interactions is expressed in 
relative luminescence units (RLU). An interaction was 
considered positive when the RLU exceeded the sum 
of the two corresponding control measurements (the 
luciferase activity observed when the constructs were co-
transfected with either the ‘empty’ pACT or the ‘empty’ 
pBIND vector, shown at the right and at the bottom). 
The activity observed for the combination of hRrp42p 
in pBIND and hCsl4p in pACT was defi ned as 100 
RLU. Interactions observed in both of the two possible 
combinations are shaded dark gray, whereas interactions 
observed in one direction only are shaded light gray.
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proteins were expressed at comparable levels (data 
not shown). An overview of the results is given 
in Figure 1. Eight interactions were observed in 
both pairwise combinations. In addition, one self-
interaction was identifi ed (hRrp41p) and four 
interactions were detected in one direction only. 
Two of these four, however, include the hCsl4p/
pBIND construct, which gives rise to a relatively 
high background value in combination with the 
‘empty’ pACT vector (Fig. 1). Because the assay 
was carried out using primate cells (COS-1), 
there is a possibility that certain interactions are 
mediated by endogenous (exosome) proteins. 
Previously, however, some of the interactions 
identifi ed in this system (hRrp42p with hCsl4p 
and hRrp46p with hCsl4p) were confi rmed by 
GST-pulldown experiments (88).
Homology between PNPase and the human 
exosome
In the PNPase proteins of most prokaryotes 
(including E. coli and Streptomyces antibioticus) 5 
distinct domains can be discerned: 2 RPDs, an 
α-helical domain, a KH domain and a domain 
showing homology with the S1 RNA bind-
ing domain (94). Six human exosome subunits 
(hRrp41p, hRrp42p, hRrp46p, PM/Scl-75, 
OIP2 and hMtr3p) also share homology with 
RNase PH and three others (hRrp4p, hRrp40p 
and hCsl4p) contain a putative S1 RNA binding 
domain (11,17). Moreover, the recently charac-
terized A. thaliana Rrp4p protein contains a KH 
domain, capable of binding RNA, which can 
also be discerned in the yeast and human Rrp4p 
and Rrp40p proteins(26). These similarities sug-
gest that there is structural homology between 
the exosome and the PNPase protein complex 
(20,21).
To identify with which of the two RPDs of 
PNPase the human and yeast exosome proteins 
that contain an RPD share the highest degree 
of homology, the RPDs of all exosomal RNase 
PH-type subunits were compared with the RPDs 
of a number of PNPases from different organisms. 
Figure 2A shows a multiple alignment of the 
segment of these RPDs that is most conserved 
among PNPases and exosome components. 
This shows that the second RPD of PNPase is 
more conserved than the fi rst and that a clear 
distinction can be made between the two RPDs 
of each PNPase. Strikingly, the RPDs of three 
human (hRrp41p, hRrp46p and hMtr3p) and 
the corresponding three yeast exosome proteins 
displayed the highest degree of sequence homol-
ogy with the second RPD of PNPases, whereas 
the other three human RNase PH-type exosome 
subunits (hRrp42p, PM/Scl-75 and OIP2) and 
the corresponding yeast counterparts appeared 
to be more homologous to the fi rst RPD of 
PNPases. To demonstrate that the same group-
ing of RPD containing exosome subunits was 
obtained when the sequence of the complete 
RPDs was taken into account a cladogram was 
generated using a multiple sequence alignment of 
the RPD sequences defi ned in the Pfam database 
(http://pfam.wustl.edu). The results confi rm the 
grouping of RPD containing exosome subunits 
described above based upon their homology with 
the two RPDs of PNPases. Only a single exo-
some subunit, the yeast Mtr3p, appeared to fall 
in the other group by this analysis. However, we 
believe that the yeast Mtr3p belongs to the RPD2 
group based upon its homology with its human 
counterpart hMtr3p and the presence of a RPD2 
signature sequence (LALXDAG) in its most 
highly conserved element (see Figure 2A).
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Figure 2. Sequence homology between bacterial PNPase and the human and yeast exosome subunits.
A. The relative positions of the fi ve protein domains that can be discerned in a typical bacterial PNPase protein are 
schematically depicted in the upper part of the Figure. The exosome proteins that share homology with these domains 
are indicated. The lower part of the fi gure shows sequence alignments of the segment of the RPDs that is most highly 
conserved among the PNPase and exosome proteins. The sequences of 12 prokaryotic and 1 plant (Spinacia oleracea) PNPase 
proteins are compared with the human and yeast RNase PH-type exosome subunits. Numbers indicated the positions of 
the fi rst and last amino acid of these segments in the respective polypeptides. Black-boxed amino acids are identical in more 
than 50% of the sequences and grey boxes indicate conservation of similar amino acids.
B. Cladogram based upon a multiple sequence alignment (generated by ClustalW) of the complete RPDs of the proteins 
shown in A. Sc, S. cerevisiae; Hs, H. sapiens; So, S. oleracea; Sa, S. antibioticus; Rp, Rickettsia prowazekii; Pp, Pseudomonas putida; Ba, 
Buchnera aphidicola; Hi, Haeomophilus infl uenza; Pl, Photorhabdus luminescens; Ye, Yersinia enterocolitica; St, Salmonella typhimurium; 
Ec, E. coli; Bs, B. subtilus; Lm, Listeria monocytogenes; Li, Listeria innocua. RPD1 and RPD2 refer to the most N-terminal and 
most C-terminal RPD, respectively. The boundaries of the RPDs (indicated by numbers of amino acid positions) were 
identifi ed using the Pfam database which is based on Hidden Markov Model searches.
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Model of the human exosome
The striking similarity of protein domains 
present in exosome subunits on the one hand and 
the PNPase entity of the degradosome on the 
other hand, as well as their functional relationship 
suggested that their architecture might also be 
similar. 
The structure of S. antibioticus PNPase as ob-
tained by X-ray crystallography has revealed that 
this protein exists as a homo-trimeric complex, 
in which the six RPDs form a ring-shaped hexa-
meric structure. The S1 and KH RNA binding 
domains are positioned at the periphery of this 
ring, which may facilitate the recruitment of the 
RNA substrates (94).
Based upon the PNPase structure and 
taking into account the observed interactions 
between different exosome subunits (Figure 1), 
a model for the human exosome was generated 
in which the six RNase PH-like subunits form 
a hexameric ring and the three proteins with S1 
(and KH) RNA binding domains are positioned 
at the outer surface of this ring. A graphical 
representation of this model is depicted in Figure 
3. The two-way interaction between hRrp46p 
and hCsl4p is omitted from this model and may 
only occur in vitro due to sequence or structural 
homology between hRrp46p and hMtr3p. In 
agreement with the S. antibioticus PNPase struc-
ture the ring-shaped hexamer is predicted to be 
comprised of three pairs of antiparallel domains. 
Based upon the presently available data it is hardly 
possible to predict which are the most closely 
interacting pairs around the ring, i.e. two exo-
some subunits that correspond to a single PNPase 
moiety. The analysis of mutants of hRrp46p, 
lacking either the N- or the C-terminus of the 
protein, demonstrated that the C-terminal part of 
hRrp46p interacts with OIP2 (data not shown). 
In PNPase the C-terminal regions of the RPDs 
mediate the intramolecular interaction between 
the two RPDs (94). This suggests that hRrp46p 
and OIP2 correspond to one PNPase moiety 
in the ring structure, and extrapolation would 
mean that PM/Scl-75 – hRrp41p and hRrp42p 
– hMtr3p represent the other pairs.
The proposed ring structure for the exo-
some is expected to contain a single copy of all 
RNase PH- and S1-like subunits. If, however, two 
or more of such rings assemble into a larger com-
Figure 3. Structural model for the human exo-
some.
This model is based on the protein-protein interactions 
identifi ed by two-hybrid analysis and the structure of 
bacterial PNPase. Shading of the proteins indicates their 
homology with the RPDs 1 (light gray, black letters) 
and 2 (gray, black letters) of bacterial PNPase and the 
S1 and KH RNA binding domains (dark gray, white 
letters). Interactions between human exosome subunits 
are indicated by solid lines (interactions detected in the 
two-hybrid system in two directions with double lines) and 
interactions reported for the exosome subunit counterparts 
of either S. cerevisiae or A. thaliana are indicated by dotted 
lines.
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plex, as has been observed for other eukaryotic 
multiprotein complexes that assemble into ring-
like structures (e.g. the proteasome and the Hsp60 
complex), at least two copies of each ring compo-
nent would reside in the complex. To investigate 
these possibilities, we expressed tagged versions of 
two human exosome components in transfected 
cells and analyzed whether the tagged protein 
and the non-tagged endogenous counterpart as-
sociated with a single exosome complex. HEp-2 
cells were transfected with constructs encoding 
either VSV-G-tagged hRrp4p (S1-type) or VSV-
G-tagged hRrp41p (RNase PH-type) and from 
these cells lysates were prepared and subjected 
to immunoprecipitations with anti-VSV-G-tag 
monoclonal antibodies. As a positive control for 
the precipitation of endogenous hRrp4p and 
hRrp41p, parallel transfections were performed 
with constructs encoding VSV-G-tagged 
hRrp40p and hRrp46p. The immunoprecipitates 
were analyzed by western blotting using rabbit 
sera directed to either hRrp4p or hRrp41p. The 
results in Figure 4 show that for both of the pro-
teins analyzed co-precipitation of the non-tagged 
endogenous counterpart was indeed observed 
(lanes 3). Importantly, no co-precipitation of the 
endogenous proteins was detectable when lysates 
from cells transfected with constructs encoding 
the VSV-G tag only were used (lanes 5) and as 
expected hRrp4p and hRrp41p were effi ciently 
coprecipitated from lysates prepared from cells 
expressing VSV-G tagged hRrp40p and hRrp46p, 
respectively (lanes 4). These data suggest that at 
least two copies of hRrp4p and hRrp41p are 
Figure 4. At least two copies of exosome components reside in a single complex.
VSV-G-tagged hRrp4p, hRrp40p, hRrp41p and hRrp46p were expressed in transiently transfected HEp-2 cells and 
subsequently cell lysates were subjected to immunoprecipitation with anti-VSV-G-tag antibodies (α-VSV IP). Co-
precipitated proteins were analyzed by western blotting using anti-hRrp4p (A) and anti-hRrp41p (B) antibodies. In both 
panels, lanes 1 and 2 contain 10% of the extracts from cells expressing only the VSV-G-tag (lanes 1), the VSV-G-tagged 
hRrp4p (A, lane 2) or hRrp41p (B, lane 2) that were used for immunoprecipitation. Immunoprecipitated proteins from 
the extracts containing VSV-G-hRrp4p (A, lane 3), VSV-G-hRrp40p (A, lane 4), VSV-G-hRrp41p (B, lane 3), VSV-G-
hRrp46p (B, lane 4), or only the VSV-G-tag (A and B, lane 5) were analyzed in lanes 3-5. The positions of (VSV-G-tagged) 
hRrp4p and hRrp41p are indicated on the left of each panel; the positions of molecular mass markers on the right (in 
kDa). The extra bands visible in lanes 3-5 (marked mIgG) are due to cross-reactivity of the rabbit sera with the mouse 
anti-VSV-G-tag IgG used for the immunoprecipitations and unidentifi ed proteins in total extracts that are recognized by 
the anti-hRrp41p rabbit serum (panel B, lanes 1 and 2) are marked by “?”. 
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present in the assembled exosome. Because both 
of these proteins are part of the proposed exo-
some ring structure, two or more of these rings 
may be present in one complex. The relatively 
weak signals for the endogenous proteins in the 
corresponding anti-VSV immunoprecipitates 
may be due to overexpression of the VSV-tagged 
proteins in transiently transfected cells in combi-
nation the use of anti-VSV-G-tag antibodies (see 
Discussion). 
Identifi cation of human PNPase
The structural similarity between the 
S. antibioticus PNPase and the exosome raised 
the question whether the exosome represents 
the eukaryotic counterpart of the eubacterial 
PNPase/degradosome. Alternatively, eukaryotes 
may also express a PNPase/degradosome and 
both complexes might have a similar evolutionary 
origin. The latter option is supported by the iden-
tifi cation of a PNPase containing degradosome 
in chloroplasts of Spinacia oleracea. To shed more 
light on this issue, several eukaryotic genome 
databases were screened for the presence of 
genes homologous to S. antibioticus PNPase. This 
resulted in the detection of PNPase homologues 
in C. elegans and D. melanogaster. The C. elegans
(acc. no. BE0003N10.1) and the D. melanogaster 
(acc. no. CG11337) amino acid sequences are 
26% and 28% identical (38% and 40% similar), 
respectively, to the S. antibioticus PNPase sequence. 
Next, the human genome was screened with the 
Figure 5. Sequence and modular structure of human PNPase.
The nucleotide sequence of the coding region of human PNPase was composed as described in the text using a 
combination of genomic and EST database entries. The derived amino acid sequence is shown below the nucleotide 
sequence. Numbering refers to the amino acid sequence. The positions of protein domains found in all identifi ed PNPases 
are indicated: two RPDs (1 and 2), separated by an α-helical region, a KH domain and an S1 RNA binding domain. The 
coding region is 2352 nucleotides long, corresponding to 783 amino acids. Nucleotides that were found to be different 
in the cDNA obtained from the cDNA library are indicated with bars below and above these nucleotides. The DNA and 
protein sequence shown here have been submitted to the EMBL database (accession number AJ458465).
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PNPase-like polypeptide sequences of C. elegans 
and D. melanogaster. This led to the detection of 
a sequence (LOC87178) on chromosome 2 that 
is homologous to the C-terminal part of these 
PNPase-like polypeptides. Both a putative S1 
RNA binding domain and a putative KH domain 
are present in the polypeptide encoded by this 
genomic sequence, as demonstrated by a screen-
ing using the Pfam protein families database 
(96). Screening of the human EST (expressed 
sequence tag) databases with this sequence al-
lowed the identifi cation of the N-terminal part 
of this polypeptide, which encompasses a puta-
tive mitochondrial targeting sequence and two 
putative RPDs (identifi ed by Pfam) separated 
by a predicted alpha-helical region (identifi ed 
by Jpred (97)). The annotated genomic sequence 
comprises only the C-terminal part of the com-
plete polypeptide, which is most likely due to an 
extra guanosine residue in the genomic sequence 
at position 1739 (adenosine of startcodon is num-
bered 1). This additional residue is not present in 
the EST sequences corresponding to this region 
and thus is likely to be a sequencing error. The 
complete coding sequence and the derived 
polypeptide sequence of the putative human 
PNPase protein, as well as its modular structure, 
are shown in Figure 5. Based upon the available 
EST sequences the 5’ and 3’ untranslated regions 
(UTR) of the putative human PNPase mRNA 
are predicted to be 26 and 118 nucleotides long, 
respectively. The putative human PNPase amino 
acid sequence is 36% identical (49% similar) to 
E. coli PNPase, 29% identical (49% similar) to S. 
antibioticus PNPase, 37% identical (51% similar) to 
C. elegans PNPase and 51% identical (64% similar) 
to D. melanogaster PNPase. A comparison of the 
putative human PNPase polypeptide sequence 
with that of the human exosome proteins re-
vealed no signifi cant homology other than the 
residues that are also conserved between the hu-
man exosome components and the prokaryotic 
PNPase proteins.
The three eukaryotic PNPase-like se-
quences described above were used to screen 
the S. cerevisiae and M. musculus genomes for a 
similar sequence, but no gene encoding a putative 
PNPase could be identifi ed for these organisms. 
The mouse EST database, however, contains a 
number of EST sequences encoding a putative 
murine PNPase homologue, substantiating the 
existence of PNPase in higher eukaryotes.
Although the human and mouse ESTs cor-
responding to the PNPase sequences indicate that 
the genes encoding this polypeptide are indeed 
transcribed in these organisms, we wanted to 
have more convincing evidence that the human 
PNPase sequence derived from the database 
entries is indeed expressed in humans. Therefore, 
human a cDNA library was used to isolate a 
complete PNPase cDNA with primers derived 
from the predicted sequence by PCR. PCR 
were products obtained from a teratocarcinoma 
cDNA library, the sequence of which appeared 
to be almost identical to that of the predicted 
human PNPase sequence. The only differences 
observed were a deletion of nucleotides 518-541 
(adenosine of startcodon is numbered 1) and a 
single nucleotide substitution at position 1390. 
The absence of nucleotides 518-541, is likely 
to be due to an alternative splicing event and 
the substitution of nucleotide 1390, which does 
not change the encoded amino acid, may be a 
polymorphism. Although the single nucleotide 
substition is also represented in the EST databases, 
all EST sequences of that region of the PNPase 
mRNA do contain nucleotides 518-541.
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Discussion
In this paper we propose a structural model 
of the human exosome based on the homology 
between the exosome and bacterial PNPase, the 
three-dimensional structure of which has been 
solved by X-ray crystallography. This model is 
strongly supported by a number of interactions 
between human exosome components, which 
were identifi ed by mammalian two-hybrid 
analyses. In addition, database searches led to 
the identifi cation of a sequence that appears to 
encode the human orthologue of the PNPase 
protein. The latter fi nding suggests that humans, 
and possibly also other eukaryotes, express two 
exoribonuclease complexes that are structurally 
similar to the bacterial PNPase, the exosome and 
the putative human PNPase.
Interactions between exosome components
Most of the interactions between human 
exosome subunits identifi ed by mammalian 
two-hybrid analysis are in agreement with the 
model presented for the human exosome. The 
only human protein which did not detectably 
interact with other subunits in this system is the 
PM/Scl-75 protein. In one of two extensive yeast 
two-hybrid screens, however, its yeast homologue 
Rrp45p was shown to interact with yeast Rrp41p 
(85), the homologue of hRrp41p, which is indeed 
interacting with PM/Scl-75 in the model shown 
in Figure 3. The inability of PM/Scl-75 to inter-
act in vitro with other proteins might point to an 
important role of the N-terminus of this protein, 
which is fused to either the transcription activa-
tion or the DNA-binding domain in the two-hy-
brid analysis and thus might be functionally im-
paired. This is substantiated by observations made 
with N- and C-terminal EGFP-fusion proteins 
of PM/Scl-75, which were unable to enter the 
nucleolus (unpublished observations), in contrast 
to other EGFP-tagged exosome subunits and to 
the endogenous PM/Scl-75 (8,88). Moreover, the 
yeast protein Rrp45p has been shown to bind in 
vitro to GST-tagged A. thaliana Rrp41p, but this 
interaction was lost when a C-terminal hexahis-
tidine tag was attached to Rrp45p (22). Taken 
together, these data suggest that both termini 
of PM/Scl-75 and Rrp45p are involved in their 
interaction with other exosome subunits.
Four of the observed two-hybrid interac-
tions are not explained by the model we gener-
ated. These include the interactions of hCsl4p 
with hRrp41p and PM/Scl-75, both of which 
were detected only with the hCsl4p/pBIND 
construct, which gives rise to relatively high 
background signals, and the interaction of 
hRrp41p with itself. The fourth two-hybrid in-
teraction our model does not account for is that 
of hCsl4p with hRrp46p. This interaction  may 
be explained by structural homology between 
hMtr3p and hRrp46p (sequence identity 25%, 
similarity 36%), which are both homologous to 
the second RPD of PNPase. This possibility is 
supported by the observation that hMtr3p binds 
to the same region of hCsl4p as does hRrp46p 
(data not shown) (88).
The model for the human exosome com-
plex proposed here (a PNPase-like ring) is ex-
pected to be applicable to the exosome of other 
organisms as well, including yeast. Interestingly, 
the very recently reported EM-structure for the 
yeast exosome fully supports the arrangement of 
the RPD containing subunits in a hexameric ring 
(21). These authors have predicted the relative 
position of the RPD-type subunits in the ring 
based upon bioinformatics data and this aspect 
of their model only partially agrees with our 
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model for the human exosome. Although the 
discrepancy might refl ect species differences, it is 
more likely due to an alternative interpretation 
of the homologies among the exosome subunit 
RPDs. Based on a predicted functional site of 5 
amino acids (which is in fact located just outside 
the approximately 200 amino acid long RPD 
as predicted by Pfam), the yeast exosomal RPD 
proteins were classifi ed as homologues of either 
RPD1 (Rrp43, Rrp46, Mtr3) or RPD2 (Rrp41, 
Rrp42, Rrp45) of PNPase. When the complete 
RPDs (as predicted by Pfam) from many exo-
some and PNPase proteins or the most highly 
conserved segment of these are used for the anal-
ysis, Rrp42, Rrp43 and Rrp45 appear to be more 
closely related to RPD1 and Rrp41, Rrp46 and 
Mtr3 appear to be more closely related to RPD2 
(Figure 2). Importantly, the arrangement of the 
RPD subunits in our model is strongly supported 
by the available protein-protein interaction data 
for both the yeast and the human exosome. The 
only two interactions identifi ed between yeast 
exosome components (Mtr3p with Rrp42p 
and Rrp41p with Rrp45p) are consistent with 
our model (Figure 3), but not with the model 
proposed by Aloy et al. (21).
Two other human exosome components, 
PM/Scl-100 and hDis3p are not incorporated 
in the model since they were unable to interact 
in vitro with other exosome subunits and no 
signifi cant sequence homology between these 
proteins and any component of the bacterial 
degradosome could be identifi ed. Currently, no 
evidence is available for the association of hDis3p 
with the human exosome, except for its homo-
logy with the yeast exosome protein hRrp44p. 
The recent purifi cation and sequencing of all 
human exosome proteins confi rmed the associa-
tion of most putative human exosome proteins, 
including PM/Scl-100, but hDis3p was not 
detected (17). PM/Scl-100 shares homology with 
the bacterial exoribonuclease RNase D (11), 
which is not associated with the degradosome. 
PM/Scl-100 and its yeast homologue Rrp6p 
have been suggested to be exclusively associated 
with the nuclear exosome complex, suggesting 
that it is indeed not a core component of the 
exosome (11). This is supported by the results 
of size-exclusion chromatography experiments, 
which demonstrated that PM/Scl-100 is only as-
sociated with the higher molecular mass exosome 
complexes (approx. 700 kDa) but not with lower 
molecular mass complexes (250 - 600 kDa), in 
contrast to four putative core components, which 
were detected in all complexes (14). The failure 
of PM/Scl-100 to interact with other exosome 
components in the mammalian two-hybrid 
system might be due to the fact that this protein 
requires more than one of the core components 
for effi cient binding. 
The results of the co-immunoprecipitation 
experiments suggest that (part of) the exo-
some complexes contain at least two copies 
of hRrp4p and hRrp41p. The relatively low 
level of co-precipitation of the endogenous, 
non-tagged, hRrp4p and hRrp41p proteins was 
expected in this experimental setting. An excess 
of a VSV-tagged subunit in a transfected cell may 
allow only part of it to become incorporated 
in exosome complexes, whereas both ‘free’ and 
exosome associated VSV-tagged protein will be 
precipitated. Moreover, not all exosome com-
plexes in a cell may be composed of two rings. 
An alternative explanation for these data, which 
may be unlikely but can not be completely ruled 
out yet, is the presence of more than one copy 
of hRrp4p and hRrp41p in a single ring. The 
observation that more than one copy of the pre-
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sumptive core components and thus more than 
one ring may be present in the same exosome 
complex raises the question what the overall 
structure of the exosome is. One option is that 
the exosome forms a proteasome- or Hsp60-
like structure (which consist of 4 or 2 stacked 
heptameric rings, respectively(98,99)) by direct 
ring-ring interactions. Another possibility is that 
PM/Scl-100 and/or hDis3p are able to associate 
with more than one ring simultaneously, thereby 
combining two or more rings into one complex. 
Interestingly, the calculated molecular mass of 
a complex containing one copy of each of the 
‘core’ subunits of the human exosome (Figure 3) 
is approx. 260 kDa, which means that a complex 
consisting of two rings and one copy of PM/Scl-
100 and hDis3p (both approx. 100 kDa) would 
indeed be around 700 kDa, in good agreement 
with the size-exclusion chromatography data 
(14). The appearance of 250-600 kDa complexes 
may represent disassembled or only partially as-
sembled exosomes. Based upon its EM-structure, 
the yeast exosome does not appear to consist of 
multiple rings (21), which is in agreement with 
its molecular mass of 300-400 kDa (12). This may 
refl ect an important structural difference between 
the human and yeast exosome complexes. The 
purifi cation of native human exosome complexes 
and subsequent structural analysis by (cryo-)EM 
will be required to shed more light on this issue.
The exosome versus PNPase
The recently identifi ed structural conserva-
tion between the prokaryotic PNPase and the 
eukaryotic exosome suggests that these two com-
plexes function by similar mechanisms (20). Both 
have been reported to be involved in the degrada-
tion of mRNA and rRNA. Although the func-
tions of both complexes seem to be redundant, 
in a number of eukaryotic organisms, including 
human, both complexes appear to exist. The 
presence of PNPase in chloroplasts has already 
been described previously (90). Chloroplasts 
(and also mitochondria) have been suggested to 
originate from eubacteria that were taken up by 
primitive eukaryotes. Many eubacteria are known 
to contain PNPase proteins (10), whereas archae-
bacteria have been shown to contain exosome 
components (86), but no PNPase homologues. 
These data suggest that the eukaryotic exosome 
has evolved from the archaeal exosome proteins, 
whereas the eukaryotic PNPase stems from a 
eubacterial protein. Whether the human PNPase, 
although encoded by a nuclear gene, is specifi c 
for mitochondria as is the plant PNPase for chlo-
roplasts remains to be investigated. Remarkably, 
all three animal PNPase proteins identifi ed (hu-
man, D. melanogaster and C. elegans) contain an 
extended N-terminal sequence in comparison 
with the bacterial PNPases, which varies from 51 
amino acids in human to 33 in C. elegans (with 
respect to the most N-terminal RPD). In all three 
cases, this sequence is enriched in hydrophobic, 
hydroxylated and positively charged amino acids 
and therefore might serve as a mitochondrial 
import signal, similar to that of known nuclear 
encoded mitochondrial proteins (100). If the 
putative human PNPase protein indeed appears 
to reside in the mitochondria, this protein may 
function in RNA processing/decay processes that 
are specifi c for this organelle, whereas the exo-
some performs similar functions in the cytoplasm, 
nucleoplasm and nucleolus of cells.
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Materials and Methods
cDNA cloning
All cDNAs used were cloned into the pACT 
and pBIND vectors (Promega). The database accession 
numbers of the cDNAs used are BC000747 (hRrp4p), 
AF281132 (hRrp40p), AF281133 (hRrp41p), D29958 
(hRrp42p), AF281134 (hRrp46p),  M58460 (PM/Scl-
75), L01457 (PM/Scl-100), AF151866 (hCsl4p), R27667 
(hDis3p), AF025438 (OIP2) and NM_058219 (hMtr3p). 
The cDNA encoding the putative human PNPase was 
submitted under accession number AJ458465.
Mammalian two-hybrid analysis
All interactions were analyzed using the CheckMate 
Mammalian Two-Hybrid System (Promega). Briefl y, ap-
prox. 3.5 x 105 COS-1 cells were transfected with 3 vectors 
(1 µg each), pACT and pBIND, either with or without 
insert, and the pG5luc reporter vector using 5 µl Fugene 
Transfection Reagent (Roche). After culturing for 40-48 
hours, cells were harvested using 500 µl Passive Lysis Buffer 
(PLB; Promega) and the expression of both the fi refl y 
luciferase and the control Renilla luciferase were quanti-
fi ed using the Dual Luciferase Reporter Assay System 
(Promega) on a Berthold Lumat LB 9507 Luminometer. 
Bioinformatics
Multiple alignments of PNPase and exosome 
protein sequences were generated with ClustalW, using 
BLOSUM30 substitution matrices. Where necessary, the 
multiple alignments obtained were corrected manually. 
Shading of identical and similar residues was done us-
ing the following groups of amino acids: hydrophobic 
residues(GAVLMI), polar residues(STCPNQ), aromatic 
residues(FYW), acidic residues(DE), basic residues(KR), 
Histidine(H). The cladogram was generated using 
TreeView. All predictions of functional domain and 
secondary structure were done using the Pfam database of 
Hidden Markov Models and the Jpred secondary structure 
prediction, respectively. Sequence database searching was 
performed using BLAST on GenBank databases contain-
ing either ESTs or genomic sequence information.
Transient transfection of HEp-2 cells 
For transfection the hRrp4p, hRrp40p, hRrp41p 
and hRrp46p open reading frames were cloned into the 
pCI-neo vector (Promega), in frame with the vesicular sto-
matitis virus G epitope (VSV-G tag) to allow expression of 
N-terminally VSV-tagged proteins. For immunoprecipita-
tion analyses approximately 10 x 106 HEp-2 cells (grown to 
80% confl uent monolayers) were transfected with 30-40 µg 
of plasmid DNA in 1600 µl of DMEM containing 10% 
FCS by electroporation, which was performed at 260V and 
950 µF using a Gene-Pulser II (Bio-Rad). After overnight 
culturing, cells were washed twice with PBS, resuspended 
in 500 µl of lysis buffer (25 mM Tris-HCl, pH 7.5, 100 mM 
KCl, 2 mM EDTA, 1 mM DTE, 0.5 mM PMSF and 0.05% 
NP-40) and homogenized by sonication. 
Immunoprecipitation
Monoclonal mouse anti-VSV-G tag antibodies 
were coupled to protein G-agarose beads (Biozym) in 
IPP500 (500 mM NaCl, 10 mM Tris-HCl, pH 8.0, 0.05% 
NP-40) by incubation for 2 h at room temperature. 
Beads were washed twice with IPP500 and once with 
IPP150 (150 mM NaCl, 10 mM Tris-HCl, pH 8.0, 0.05% 
NP-40). For immunoprecipitations, cell extracts were 
incubated in IPP150 with the antibody-coated beads for 
1 h at 4°C. Subsequently, beads were washed three times 
with IPP150 and precipitated proteins were eluted from 
the beads by the addition of SDS sample buffer. Finally, 
samples were resolved by 11.5% SDS-PAGE and were 
blotted on nitrocellulose membranes. 
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Western blot analysis
For western blot analysis, α-hRrp4p and α-hRrp41p 
rabbit antisera (14) were diluted 250-fold in blocking buffer 
(PBS containing 4% non-fat dried milk and 0.1% NP-40). 
As secondary antibody, horseradish peroxidase-conjugated 
swine anti-rabbit IgG (Dako Immunoglobulins) was used 
after 1000-fold dilution in blocking buffer. Visualization 
was performed by chemiluminescence.
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Introduction
The processing and degradation of RNA is 
a process equally important for the organisms of 
all three domains of life, eubacteria, archaebacte-
ria and eukaryotes. Many (stable) RNAs present 
in the cell require extensive modifi cation after 
their transcription to become functional. Three 
of the four eukaryotic ribosomal RNAs (rRNAs), 
for example, are transcribed as a single precur-
sor molecule which subsequently undergoes a 
number of endoribonucleolytic cleavages, exo-
ribonucleolytic processing at the RNA termini 
and single nucleotide modifi cations to obtain 
the mature rRNAs (101). Also, degradation of 
mRNA plays an important role in the regulation 
of gene expression, since removal of its mRNA 
will prevent the synthesis of new copies of a pro-
tein (102). To accomplish effi cient processing and 
degradation of RNA, several molecular machines 
have evolved. Key enzymes in the degradation of 
prokaryotic RNA are exoribonucleases, which 
work in a 3’ – 5’ manner (103), whereas in eu-
karyotes RNA can be degraded both by 3’ – 5’ 
and by 5’ – 3’ exoribonucleases (56).
All known exoribonucleases can be classi-
fi ed in one of seven protein families. For some 
families (YhaM and RBN) members are only 
found in prokaryotes, whereas members of the 
5PX exoribonuclease family (the only family of 
5’ – 3’ exoribonucleases) are exclusively present 
in eukaryotes. Exoribonucleases belonging to 
the DEDD and RNR families are usually only 
found in eubacteria and eukaryotes and the 
proteins of the RRP4 family in archaebacteria 
and eukaryotes. The PDX family is represented 
in all three domains of life (104,105). The PDX 
proteins are characterized by the presence of 
one or two domains homologous to RNase 
PH (RPDs) and representatives of this family 
are associated with the eubacterial degradosome 
complex (PNPase) and the eukaryotic exosome 
Polynucleotide phosphorylase (PNPase) plays a key role in the degradation of 
diff erent RNA species in bacteria. The eukaryotic exosome complex is both 
structurally and functionally related to the bacterial PNPases. Recently, PNPase 
homologues have been identifi ed in eukaryotes, the fi rst of which was found to 
reside in spinach chloroplasts. Mammalian PNPases appeared to contain N-ter-
minal extensions reminiscent of mitochondrial import signals and were proposed 
to be involved in the degradation of mitochondrial RNAs. Here, we demonstrate 
that the human PNPase indeed accumulates in mitochondria, which is mediated 
by an N-terminal transition peptide. In addition, we show that both RNase PH 
domains of human PNPase display exoribonuclease activity in vitro. Phyloge-
netic data indicate that the mitochondrial and chloroplast RNA degradation 
machinery has evolved from the eubacterial PNPase. In contrast, the eukaryotic 
proteins involved in nuclear and cytosolic RNA degradation and processing, i.e. 
the exoribonucleases associated with the exosome, are more closely related 
to archaeal proteins. Finally, we discuss the alternative exoribonucleases which 
are used by organisms lacking both PNPase and the exosome complex. Taken 
together, our data are fully consistent with a eubacterial origin of the organellar 
exoribonuclease machinery and an archaeal origin of the nuclear and cytosolic 
RNA degradation machinery.
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(Rrp41, Rrp42, Rrp43, Rrp45, Rrp46, Mtr3) 
(10,106). In addition, the domains present in the 
RRP4 family members of the human exosome 
(Rrp4p, Rrp40p and Csl4p), the S1 and KH 
RNA binding domains, are also found in eubac-
terial PNPase. Recently, a structural model has 
been proposed for the eukaroytic exosome, partly 
based on the structural homology between exo-
some subunits and eubacterial PNPase (21,106). 
The exoribonuclease families and a few examples 
of proteins belonging to each family are listed in 
Table 1.
The proteins RNase II and RNase R 
(RNR family) and PNPase (PDX family) are the 
most important exonucleases in eubacteria and 
members of both families are present in virtually 
all eubacteria that have been sequenced to date. A 
double-minus mutant of RNase II and PNPase 
is lethal in Escherichia coli and, although some 
eubacteria are known that lack either RNR fam-
ily exoribonucleases (e.g. the Actinobacteria) or 
PDX exoribonucleases (e.g. Mycoplasma) (103), 
only one eubacterium has been found lacking 
both enzymes (Streptomyces coelicolor). Remarkably, 
the domain of the archaebacteria has developed 
a different set of enzymes to deal with RNA 
degradation. In most archaea, no RNR family 
exoribonucleases and PNPase proteins are found. 
Instead, the genomes of these organisms usu-
ally encode two proteins that show homology to 
E. coli RNase PH (PDX family) and one protein 
homologous to the yeast exoribonuclease Rrp4p 
(RRP4 family) (104). Most likely, these archaeal 
proteins assemble into a single complex similar 
to the yeast and human exosome (86). Eubacteria 
usually also encode a single RNase PH homo-
logue but in E. coli this gene (which is involved 
in tRNA maturation) is not essential, except in 
strains lacking a large number of other ribonu-
cleases (107). Of all sequenced archaeal genomes, 
only two, those of Methanococcus jannaschii and 
Halobacterium NRC-1, do not contain genes en-
coding exosome subunits. To compensate for the 
missing exosome complex, both have acquired 
alternative enzymes to deal with RNA degrada-
tion. A homologue of the protein YhaM, which 
was recently identifi ed as an exoribonuclease in 
Bacillus subtilis (105), is present in M. jannaschii, 
Table 1. Overview of exoribonuclease families
Family Activity Distribution Prokaryotic examples Eukaryotic examples
YhaM 3’-5’ some eubacteria
some archaea
YhaM -
RBN 3’-5’ some eubacteria RNase BN -
5PX 5’-3’ all eukaryotes - Xrn1
Rat1
DEDD 3’-5’ some eubacteria
all eukaryotes
RNase D PM/Scl-100
RNR 3’-5’ most eubacteria
all eukaryotes
RNase R
RNase II
Dis3
Msu1
PDX 3’-5’ all domains PNPase (eubacteria)
RNase PH (eubacteria)
exosome subunits (archaea)
PNPase
exosome subunits
RRP4 3’-5’ most archaea
all eukaryotes
exosome subunits exosome subunits
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whereas Halobacterium NRC-1 contains an RNR 
family exoribonuclease. 
In eukaryotes, the situation is somewhat 
more complex, because there is 5’-3’ RNA deg-
radation in addition to 3’-5’ RNA degradation. 
In Saccharomyces  cerevisiae 5’-3’ degradation is the 
main pathway for mRNA degradation, whereas 
in human cells the 3’-5’ pathway is the more 
common mechanism. A major player in the latter 
pathway is the exosome (56), which mediates the 
degradation and processing of a large number 
of different RNA species in yeast and human 
cells (106). Homologues of exosome subunits 
are found in all eukaryotes, including plants 
(26). An overview of the number of functional 
exoribonuclease genes of the PDX, RNR and 
RRP4 families in eubacteria, archaebacteria and 
eukaryotes is given in Table 2.
The protein PNPase was long believed 
to be an exclusively eubacterial protein until it 
was also found in chloroplasts of Spinacia oleracea 
(90). Recently, we have shown the existence of 
nuclear genes encoding PNPase homologues in 
Homo sapiens and Mus musculus and confi rmed 
that these genes are indeed expressed. Surpris-
ingly, the polypeptides encoded by these genes 
both appeared to contain putative mitochondrial 
localization signals (106). A comparison of the 
schematic structures of the eubacterial, mam-
malian and spinach PNPases is shown in Figure 1. 
Table 2.  The occurrence of functional exoribonuclease genes of the PDX, RNR and RRP4 families in the 
three domains of life.
all required for a functional exosome 
PNPase proteins RNase R/II 
proteins
RNase PH-like proteins RRP4-like 
proteins
Exoribonuclease 
family
PDX RNR PDX PDX RRP4
COGs1 COG1185 COG0557 COG0689 COG2123 COG1097
Eubacteria
(general)
1 1/2 1 - -
B. subtilis 1 2 1 - -
Mycoplasma - 1 - - -
Actinobacteria 1 - 1 - -
S. coelicolor - - 1 - -
Archaebacteria 
(general)
- - 1 1 1
Halobacterium
NRC-1
- 1 - - -
M. jannaschii - - - - -
Eukaryotes 
(general)
0-2 >2 3 3 3
S. cerevisiae - >2 3 3 3
A. thaliana 2 >2 3 3 3
H. sapiens 1 >2 3 3 3
1  The COG number corresponds to the entry number of a particular protein group in the clusters of orthologous groups 
(COGs) database.
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All PNPases contain the main structural domains 
in the same order: two RPDs separated by an 
alpha-helical domain and KH and S1 domains 
near the C-terminus. The main differences are 
the length of the alpha-helical domain and 
the presence of  mitochondrial and chloroplast 
transition peptides (TPs) near the N-termini of 
the eukaryotic PNPases. Remarkably, the spinach 
protein also contains a mitochondrial transition 
peptide (mTP) fl anking the chloroplast transition 
peptide (cTP, Figure 1). 
In this study we investigated the subcellular 
localization of the human PNPase, which indeed 
appeared to accumulate in the mitochondria. In 
addition, we present phylogenetic data indicating 
that the mitochondrial and chloroplast RNA 
degradation machinery has evolved from the 
eubacterial PNPase and that the exoribonucleases 
associated with the exosome are more closely 
related to archaeal proteins.
Results and Discussion
Subcellular localization of human PNPase
To investigate the subcellular localization of 
the mammalian PNPases, the human cDNA was 
cloned into the pEGFP-N3 vector, in-frame with 
the coding sequence of the enhanced green fl uo-
rescent protein (EGFP). As can be seen in Figure 
2, analysis of HEp-2 cells expressing the PNPase-
EGFP fusion protein by confocal microscopy 
indeed demonstrated a mitochondrial localization 
for the human PNPase protein (Figure 2, panels 
A-C). A detailed comparison of the staining by 
PNPase-EGFP and by MitoTracker-Red (Figure 
2, panels D-F) suggests that the distribution of 
PNPase in the mitochondria is not uniform. 
For yet unknown reasons PNPase seems to be 
enriched in certain regions of the mitochondria. 
Transfection of HEp-2 cells with a construct 
containing the PNPase sequence at the C-ter-
minus of EGFP (pEGFP-C3 vector) resulted in 
a diffuse cytoplasmic staining (Figure 2, panel 
G) (111). The latter result is most likely due to 
masking of the mitochondrial import signal at 
the N-terminus of PNPase in the EGFP-PNPase 
fusion protein. Note that mitochondrial transition 
peptides are often located close to the N-termi-
nus of mitochondrial proteins (100). To confi rm 
the presence of an N-terminal mTP in the hu-
man PNPase protein, the sequence encoding the 
fi rst 45 amino acids of  this protein was cloned 
into the EGFP-N2 vector, in-frame with the 
coding sequence of EGFP. The results in Figure 3 
demonstrate that this N-terminal element, which 
shows structural characteristics similar to known 
Figure 1. Schematic representation of the structure of eubacterial and eukaryotic PNPases. 
The relative positions of the chloroplast and mitochondrial transition peptides (cTP and mTP), the two RPDs, the α-
helical domain, and the KH and the S1 RNA binding domains are indicated.
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mTPs (112), was indeed able to target EGFP to 
the mitochondria of HEp-2 cells.
Because mTP-like elements are also found 
in the PNPase homologues of other animals, 
we predict that this enzyme also resides in the 
mitochondria of other animals and possibly all 
other multicellular eukaryotes. In this respect, it 
is important to note that the only completely 
sequenced plant genome, that of Arabidopsis tha-
liana, encodes two distinct PNPases, one which 
is predicted to accumulate in chloroplasts and 
another which contains a putative mitochondrial 
localization signal (113). Apparently, eukaryotic 
PNPases are important for the degradation and/
or processing of RNA in both main eukaryotic 
organelles of eubacterial origin (it is believed that 
eubacteria engulfed by primitive eukaryotes led 
to a symbiosis of the two organisms and that the 
engulfed bacteria later evolved into the mito-
chondria and chloroplasts (114)). The eubacteria 
Figure 2. Mitochondrial localiza-
tion of human PNPase.
HEp-2 cells were transfected with 
a construct encoding EGFP fused 
to the C-terminus of hPNPase. 
After 16 hours the expressed fusion 
proteins were visualized by confocal 
fl uorescence microscopy (panel A). In 
panel B, the mitochondria of the cells 
were visualized using MitoTracker-
Red CMX Ros. The overlay of both 
images is shown in panel C. Panels 
D-F show a magnifi cation of a part 
of the lower cell shown in panels A-C. 
Panel G shows the diffuse cytoplasmic 
staining by a fusion protein of EGFP 
fused to the N-terminus of hPNPase. 
Each bar represents 5 µm.
Figure 3. Human PNPase contains an N-terminal mitochondrial import signal.
HEp-2 cells were transfected with a construct encoding the fi rst 45 amino acids of PNPase fused to the N-terminus of 
EGFP. After 16 hours the fusion protein was visualized by fl uorescence microscopy (panel A). In panel B, the mitochondria 
of the same cells were visualized using MitoTracker-Red CMX Ros. Panel C shows the overlay of both images. Each bar 
represents 5 µm.
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that are most closely related to the chloroplasts 
and the mitochondria (Synechocystis sp. and Rick-
ettsia prowazekii, respectively (115)) both contain 
a PNPase encoding gene. A comparison of the 
amino acid sequences of a number of eubacterial 
and eukaryotic PNPases and of their exosome 
counterparts in human and archaea demonstrated 
that all known mitochondrial PNPase sequences 
from animals are more closely related to each oth-
er than to those of the eubacterial or chloroplast 
PNPases (Figure 4). To obtain a reliable alignment 
of exosome subunits and PNPase proteins, the 
Pfam database (96) was used to determine the 
borders of the RPDs and S1 RNA binding do-
mains in these proteins. Subsequently, the amino 
acids sequences of the individual domains were 
combined  to obtain pseudoproteins encompass-
ing the RPDs and the S1 domains of exosome 
and PNPase proteins from a number of organ-
isms. For the human and archaeal exosome, the 
domains were combined according to our current 
knowledge on the assembly of exosome proteins 
in a PNPase-like structure (106). These pseudo-
proteins were used to generate an alignment and 
a phylogram demonstrating the relationship be-
tween the proteins. The A. thaliana mitochondrial 
PNPase can not be clearly grouped with either 
the chloroplast or the mitochondrial PNPases, but 
does not contain a chloroplast transition peptide 
(cTP). Future studies and the completion of other 
plant genomes will learn whether all plants, like 
A. thaliana, contain two distinct PNPases. It would 
not be surprising if some plants contain only a 
single functional PNPase gene that might suffi ce 
Figure 4. Phylogram of PNPase and exosome proteins of several prokaryotic and eukaryotic organisms. 
The phylogram was generated based upon a ClustalW multiple sequence alignment of pseudoproteins composed of the 
two RPDs and the S1 domain of exosome subunits or of the PNPase. The human exosome subunits were combined 
based upon structural models for this complex: hRrp42p/hMtr3p/hCsl4p, OIP2/hRrp46p/hRrp40p, and PM/Scl-75/
hRrp41p/hRrp4p. The scale bar corresponds to 0.1 substitutions per site.
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for both the chloroplasts and the mitochondria, 
since a number of other plant proteins have been 
identifi ed that can enter both organelles (115). 
Moreover, all identifi ed chloroplast PNPase pro-
teins contain a putative mTP in addition to the 
cTP (see schematic structure for spinach PNPase 
in Figure 1). The homology between eubacterial 
and nuclear encoded organellar proteins is not 
only observed for PNPase, but also for other 
proteins, for example some proteins involved 
in RNA metabolism, like the organellar RNA 
polymerases. The RNA polymerases of eubacte-
ria are more homologous to the chloroplast and 
mitochondrial RNA polymerases of eukaryotes 
than to the nuclear RNA polymerases, which 
display more homology to archaebacterial RNA 
polymerases (data not shown). Similar relation-
ships between nuclear and archaeal sequences and 
between organellar and eubacterial sequences 
have been observed for the ribosomal protein 
rpl14 (116).
Evolution of PNPase
Since there is signifi cant homology in 
domains and structure between PNPase and exo-
some proteins it is not unlikely that these protein 
have a common ancestor. In Figure 5 a model 
for the evolution of these proteins is presented. 
The earliest common ancestor of PNPase and the 
exosome most likely has been a protein contain-
ing a single RPD. Domain duplication of the 
RPD, followed by the addition of the KH and 
S1 domains might have resulted in a polypeptide 
displaying the same modular structure as present-
day PNPases (although the KH and S1 domains 
might have been attached already to the protein 
containing only one RPD). Shortly after RPD 
duplication, both copies of this domain have 
diverged with conservation of the exoribo-
nuclease activity in the second domain (RPD2). 
The N-terminal domains (RPD1) display less 
homology to the PDX family than RPD2 and 
the ancient RPD1 has therefore been suggested 
to have lost its exoribonuclease activity and may 
have acquired a new (enzymatic) activity (94). 
In eubacteria PNPases are still present, although 
these organisms often contain an additional 
RNase PH protein, which most likely originated 
from a duplication of the RPD2 of eubacterial 
PNPase. In archaea and eukaryotes, the domains 
of the ancient PNPase protein were separated in 
three individual proteins. Interestingly, the three 
exosome genes display a tandem arrangement 
in the genomes of many archaebacteria (86). 
Remarkably, in comparison with all PNPases the 
relative positioning of the S1 and KH domains 
has switched in all ‘descendants’, both archaeal 
and eukaryotic (referred to as the RRP4 exoribo-
nuclease family). In eukaryotes, a number of gene 
duplications led to the presence of six RPD con-
taining exosome subunits and three RRP4-type 
exosome proteins (of which one has lost the KH 
domain).  The hypothesis that eubacterial RNase 
PH originates from a duplication of RPD2 (and 
thus is exclusively present in eubacteria), and thus 
is only distantly related to the RPD-type exo-
some subunits, is supported by the observation 
that the RPD of eubacterial RNase PH has a 
higher degree of homology with the RPD2 of 
eubacterial PNPase than with eukaryotic exo-
some subunits (data not shown). Finally, PNPase 
was introduced into eukaryotes concomitant with 
the generation of mitochondria and chloroplasts. 
Later, a number of eukaryotes may have lost the 
PNPase gene during evolution.
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Exoribonuclease activity of human PNPase 
The divergence between the sequences of 
the two RPDs in PNPase has been suggested 
to refl ect a functional difference, in particular 
because only RPD2 appeared to contain an ac-
tive site similar to that of eubacterial RNase PH 
(94). To analyse which domains of the human 
PNPase contains ribonuclease activity, constructs 
were generated encoding either RPD1, RPD2 
or the combined KH and S1 domain, each fused 
to the C-terminus of GST. After expression and 
purifi cation the ribonuclease activity of the fu-
Figure 5. Model for the evolution of eukaryotic PNPase and the exosome.
A schematic overview of the evolutionary events leading from one common ancestor to the presence of both PNPase and 
the exosome in present day multicellular eukaryotes. Note that the α-helical domain of PNPase has been omitted from 
this model.
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sion proteins was analysed by incubation at 37°C 
with a uniformly 32P-labeled substrate RNA. As 
can been seen in Figure 6, both RPDs exhibited 
ribonuclease activity (panel A, lanes 5-10), in 
contrast to the KH/S1 domain (lanes 11-13) and 
GST alone (lanes 2-4). Remarkably, both RPDs 
appeared to degrade the substrate RNA in a 
different manner. The results are consistent with 
a processive exoribonuclease activity for RPD1 
and a distributive exoribonuclease activity for 
RPD2. Moreover, the activity of RPD1 appeared 
to be independent of phosphate, whereas that of 
RPD2 requires phosphate (results not shown). 
Previously, the RPD1 domain has been sug-
gested to be functionally distinct from RPD2 and 
RNase PH, since PNPase of S. antibioticus, which 
was crystallized in the presence of the phosphate 
analog tungstate, only showed incorporation of 
tungstate in RPD2 and not in RPD1 (94). Thus 
surprisingly, although being evolutionarily related 
to RNase PH, the RPD1 of PNPase seems to 
have lost its dependency for phosphate to degrade 
RNA.
In agreement with recently published data 
(111), also the full-length human PNPase displayed 
exoribonuclease activity in vitro, as demonstrated 
by the degradation of the substrate RNA by the 
PNPase-EGFP fusion protein immunoaffi nity-
purifi ed from transfected HEp-2 cell extracts. 
Degradation by the full-length PNPase appeared 
to proceed mainly in a processive manner (Figure 
6, panel B). In bacteria, PNPases generally display 
phosphate dependent processive activities and 
RNase PH distributive activities (104). 
With regard to the function of human 
PNPase in mitochondria, it has been described 
that stimulation of human cells with interferons 
leads to upregulation of PNPase (111) and a 
decrease in the levels of most of the 13 mitochon-
drial mRNAs (117), strongly suggesting a role 
for PNPase in the regulation of mitochondrial 
mRNA levels.
PNPase defi cient eukaryotes 
Although PNPase genes seem to be present 
in all multicellular eukaryotes (106), no genes en-
Figure 6. Exoribonuclease activity of human PNPase in vitro. 
Recombinant GST fusion protein of several PNPase domains (panel A) or material (co-)precipitated with anti-EGFP 
antibodies from HEp-2 cells expressing hPNPase-EGFP (panel B) was incubated with a uniformly 32P-labeled substrate 
RNA of 37 nucleotides. Samples were taken at the indicated time points and analyzed by denaturing polyacrylamide gel 
electrophoresis and autoradiography. Either GST alone (panel A) or GFP alone (panel B) was used as a negative control.
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coding PNPase homologues exist in the genomes 
of S.  cerevisiae or Schizosaccharomyces pombe. 
 The mitochondria of S. cerevisiae, however, 
are known to contain a different enzyme-com-
plex involved in the degradation of RNA, the 
mitochondrial degradosome (also designated 
mtEXO complex). This complex contains an 
exoribonuclease belonging to the RNR family 
(MSU1) in addition to an RNA helicase (118). 
Apparently, in comparison with multicellular 
eukaryotes, which do not encode an obvious 
homologue of MSU1, the mitochondria of yeast 
have developed an alternative machinery for the 
degradation of RNA. Interestingly, the organism 
which is believed to be most closely related to 
eukaryotic mitochondria, R. prowazekii, does not 
contain genes encoding RNR family exoribo-
nucleases, but, as described above, does contain 
a PNPase gene. The apparent difference in the 
mitochondrial RNA degradation machinery 
between yeasts and multicellular eukaryotes 
is diffi cult to explain. A possibility is that the 
eubacterial ancestor of mitochondria contained 
exoribonucleases of both the PDX and RNR 
families and that eukaryotes have lost one of these, 
PDX in yeasts and RNR in other eukaryotes. 
Similarly, R. prowazekii may have lost the RNR-
type exoribonuclease. Another possibility is that 
the RNR-type gene in yeasts is of nuclear instead 
of mitochondrial origin. 
The eukaryotic PDX- and RNR-type exo-
ribonucleases are all encoded by nuclear genes. 
This is probably the result of the transfer of genes 
from the mitochondrial to the nuclear genome by 
horizontal gene transfer, which is very common 
for genes encoding mitochondrial proteins.   
Concluding remarks
The observation that all organisms with 
completely sequenced genomes (except for 
M. jannaschii) appear to encode RNA degrading 
enzymes similar to PNPase and/or RNase II / 
RNase R underscores the essential role of these 
enzymes for life on earth. Especially the PDX 
family-based RNA degradation machinery (in 
the form of either PNPase or the exosome) is 
widely spread throughout all three domains of 
life, eubacteria, archaebacteria and eukaryotes. 
The presence of these proteins in eukaryotic 
organelles is most likely required for the degrada-
tion and processing of RNAs encoded by the 
organellar genomes.  Very recently it has been 
reported that overexpression of human PNPase 
in melanoma cells leads to cell-cycle arrest and 
apoptosis, following down-regulation of the 
nuclear-encoded gene c-myc, similar to the 
effects of retinoic acid-induced cell cycle arrest 
(119). Since retinoic acids are known to lead to 
mitochondrial instability prior to apoptosis (120), 
the overexpression of human PNPase might lead 
to similar mitochondrial defects, followed by 
apoptosis.
Although our current knowledge on eu-
karyotic PNPases is consistent with the theory 
that mitochondria and chloroplasts have evolved 
from symbiotic eubacteria, it remains unclear 
why some eukaryotes have developed a com-
pletely different machinery for mitochondrial 
RNA degradation (PNPase based in multicellular 
eukaryotes, RNase R based in yeasts). 
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Material and Methods 
Transient transfection of HEp-2 cells and fl uorescence 
microscopy
All transfections were carried out as described before 
(106). Briefl y, the open reading frame of human PNPase 
was cloned into the pEGFP-N3 vector (Clontech), in frame 
with the enhanced green fl uorescent protein (EGFP). Ap-
proximately 2 x 106 cells  were transfected with 10-20 µg 
of DNA in 800 µl of DMEM containing 10% FCS by 
electroporation. After transfection, cells were seeded onto 
coverslips and cultured overnight. Cells were washed twice 
with PBS and mounted in colourless medium. To allow 
visualization of mitochondria, cells were incubated with 
MitoTracker-Red CMX Ros (Molecular Probes), diluted 
1:25,000 in medium for 3 minutes prior to analysis. Con-
focal fl uorescence microscopy was performed using a Leica 
DM IRBE confocal microscope with living cells.
Expression and purifi cation of recombinant proteins
The GST (fusion) proteins were expressed in 
bacteria and purifi ed as described previously (87). After 
expression and affi nity-purifi cation by gluthatione-Sepha-
rose chromatography, recombinant proteins were further 
purifi ed by ammoniumsulfate precipitation to remove all 
traces of bacterial ribonuclease activity. Finally, the proteins 
were dissolved in PBS.
Immunoprecipitation
Polyclonal rabbit antibodies were coupled to Protein 
A-agarose beads (Biozym) in IPP500 (500 mM NaCl, 
10 mM Tris-HCl, pH 8.0, 0.05% NP-40) by incubation 
for 2 h at room temperature. Beads were washed twice 
with IPP500 and once with IPP150 (150 mM NaCl, 
10 mM Tris-HCl, pH 8.0, 0.05% NP-40). For each im-
munoprecipitation, cell extract was incubated with the 
antibody-coupled beads for 1 h at 4°C. Subsequently, beads 
were washed three times with IPP150 and two times with 
buffer A (10 mM Tris-HCl, pH 7.5, 50 mM KCl, 5 mM 
MgCl
2
, 1 mM Na
2
HPO
4
).
Exoribonuclease activity assay
Substrate solution (approx. 100 ng 32P-labeled 
substrate in 40 µl buffer A) was added to the immu-
noprecipitates or to approximately 10 µg of purifi ed 
recombinant protein and the samples were incubated at 
37 °C with gentle agitation. Formamide loading buffer 
was added to 10 µl samples taken at regular intervals and 
these were immediately frozen. Samples were analyzed by 
denaturing polyacrylamide gel electrophoresis followed by 
autoradiography. Substrate RNA was generated by in vitro 
transcription in the presence of [32P]UTP, using T3 RNA 
polymerase and an XbaI-linearized pBS(-) (Stratagene) 
plasmid as template.
Bioinformatics
Multiple alignments of PNPase and exosome 
amino acid sequences were generated with ClustalW, using 
BLOSUM30 substitution matrices. To obtain a reliable 
alignment of exosome subunits and PNPase proteins, the 
exact position of the RNase PH and S1 domains in these 
proteins was determined using Pfam (96). The amino acid 
sequences of these domains were subsequently combined 
into a single pseudoprotein, which was used in the align-
ment. The phylogram was generated using TreeView. The 
presence of specifi c genes in the fully sequenced genomes 
of prokaryotes was analysed using the database of COGs 
(Clusters of Orthologous Groups) (108) and the Search 
Tool for the Retrieval of Interacting Genes/Proteins 
(STRING) at the EMBL (109). Secondary structure pre-
dictions were performed using the PSIPRED algorithm 
(110).
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Introduction
The PM/Scl-75 protein (encoded by gene 
PMSCL1) was the fi rst protein of the PM/Scl 
complex to be characterized (8). The PM/Scl 
complex was originally described as a complex 
consisting of 11-16 proteins, some of which are 
autoantigenic in autoimmune patients. Autoan-
tibodies to this complex are most frequently 
found in patients suffering from polymyositis/
scleroderma (PM/Scl) overlap syndrome, but are 
also present in some patients with myositis or 
scleroderma alone (5,6). The subunits PM/Scl-
75, PM/Scl-100 and hRrp4p have been shown 
to carry the main autoantigenic determinants 
for polymyositis/scleroderma overlap syndrome 
autoantibodies (78,79). Following the identi-
fi cation of two of its subunits, PM/Scl-75 and 
PM/Scl-100 (7,9) and their characterization 
as putative exoribonucleases (10) the PM/Scl 
complex was shown to be related to the yeast 
exosome, a complex containing approximately 10 
exoribonucleases (11).
The exosome functions in a variety of 
processes involving the 3’→5’  processing or 
degradation of RNA. Among these processes 
are the maturation of 5.8S rRNA (12,31,32), the 
processing of many small nuclear and nucleolar 
RNAs (33,38,42) and the turnover of differ-
ent types of mRNAs (82,83), especially ARE 
(AU-rich element) containing mRNAs (17,57). 
PM/Scl-75 has been suggested to be an AU-rich 
element binding protein (AUBP), involved in 
the recruitment of the exosome to this class of 
mRNAs (57).
Like fi ve other exosome proteins, PM/
Scl-75 contains an RNase PH domain, which 
is homologous to the prokaryotic 3’-5’ exo-
ribonuclease RNase PH. Based on mutual 
interactions between exosome components and 
structural similarity with the bacterial protein 
polynucleotide phosphorylase (PNPase), a com-
ponent of the bacterial degradosome, recently a 
model for the structure of the human exosome 
was generated. In this model the six proteins con-
taining an RNase PH domain (RPD) form the 
The exosome is a complex of 3′ → 5′ exoribonucleases, which functions in a va-
riety of cellular processes, all concerning the processing or degradation of RNA. 
Paradoxically, the previously described cDNA for the human autoantigenic exo-
some subunit PM/Scl-75 (Alderuccio et al. (1991) J.Exp.Med. 173, 941-952) 
encodes a polypeptide that failed to interact with the exosome complex. Here, we 
describe the cloning of a more complete cDNA for PM/Scl-75 encoding 84 addi-
tional amino acids at its N-terminus. We show that only the longer polypeptide is 
able to associate with the exosome complex. This interaction is most likely medi-
ated by protein-protein interactions with two other exosome subunits, hRrp46p 
and hRrp41p, one of which was confi rmed in a mammalian 2-hybrid system. In 
addition we show that the putative nuclear localization signal present in the 
C-terminal region of PM/Scl-75 is suffi  cient, though not essential for nuclear 
localization of the protein. Moreover, the deletion of this element abrogated the 
nucleolar accumulation of PM/Scl-75, although its association with the exo-
some was not disturbed. This suggests that this basic element of PM/Scl-75 
plays a role in targeting the exosome to the nucleolus.
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core of the exosome, which adopts a hexameric 
ring structure (106). 
Cloning of a cDNA encoding the human 
PM/Scl-75 protein revealed an acidic polypep-
tide sequence of only 39.2 kDa. Its migration 
at 75 kDa in SDS-PAGE was explained by its 
highly charged C-terminal half (8). In immun-
ofl uorescence experiments the protein showed 
mainly nucleolar localization (8), although it 
was also found to be present in the cytoplasm 
and nucleoplasm of human cells (57). The N-
terminal half of the protein shows homology 
to the bacterial RNase PH protein (10) and the 
C-terminal half is characterized by a region of 
approximately 100 amino acids highly enriched 
in acidic residues. Close to the C-terminus a pu-
tative nuclear localization signal (NLS) is located 
consisting of seven basic residues (KRRKKKR) 
(8). This cDNA of PM/Scl-75 has been used in 
a number of transfection experiments to study 
its subcellular localization and association with 
the exosome. Although similar experiments with 
most other exosome components were successful, 
EGFP fusion proteins of PM/Scl-75 were unable 
to enter the nucleolus and PM/Scl-75 failed to 
interact with other exosome components in a 
mammalian 2-hybrid system (106).
Here, we show that the previously described 
protein sequences of PM/Scl-75 are most likely 
incomplete. We have cloned and characterized 
additional cDNAs encoding PM/Scl-75 that in 
comparison with the original sequence, encode 
84 additional amino acid residues at its N-termi-
nus. In contrast to the previously described PM/
Scl-75 polypeptide, this longer variant appeared 
to be able to associate with the exosome and to 
accumulate in the nucleolus.
Results
Amino acid  sequence of PM/Scl-75
Several amino acid sequences for the human 
PM/Scl-75 polypeptide have been reported pre-
viously. Besides the fi rst sequence ever described 
(here referred to as PM/Scl-75a-α, acc. number 
M58460) (8) a splicing variant containing the se-
quence encoded by an additional exon (‘PM/Scl-
75a-β’, acc. number HSU09215) and a sequence 
containing 68 additional amino acid residues at 
the N-terminus (‘PM/Scl-75b-α’, acc. number 
Q06265) have been reported. Moreover, the 
sequence reported for Mus musculus PM/Scl-75 
(acc. number Q9JHI7) contains, compared to the 
human PM/Scl-75a-α, 84 additional amino acids 
residues at the N-terminus (122). The reported 
heterogeneity in sequences for the N-terminal 
region of the human PM/Scl-75 prompted us to 
screen the human EST (expressed sequence tag) 
databases with the available human and mouse 
PM/Scl-75 cDNA sequences. These analyses 
demonstrated that in humans PM/Scl-75 se-
quences are expressed that fully correspond to the 
N-terminal region of the mouse protein. Thus, 
in comparison with PM/Scl-75a also the human 
protein may contain 84 additional amino acids. 
Based upon these data extended open reading 
frames for the human PM/Scl-75 were gener-
ated (‘PM/Scl-75c-α’ and ‘PM/Scl-75c-β’) and 
submitted to the EMBL database under accession 
numbers AJ505989 and AJ517294. Figure 1A 
shows the sequence of PM/Scl-75c in which the 
differences with previously described PM/Scl-75 
sequences are indicated. In Figure 1B a schematic 
overview of the human polypeptides and their 
mRNAs is shown. It is important to note that 
PM/Scl-75a lacks a signifi cant part of the RNase 
PH domain (RPD) as predicted by Pfam (96). 
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Figure 1. The different isoforms of PM/Scl-75.
A. Overview of the sequence of PM/Scl-75, in which the N-termini of the different isoforms are indicated (arrows and 
sequence in italics), as well as the position of the sequence encoded by the extra exon 10* (sequence in italics indicated 
by PM/Scl-75-α/β). The RNase PH domain (underlined) and the putative NLS sequence (in bold) are also marked in 
the sequence. B. Schematic representation of the domains present in the different isoforms of the PM/Scl-75 protein. The 
RNase PH domain (which is incomplete in PM/Scl-75a), the negatively charged region, the site at which the amino acids 
encoded by the extra exon 10* are inserted in PM/Scl-75-β and the putative nuclear localization signal (NLS) are indicated. 
Below the proteins schematic representations of the corresponding mRNAs are shown. The relative lengths of the coding 
sequence (CDS), the 5’ and 3’ untranslated regions (UTR) and the number of thymidine residues in the thymidine stretch 
are indicated. C. A schematic overview of the fi rst 4 exons (1-4) of the PMSCL1 gene, its putative transcription initiation 
sites (marked ‘>’) and mode of splicing, leading to the various N-terminally different forms of PM/Scl-75. The fi rst four 
amino acids of these ORFs (a, b, and c) are indicated. D. A schematic overview of the last 4 exons (10, 10*, 11 and 12) of 
the PMSCL1 gene and its mode of splicing, leading to the α and β isoforms of PM/Scl-75. The exon present only in the
β form of PM/Scl-75 is designated exon 10* (‘*’ in the fi gure). The stop codon (TAA) is located in exon 12.
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The RPD is expected to be important for the 
interactions of PM/Scl-75 with other exosomal 
proteins in the core of the exosome (106).
When the cDNA sequences are compared 
with the human genome, it is clear that the 
difference between the sequences is due to the 
use of an apparent alternative promotor in the 
PM/Scl-75 gene or to alternative splicing of the 
PM/Scl-75 pre-mRNA, as is illustrated in Figure 
1C. The 5’-end of the cDNAs of PM/Scl-75c is 
encoded by an alternative fi rst exon and lacks the 
fi rst 234 nucleotides of the fi rst exon of PM/Scl-
75a. The protein sequence of PM/Scl-75b was 
derived from a cDNA very similar to that of 
PM/Scl-75a. The PM/Scl-75b cDNA contains 
a stretch of 8 instead of 7 thymidine residues 
at position 395-402 (which may be due to a 
sequencing error of the original clone), leading to 
a longer open reading frame (122). To investigate 
which of the corresponding mRNAs are actually 
expressed in human cell lines, RNA isolated from 
HEp-2, HeLa, 293, Jurkat and MOLT-4 cells was 
analysed by RT-PCR using primers specifi c for 
the PM/Scl-75a/b and PM/Scl-75c mRNAs. 
Both mRNAs were found to be present in all 
cells lines (results not shown). To discriminate 
between PM/Scl-75a and PM/Scl-75b, the RT-
PCR products were cloned and sequenced. The 
results showed that the T-stretch consisted of 8 
thymidine residues in all cases, indicating that the 
expressed mRNA corresponds to PM/Scl-75b. 
Strikingly, however, no evidence for the exist-
ence of mRNAs encoding either PM/Scl-75a 
or PM/Scl-75b was found in the EST databases, 
strongly suggesting that PM/Scl-75c is the most 
abundantly expressed isoform of the protein. 
To generate cDNAs encoding PM/Scl-75c, we 
performed PCR on human teratocarcinoma and 
placenta cDNA libraries using primers specifi c 
for the 5’ region of PM/Scl-75c. The PCR prod-
ucts obtained were sequenced and found to be 
identical to the sequence of the cDNA encoding 
PM/Scl-75c as derived from the EST databases.
The polypeptides encoded by the PM/Scl-
75a-α and PM/Scl-75c-α cDNAs were produced 
by in vitro transcription/translation and their 
migration in SDS-PAGE gels was compared with 
that of PM/Scl-75 from a cytoplasmic HeLa cell 
extract, which was detected by immunoblotting 
using anti-PM/Scl-75 rabbit antibodies (Figure 
2). The results showed that the migration of 
Figure 2. The electrophoretic mobility of in vitro 
translated PM/Scl-75c-α is similar to that of HeLa 
cell PM/Scl-75. 
In vitro translated, 35S-labelled PM/Scl-75a-α (lane 1) 
and PM/Scl-75c-α (lane 2) were separated by SDS-
PAGE in parallel with a cytoplasmic HeLa cell extract 
(lane 3) and transferred to a nitrocellulose blot. In vitro 
translated proteins were visualized by autoradiography 
and the lane containing the HeLa cell proteins was 
stained by immunoblotting using rabbit anti-PM/Scl-75 
antibodies (note that PM/Scl-75-β is underrepresented 
in cytoplasmic HeLa extracts, as demonstrated in Figure 
6). The position of molecular weight markers in the gel is 
indicated on the left.
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PM/Scl-75c was identical to that of HeLa cell 
PM/Scl-75. The migration of in vitro translated 
PM/Scl-75a was clearly different, in agreement 
with previous observations (8). 
To investigate the occurrence of the extra 
exon (‘10*’) that is present in the β variant of 
PM/Scl-75 (Figure 1D, exon a), the Genbank 
EST database was screened for sequences con-
taining the exon-exon junctions 10*-11 and 
10-11. In total, 52 ESTs encompassing this region 
were identifi ed, 10 of which contained exon 10*, 
indicating that both splice variants of PM/Scl-75 
are expressed, but that the isoform lacking exon 
10* may be more abundant. 
Taken together, these results indicate that 
PM/Scl-75c-α is the predominant isoform of 
PM/Scl-75, but that at least four splice variants 
exist, which differ by their N-terminus and the 
presence or absence of 17 amino acids encoded 
by exon 10*.
The subcellular localization of PM/Scl-75 
To investigate the subcellular localization 
of PM/Scl-75 polypeptides, constructs encoding 
Figure 3. Subcellular localization of PM/Scl-75. 
HEp-2 cells were stained by immunofl uorescence using 
rabbit anti-PM/Scl-75 antibodies (A). Panels B-G show 
HEp-2 cells transfected with constructs encoding EGFP 
fusion proteins of PM/Scl-75a-α (B), PM/Scl-75c-α (C), 
PM/Scl-75c-β (D), PM/Scl-75a-α ∆NLS (E), PM/Scl-
75c-α ∆NLS (F) and the NLS of PM/Scl-75 (G). After 
overnight culturing cells were fi xed and the expressed 
fusion proteins were visualized by fl uorescence microscopy. 
The corresponding phase-contrast images  are shown on 
the right of each fl uorescence image. Each bar represents 
10 µm.
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PM/Scl-75a-α, PM/Scl-75c-α and PM/Scl-75c-
β tagged with EGFP (enhanced green fl uorescent 
protein) were generated. The fusion proteins were 
expressed in transiently transfected HEp-2 cells 
and as a control the endogenous PM/Scl-75 
protein in  HEp-2 cells was visualized by im-
munofl uorescence using rabbit anti-PM/Scl-75 
antibodies. Whereas the highest concentration 
of the endogenous PM/Scl-75 protein was 
found in the nucleoli (Figure 3, panel A), EGFP-
PM/Scl-75a-α failed to enter the nucleoli and 
accumulated in the nucleoplasm (Figure 3, panel 
B). In contrast, EGFP-tagged PM/Scl-75c-α and 
PM/Scl-75c-β effi ciently entered the nucleolus 
of HEp-2 cells (Figure 3, panels C and D. These 
data indicate that the N-terminal 84 amino acids 
of PM-Scl-75c are important for nucleolar accu-
mulation and that the 17 amino acids encoded by 
exon 10* do not affect this process. To investigate 
whether the N-terminal region of PM/Scl-75c is 
suffi cient for nucleolar targeting, the N-terminal 
98 amino acids of PM/Scl-75c were fused to 
the N-terminus of EGFP and the subcellular 
localization of this fusion protein was analyzed in 
transfected HEp-2 cells. This fusion protein dis-
tributed throughout HEp-2 cells, similar to EGFP 
alone (data not shown). Previously, a sequence 
element (KRRKKKR) with similarity to nuclear 
Figure 4. Association of PM/Scl-75 with the human exosome.
A. Co-immunoprecipitation experiments were performed using anti-EGFP antibodies and extracts of transfected HEp-2 
cells expressing either EGFP alone (lane 1) or EGFP-fusion proteins of hCsl4p, PM/Scl-75a-α, PM/Scl-75a-α ∆NLS, 
PM/Scl-75c-α or PM/Scl-75c-α ∆NLS (lanes 2-6). Lane 7 contains proteins immunoprecipitated by anti-PM/Scl-75 
rabbit antibodies from a nuclear HeLa cell extract. (Co-immunoprecipitated) proteins were visualized by immunoblotting 
using an anti-PM/Scl positive patient serum (Ven96). Arrows indicate the positions of co-precipitated autoantigenic 
exosomal proteins. The positions of molecular weight markers are indicated on the left.
B. A similar experiment as described above was performed using transfected HEp-2 cells expressing either EGFP alone 
(lane 1), PM/Scl-75c-α (lane 2) or PM/Scl-75c-β (lane 3). 
71
5
Characterization of the complete PM/Scl-75 protein
localization signals (NLSs) has been reported to 
reside at the C-terminal end of PM/Scl-75 (8). 
To investigate the role of this element in nuclear 
and nucleolar entry, mutants of PM/Scl-75a-α
and PM/Scl-75c-α lacking the C-terminal 39 
amino acids were generated (∆NLS). As can be 
seen in Figure 2E, PM/Scl-75a-α ∆NLS failed 
to enter the nucleus. Remarkably, PM/Scl-75c-α
∆NLS still was transported to the nucleus, but was 
unable to enter the nucleolus (Figure 2F). Finally, 
an EGFP fusion protein was expressed containing 
only the C-terminal 39 amino acids of PM/Scl-
75. Figure 2G shows that this element is suffi cient 
for transportation of EGFP to the nucleus. These 
data show that both N- and C-terminal elements 
of PM/Scl-75 are involved in its nuclear entry 
and that the C-terminal elements (also) play a role 
in nucleolar targeting.
The association of PM/Scl-75 with the exosome
In addition to elements directly involved in 
subcellular transport processes, also the association 
with the exosome may play a role in the subcel-
lular localization. To investigate the effect of the 
mutations on the association with the exosome, 
immunoprecipitations with anti-EGFP antibod-
ies were performed using lysates of HEp-2 cells 
transfected with constructs encoding the EGFP-
tagged PM/Scl-75 mutants. The immunoprecipi-
tated material was analyzed by western blotting, 
using a human serum (Ven96) reactive with 
several exosome proteins (including PM/Scl-100, 
PM/Scl-75, hRrp4p, hRrp41p and hRrp42p). 
The patient serum stained the different PM/Scl-
75 fusion proteins very effi ciently, which shows 
that all variants/mutants were expressed at similar 
levels. The results showed that many endogenous 
exosome proteins (although PM/Scl-100 was not 
detected in the immunoprecipitates) co-precipi-
tated with both PM/Scl-75c-α and PM/Scl-75c-
α∆NLS, but not with PM/Scl-75a-α (Figure 4a). 
In a similar type of experiment we demonstrated 
that both the α and β form of PM/Scl-75c can 
be incorporated in the exosome complex (Figure 
4b). 
Previously, we demonstrated that PM/Scl-
75a-α was not able to interact directly with any 
other exosome component in a mammalian 
two-hybrid system, although its yeast counter-
part (Rrp45p) is known to interact with yeast 
Rrp41p (106).The full-length cDNAs encoding 
PM/Scl-75a-α, PM/Scl-75c-α and 10 (putative) 
human exosome components (hRrp4p, hRrp40p, 
hRrp41p, hRrp42p, hRrp46p, PM/Scl-100, 
hCsl4p, hRrp44p/hDis3p, OIP2 and hMtr3p) 
were cloned in both the pACT (in-frame with 
the sequence encoding the VP16 transcription 
Figure 5. Two-hybrid interactions between PM/
Scl-75a-α, PM/Scl-75c-α and other exosomal 
proteins. 
COS-1 cells were cotransfected with constructs encoding 
PM/Scl-75a-α, PM/Scl-75c-α and other exosomal 
proteins, fused to either the VP16 transcription activation 
domain (pACT constructs) or the GAL4 DNA binding 
domain (pBIND constructs), simultaneously with a 
reporter plasmid. The resulting luciferase activity is 
depicted in relative luminescence units (RLU). The activity 
observed for the combination of hRrp42p in pBIND and 
hCsl4p in pACT was defi ned as 100 RLU (88).
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activation domain) and pBIND (in-frame with 
the sequence encoding the GAL4 DNA binding 
domain) vectors of the Checkmate Mammalian 
Two-Hybrid system. COS-1 cells were co-trans-
fected with each pair of these constructs and after 
40-48 hours the luciferase activity of extracts 
prepared from these cells was determined. This 
revealed that, in contrast to PM/Scl-75a-α, 
PM/Scl-75c-α fused to the GAL4 DNA binding 
domain was able to interact with hRrp41p fused 
to the VP16 activation domain (Figure 5). This 
interaction was confi rmed by a complementary 
experiment in which the fusion domains were 
exchanged (data not shown). The interaction 
of PM/Scl-75c with hRrp41p adds further 
evidence to the model for the human exosome, 
in which PM/Scl-75 is fl anked by hRrp41p and 
hRrp46p (106).
Alternative splicing of PM/Scl-75
As can be seen in Figures 3 and 4, the sub-
cellular localization and exosome association of 
the PM/Scl-75c-β isoform, containing the extra 
exon 10*, in living cells was indistinguishable 
from that of the PM/Scl-75c-α isoform. The 
data from the EST libraries (see above) suggested 
that the α isoform is more abundantly expressed 
than the β isoform. To shed more light on this 
issue, we studied their expression in several cell 
lines by western blotting. The ratio between the 
amounts of the α and β isoforms appeared to vary 
signifi cantly between different cell lines, although 
in most cells analyzed PM/Scl-75-α was at least 
as abundant as PM/Scl-75-β. Figure 6 shows 
that in Jurkat, HeLa and HEp-2 cells (lanes 1-3) 
the amount of both isoforms is comparable. In 
COS1 and 293 cells (lanes 4-5) the α isoform of 
PM/Scl-75 appears to be the most abundant one. 
In HeLa cells, the relative level of PM/Scl-75-β
was signifi cantly higher in nuclear extracts than in 
cytoplasmic extracts (lanes 6-7), suggesting a pre-
dominant nuclear localization for PM/Scl-75-β.
Discussion
In this study we have shown that the previ-
ously reported cDNA and amino acid sequences 
for the human polymyositis/scleroderma autoan-
tigen PM/Scl-75 are probably incomplete. We 
cloned a cDNA with an extended N-terminus 
and only the longer form of PM/Scl-75 was able 
to associate with the exosome complex, to inter-
act with at least one other exosome subunit and 
to enter the nucleolus, three functional activities 
that are shared with other exosome subunits. The 
presence of exon 10* in the coding sequence of 
PM/Scl-75 (observed in a previously reported 
splice variant) did not affect the behavior of PM/
Scl-75 with regard to its subcellular localization 
and exosome association. In addition, PM/Scl-75 
was shown to contain both N- and C-terminal 
Figure 6. The PM/Scl-75-α and β splice variants 
are expressed in various cell lines.
Western blots containing extracts of several cell lines 
were stained with rabbit anti-PM/Scl-75 antibodies. 
Total cell extracts of Jurkat, HeLa, HEp2, COS1 and 293 
cells are shown in lanes 1-5. Lanes 6 and 7 contain HeLa 
cytoplasmic and nuclear extract, respectively. The positions 
of molecular weight markers are indicated on the left and 
the positions of the α and β isoforms on the right.
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elements involved in its nuclear localization, the 
latter of which also appeared to be responsible for 
nucleolar accumulation of this protein.
The amino acid sequence of PM/Scl-75 
The cDNA of PM/Scl-75a-α (8) lacks the 
fi rst exon compared to the cDNA of PM/Scl-
75c-α and as a consequence the open reading 
frame starts at another methionine. Note that the 
5’ end of the PM/Scl-75b-α cDNA is identical 
to that of PM/Scl-75a-α, with the exception of 
one additional nucleotide in the former, leading 
to a longer open reading frame in the 5’ region 
(122). The expression of mRNAs corresponding 
to these two types of cDNAs is most likely due to 
the existence of alternative promoters and tran-
scription initiation sites in the gene of this protein 
(see Figure 1C). In contrast to PM/Scl-75c-α the 
expression of PM/Scl-75a-α and PM/Scl-75b-α 
mRNAs is not supported by entries in the EST 
databases. A TBLASTN search of the human 
EST database with the N-terminal 80 amino 
acids of the mouse sequence resulted in 49 out 
of 50 hits that fully matched the N-terminus of 
the additional sequence. No ESTs were observed 
encoding the sequence corresponding to the 
N-terminus of PM/Scl-75a or PM/Scl-75b. 
Nevertheless, the latter was detected in several 
cell lines by RT-PCR, followed by sequencing of 
the products. 
The lack of expression of  PM/Scl-75a-α 
is supported by the observation that the cor-
responding in vitro translated protein migrates 
faster than the PM/Scl-75 protein from HeLa 
cells (Figure 2) (8). However, immunoblotting of 
primate cell extracts with rabbit anti-PM/Scl-75 
antibodies revealed several minor polypeptide 
bands, including one with an apparent molecular 
mass of approximately 60 kD (Figures 2 and 6), 
which is similar to the migration of PM/Scl-
75a-α. Taken together, these data suggest that 
the N-terminal region of the major PM/Scl-75 
isoform corresponds to the sequence encoded 
by PM/Scl-75c-α and that as a result of an al-
ternative promoter PM/Scl-75b-α is produced. 
The expression of mRNAs either containing or 
lacking exon 10* (Figure 1D) is supported by a 
series of database entries and thus is consistent 
with the expression of two splicing variants 
(designated α and β). Western blot analyses of 
extracts of several primate cell lines indeed show 
a doublet for PM/Scl-75, in agreement with the 
simultaneous expression of these splice variants in 
a variety of cells. Interestingly, the results of HeLa 
cell fractionation experiments suggested that the 
β isoform might accumulate somewhat more ef-
fi ciently in the nucleus than the α isoform.
Transport of PM/Scl-75 to nucleus and 
nucleolus
Previously, the C-terminal element of PM/
Scl-75, rich in basic amino acids, was proposed 
to be a nuclear localization sequence. Here, we 
have shown that this element indeed can direct 
a reporter protein to the nucleus. However, this 
element did not appear to be essential for nuclear 
import of PM/Scl-75, as long as PM/Scl-75 was 
able to interact with the rest of the exosome 
complex. On the other hand, the basic sequence 
element of PM/Scl-75 is important for nucleolar 
accumulation of this protein. Based upon the 
presence of putative NLS sequences in at least 
two other exosome proteins, hRrp41p (aa 85-
90, ‘ERKRRP’) and PM/Scl-100 (aa 752-758, 
‘AKKRERA’) two mechanisms for nuclear 
entry of the exosome can be envisaged. First, the 
nuclear import of the completely assembled exo-
some may be mediated by the concerted action of 
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several signals. Second, partially assembled parts of 
the exosome may enter the nucleus and assemble 
into a complete exosome in the nucleoplasm or 
nucleolus. All these basic elements may also be 
involved in nucleolar targeting of the exosome, 
because elements rich in basic residues have been 
demonstrated to play an essential role in nucleolar 
accumulation (123).
Association of PM/Scl-75 with the exosome
The direct interaction between PM/Scl-75c 
and hRrp41p supports the model for the human 
exosome that we recently proposed, as illustrated 
in Figure 7 (106). The minor isoform of the pro-
tein, PM/Scl-75b, most likely is also capable of 
interacting with hRrp41p and the exosome, 
because it contains the complete RNase PH 
domain (Figure 1b). Another interaction pre-
dicted by that model, between PM/Scl-75 and 
hRrp46p (Figure 7), could not be detected in 
the mammalian two-hybrid system. PM/Scl-75 
represents together with hRrp41p the equiva-
lent of one PNPase subunit in the structurally 
related PNPase trimer and the two RNase PH 
domains of PNPase interact with each other via 
their most C-terminal sequences. The failure of 
PM/Scl-75 to interact with its putative neighbor 
hRrp46p, which is predicted to be mediated 
by the N-terminal regions of their RNase PH 
domains, might be due to the fact that also the 
hRrp46p cDNA that was used is incomplete. Very 
recently an alternative sequence for hRrp46p was 
published (80), which contains an N-terminus 
with 33 additional amino acids. Although the 
complete RNase PH domain is present in the 
original sequence of hRrp46p, it is possible that 
some fl anking amino acids might be required for 
the interaction with PM/Scl-75, either by mak-
ing direct contacts or by stabilizing the proper 
conformation of the RNase PH domain. Another 
explanation might be the possible interference of 
the fusion parts of the mammalian two-hybrid 
constructs, which are both attached to the N-
terminus of the proteins to be analyzed. Whether 
the AU binding properties of PM/Scl-75 (19) are 
also infl uenced by the extra N-terminal sequence 
remains to be investigated, although this activity 
is most likely mediated by the C-terminal part 
of the protein, because the RNase PH domain 
is responsible for the interaction of the protein 
with the exosome complex. Since no functional 
differences were found between the splice vari-
ants PM/Scl-75-α and PM/Scl-75-β and both 
PM/Scl-75b and PM/Scl-75c contain the 
complete RNase PH domain, the function of this 
multiplicity of PM/Scl-75 splice variants remains 
to be identifi ed, although the function of the β
form might be specifi c for the nucleus given its 
increased nuclear accumulation.
Figure 7. Model of the human exosome and the 
identifi ed protein-protein interactions.
This model is based on previously described protein-
protein interactions (dotted lines) (106) and the interactions 
of PM/Scl-75 identifi ed in this study (solid lines). Double 
lines indicate interactions identifi ed in both directions in 
the two-hybrid system.
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Materials and Methods
cDNA cloning and construction of deletion mutants
All cDNAs used were cloned into pACT and 
pBIND vectors (Promega) or suitable pEGFP vectors 
(Clontech) by PCR or via available restriction sites. 
The database accession numbers of the cDNAs used are 
BC000747 (hRrp4p), AF281132 (hRrp40p), AF281133 
(hRrp41p), D29958 (hRrp42p), AF281134 (hRrp46p), 
M58460 (PM/Scl-75a), L01457 (PM/Scl-100), AF151866 
(hCsl4p), R27667 (hDis3p), AF025438 (OIP2) and NM_
058219 (hMtr3p). The sequences of the cDNAs encoding 
PM/Scl-75c-α and PM/Scl-75c-β were submitted under 
accession numbers AJ505989 and AJ517294, respectively. 
Deletion mutants of PM/Scl-75 were constructed using 
suitable internal restriction sites. 
Bioinformatics
Predictions of functional domains and putative 
nuclear localization signals (NLSs) were done using the 
Pfam database of Hidden Markov Models (96) and the 
PredictNLS server (121), respectively. Sequence database 
searching was performed using BLAST on GenBank 
databases containing either ESTs or genomic sequence 
information.
Immunoblot analysis
For immunoblot analysis, proteins were separated by 
SDS-PAGE, and transferred to nitrocellulose membranes. 
To visualize the proteins, blots were incubated with 
autoimmune patient or rabbit sera, diluted 5000- and 
500-fold, respectively, in blocking buffer (4% skimmed 
milk, phosphate-buffered saline (PBS), 0.1% NP-40). As 
secondary antibody, horseradish peroxidase-conjugated 
rabbit-anti human IgG or swine anti-rabbit IgG (Dako 
Immunoglobulins) were used, 5000-fold diluted in 
blocking buffer. Visualization was performed by chemilu-
minescence.
In vitro translation
Radioactively labeled proteins were produced using 
the Reticulocyte Lysate System (Promega) according to 
the manufacturer’s procedure, in a total volume of 25 µl, 
containing approximately 1 µg of circular plasmid DNA 
(pCI-neo, Promega), containing the coding sequence of 
the protein, and in the presence of  [35S]methionine.
Reverse transcriptase-polymerase chain reaction 
(RT -PCR)
RNA was isolated from cells using Trizol reagent 
(Gibco BRL) according to the manufacturers instructions. 
Synthesis of cDNA from 1 µg of RNA was performed 
using the Reverse Transcription System (Promega) with 10 
pmol of PM/Scl-75 specifi c primer. The reaction mixture 
was incubated for 10 min at room temperature, followed 
by 90 min at 42°C. For RT-PCR 1 µl cDNA was added 
to 49µl mastermix containing 75 mM Tris-HCl, pH 8.8, 
20 mM (NH
4
)
2
SO
4
, 0.01% (v/v) Tween-20, 2 mM MgCl
2
, 
0.2 mM dNTPs, 20 pmol forward and reverse primer and 
8 U Taq DNA polymerase. PCR was performed using a 
T3 thermocycler (Biometra): 2 min 94°C, 35 cycles of 
(30 s, 94°C; 30 s, 60°C; 30 s, 72°C), 5 min 72°C. 10 µl 
PCR product was analyzed on a 1.5% agarose gel. The 
following primers were used: RT primer 5’-CAGGT-
GTAGAAACAACTTCTGAAGGAGG-3’; PM/Scl-75 
reverse primer 5’-CACCAAGAGATCTGACTGCCTGC
CAG -3’; PM/Scl-75a forward primer 5’-AGATCTCGAG 
CCTGTATGGGCGGGCTGGTTAGGATTC-3’; PM/
Scl-75c forward primer 5’-AGATCTCGTCGAC-
CGAATTCCATGAAGGAAACGCCACTC-3’.
Transient transfection of HEp-2 cells and direct 
immunofl uorescence
For transfection, cDNAs were cloned into suitable 
pEGFP vectors (Clontech), allowing expression of the pro-
teins fused to the C-terminus of the EGFP protein. HEp-2 
(human epithelioma, ATCC No.: CCL-23) cells were 
grown to 80% confl uent monolayers by standard tissue 
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culture techniques in Dulbecco’s modifi ed Eagle’s medium 
(DMEM, Life Technologies Inc.) containing 10% fetal calf 
serum (FCS). For immunoprecipitation, approximately 
10 x 106 cells  were transfected with 20-30 µg of DNA in 
1600 µl of DMEM containing 10% FCS by electropora-
tion, which was performed at 270V and 950 µF using a 
Gene-Pulser II (Bio-Rad). After transfection, cells were 
seeded in 75-cm2 culture fl asks and cultured overnight. 
After washing twice with PBS, the cells were resuspended 
in 500 µl of lysis buffer (25 mM Tris-HCl pH 7.5, 100 mM 
KCl, 2 mM EDTA, 1 mM DTE, 0.5 mM PMSF and 0.05% 
NP-40) and homogenized by sonication. For fl uorescence 
microscopy, approximately 2 x 106 cells  were transfected 
with 10-20 µg of DNA in 800 µl of DMEM containing 
10% FCS by electroporation, as described above. After 
transfection, cells were seeded onto coverslips and cultured 
overnight. Cells were washed twice with PBS, fi xed with 
4% paraformaldehyde in PBS for 20 minutes, washed in 
PBS twice, briefl y rinsed in acetone, dried and fi nally 
mounted with PBS/glycerol. The expressed EGFP-tagged 
proteins were visualized by fl uorescence microscopy.
Immunoprecipitation
Polyclonal antibodies from rabbits and patients 
were coupled to protein A-agarose beads (Biozym) in 
IPP500 (500 mM NaCl, 10 mM Tris-HCl, pH 8.0, 0.05% 
NP-40) by incubation for 2 h at room temperature. Beads 
were washed twice with IPP500 and once with IPP150 
(150 mM NaCl, 10 mM Tris-HCl, pH 8.0, 0.05% NP-40). 
For each immunoprecipitation, cell extract was incubated 
with the antibody-coupled beads for 1 h at 4°C. Subse-
quently, beads were washed three times with IPP150, and 
the co-immunoprecipitated proteins were analyzed by 
immunoblotting.
Mammalian two-hybrid analysis
All interactions were analyzed using the CheckMate 
Mammalian Two-Hybrid System (Promega) essentially 
according to the manufacturer’s protocol. Briefl y, 3-4 x 
105 COS-1 cells seeded in one well of a 6-wells plate were 
transfected with 3 vectors (1 µg each), pACT and pBIND, 
either with or without insert, and the pG5luc reporter vec-
tor using 5 µl Fugene Transfection Reagent (Roche), as de-
scribed by the manufacturer. After 40-48 hours of growth, 
cells were harvested using 500 µl Passive Lysis Buffer (PLB; 
Promega) and the activity of both the fi refl y luciferase and 
the control Renilla luciferase were determined using the 
Dual Luciferase Reporter Assay System (Promega) on a 
Berthold Lumat LB 9507 Luminometer. In brief, 100 
µl of fi refl y luciferase substrate solution was added to 20 
µl of cell extract and the luminescence was measured to 
determine the effi ciency of the interaction. Next, 100 µl of 
Renilla luciferase substrate solution (containing a quencher 
for the fi refl y luciferase activity) was added and again the 
luminescence was determined to monitor the transfection 
effi ciency.
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Introduction
Systemic autoimmune diseases are charac-
terized by the presence of autoantibodies reactive 
with a wide variety of autoantigens. Why these 
autoantibodies, which escape the normal mecha-
nisms ensuring self tolerance, are made is still not 
fully understood. However, the occurrence of 
modifi ed self-antigens during (either apoptotic 
or necrotic) cell death in combination with a de-
fective clearance of dead cells has been proposed 
to play a role in the development of autoimmu-
nity (reviewed in (124,125)). Many autoantigenic 
proteins or complexes have been shown to be 
modifi ed in dying cells. The modifi cation of 
these proteins, for example specifi c cleavage by 
caspases, might generate antigenic determinants 
to which no tolerance exists, thereby eliciting a 
primary immune response. Via epitope spreading, 
the initial response, directed to the neo-epitope 
resulting from the modifi cation, could evolve to 
a secondary response in which antibodies arise 
that are reactive with other, unmodifi ed parts of 
the protein or with proteins that are associated 
with the modifi ed antigen (124,125). Besides 
proteolytic cleavage by caspases, a number of 
other apoptotic and necrotic modifi cations have 
been observed in known autoantigens, including 
(de)-phosphorylation, citrullination and RNA 
cleavage (reviewed in (126)).
Patients suffering from myositis and scle-
roderma (Scl), which is called the polymyositis/
scleroderma overlap syndrome (PM/Scl), produce 
antibodies against a variety of autoantigens. Some 
of these are also found in patients suffering from 
myositis or scleroderma alone. Autoantibodies 
recognizing the so-called PM/Scl autoantigen are 
found in approximately 24% of all patients with 
PM/Scl (2,68,69), and in only 2-6% of patients 
suffering from myositis or scleroderma alone 
(68,77). Of all patients positive for anti-PM/Scl 
antibodies, between 43% and 88% are diagnosed 
Recent studies have implicated the dying cell as a potential reservoir of modifi ed 
autoantigens that might initiate and drive systemic autoimmunity in suscepti-
ble hosts. A number of subunits of the exosome, a complex of 3′ → 5′ exoribo-
nucleases which functions in a variety of cellular processes, are recognized by the 
so-called anti-PM/Scl autoantibodies, found predominantly in patients suff ering 
from an overlap syndrome of myositis and scleroderma. Here we show that one of 
these subunits, PM/Scl-75,  is proteolytically cleaved in apoptotic cells. Cleavage 
of the PM/Scl-75 protein occurs in the C-terminal part of the protein, leaving 
the more N-terminally located RNase PH domain intact. The N-terminal fragment 
of PM/Scl-75 remains associated with the exosome complex in apoptotic cells. 
PM/Scl-75 cleavage is dependent on caspase activation, but the exact cleavage 
site(s) remain to be identifi ed. The analysis of PM/Scl-75 cleavage by recom-
binant caspase proteins and the inhibition of cleavage by diff erent caspase in-
hibitors indicates that PM/Scl-75 is a substrate of diff erent caspases, including 
caspase-1 and caspase-8, both in vitro and in vivo. The implications of PM/Scl-75 
cleavage for exosome function and the generation of anti-PM/Scl-75 autoanti-
bodies are discussed.
80
with a myositis/scleroderma overlap syndrome 
(68,73). The PM/Scl autoantigen consists of a 
multiprotein complex representing the human 
homologue of the yeast exosome, which contains 
at least ten proteins, all displaying exoribonuclease 
characteristics. The exosome has been shown to 
be involved in the degradation and processing 
of many different RNA species (11). Although 
many of the proteins associated with the human 
exosome complex are to some extent autoanti-
genic (79), three of the proteins carry the main 
autoantigenic epitopes, PM/Scl-100, PM/Scl-75 
and hRrp4p (7-9,79). Until now, none of the 
subunits of the exosome complex had been 
shown to be modifi ed during apoptosis, promp-
ting us to investigate the behaviour of exosome 
subunits after induction of apoptosis. Here, we 
show that the PM/Scl-75 protein is cleaved in a 
caspase dependent manner during apoptosis and 
that this cleavage occurs in the C-terminal half of 
the protein. 
Results
Cleavage of PM/Scl-75 during apoptosis
To study the potential modifi cation of hu-
man exosome components during apoptosis, Ju-
rkat cells were treated with the agonistic anti-Fas 
antibody 7C11 and cell extracts were analyzed by 
western blotting using a patient serum (Ven96) 
known to be reactive with PM/Scl-100, PM/Scl-
75 and hRrp4p. As can be seen in Figure 1A, the 
intensity of the PM/Scl-75 band was strongly 
reduced after the induction of apoptosis, whereas 
Figure 1. Cleavage of the PM/Scl-75 protein during anti-Fas induced apoptosis.
Jurkat cells were treated with the anti-Fas monoclonal antibody 7C11 for the indicated time periods. Protein extracts 
were analyzed by 10% SDS-PAGE and western blotting using the anti-PM/Scl patient serum Ven96 (A), the anti-PM/Scl-
100 polyclonal rabbit serum (B) or the anti-PM/Scl-75 polyclonal rabbit serum (C). Jurkat/Neo and Jurkat/Bcl-2 were 
treated with the anti-Fas monoclonal antibody 7C11 for the indicated time periods. Protein extracts were analyzed by 
10% SDS-PAGE and western blotting using the anti-PM/Scl-75 polyclonal rabbit serum (D). In each panel, the positions 
of molecular weight markers are indicated on the right and the positions of the relevant polypeptides on the left. Closed 
arrowheads indicate full-length proteins and open arrowheads indicate cleavage products.
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the level of PM/Scl-100 and hRrp4p were only 
slightly diminished. To analyze this phenomenon 
in more detail, identical blots were analyzed with 
rabbit sera recognizing either PM/Scl-100 or 
PM/Scl-75 (Figures 1B and 1C, respectively). 
These results confi rmed that the majority of 
full-length PM/Scl-100 polypeptides remains 
intact during apoptosis (Figure 1B). However, 
PM/Scl-75, in particular the β splice variant of 
this protein, disappeared during apoptosis, con-
comitant with the appearance of a specifi c smaller 
fragment migrating at approximately 45 kDa 
(Figure 1C). To investigate whether this appar-
ent PM/Scl-75 cleavage was indeed dependent 
on the induction of apoptosis, the cleavage of 
PM/Scl-75 was analyzed in anti-Fas stimulated 
Jurkat cells (Jurkat/Neo) and cells overexpressing 
Bcl-2 (Jurkat/Bcl-2). In the Jurkat/Bcl-2 cells the 
induction of apoptosis has been demonstrated 
to be delayed considerably (127). Indeed, the 
PM/Scl-75 cleavage product was present in the 
Jurkat/Neo cells, but could not be detected in de 
Jurkat/Bcl-2 cells, not even after 8 hours of anti-
Fas treatment (Figure 1D).
To investigate whether cleavage of PM/
Scl-75 also occurred in cells exposed to other 
apoptotic stimuli, we analyzed lysates of other 
cell lines in which apoptosis had been induced 
in various ways. CCRF-CEM cells were exposed 
to actinomycin D, anisomycin, cycloheximide, 
staurosporin or anti-Fas antibodies and Peer cells 
were cultured in the presence of actinomycin D, 
anisomycin, cycloheximide or staurosporin, and 
after 8 hours extracts of these cells were analyzed 
by western blotting (Figure 2). Except for the 
actinomycin D (lane 2) and cycloheximide 
(lane 4) treated CCRF-CEM cells, the cleav-
age product of PM/Scl-75 was detected in all 
lysates, indicating that PM/Scl-75 cleavage is 
a general phenomenon in apoptotic cells. The 
anti-PM/Scl-75 rabbit serum used to stain the 
protein also showed reactivity with a number 
of yet unidentifi ed proteins, including a protein 
of about 50 kDa, that also disappears upon the 
induction of apoptosis. 
The PM/Scl-75 cleavage product remains 
associated with the exosome complex
To analyze if the apoptotic cleavage of 
PM/Scl-75 could occur when the protein is 
associated with the exosome complex, immuno-
precipitations were performed using extracts from 
control and apoptotic Jurkat cells. Figure 3 shows 
that not only anti-PM/Scl-75 rabbit sera and 
patient serum Ven96, but also rabbit antibodies to 
hRrp46p, another exosome subunit, can precipi-
Figure 2. Cleavage of the PM/Scl-75 
protein in cells treated with different 
apoptosis inducers. 
Cells (CCRF-CEM and Peer) were 
treated with anti-Fas mAb 7C11 (α-Fas), 
actinomycin D (A), anisomycin (AN), 
cycloheximide (C), or staurosporin (S). 
Cell extracts were analyzed by 10% 
SDS-PAGE and Western blotting using 
the anti-PM/Scl-75 polyclonal rabbit 
serum. The positions of molecular weight 
markers are indicated on the right and 
the positions of the relevant polypeptides 
on the left. Closed arrowheads indicate 
full-length proteins and open arrowheads 
indicate cleavage products.
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tate both the wild-type and the cleaved PM/Scl-
75 protein.  This indicates that PM/Scl-75 can be 
cleaved while it is associated with hRrp46p and 
probably the entire exosome and suggests that 
cleavage does not abrogate its association with 
the complex.
PM/Scl-75 cleavage is caspase mediated
Because the activation of caspases is a 
common feature of apoptotic cells and because 
activated caspases are capable of cleaving a large 
number of (autoantigenic) proteins, it was investi-
gated whether caspase activation was required for 
cleavage of PM/Scl-75. Jurkat cells were cultured 
Figure 3. The apoptotic cleavage product of PM/Scl-75 remains associated with the exosome.
Immunoprecipitations from control and apoptotic (8 h incubated with anti-Fas antibody) Jurkat cell extracts were 
performed using normal rabbit serum (lanes 3 and 4), anti-PM/Scl-75 (lanes 5 and 6) and anti-hRrp46p (lanes 7 and 8) 
polyclonal rabbit serum, and patient serum Ven96 (lanes 9 and 10). Immunoprecipitates were analyzed by 10% SDS-PAGE 
and Western blotting using anti-PM/Scl-75 polyclonal mouse serum. The positions of the PM/Scl-75 protein (closed 
arrowhead) and its cleavage product (open arrowhead) are indicated on the left. In lanes 1 and 2 input samples, 20% of the 
total control and apoptotic cell extracts, respectively, were loaded
Figure 4. Inhibition of PM/Scl-75 cleavage by caspase inhibitors. 
Jurkat cells were incubated for 1h at 37 °C in the presence of four cell permeable tetrapeptide caspase inhibitors: 2 µM 
(lanes 4, 6, 8, 10) or 20 µM (lanes 5, 7, 9, 11) of inhibitors for caspase-1 (YVAD-CMK), caspase-3 (DEVD-FMK), caspase-8 
(IETD-FMK) and caspase-9 (LEHD-FMK). Subsequently, cells were cultured for 8 hours in the presence of anti-Fas mAb. 
In lane 1 control extract from mock-treated Jurkat cells was loaded. In lanes 2 and 3 extracts from control and apoptotic 
(8 h, anti-Fas mAb) Jurkat cells, respectively, were analyzed. Total protein extracts were analyzed by 10% SDS-PAGE 
and western blotting using the anti-PM/Scl-75 polyclonal rabbit serum. The positions of molecular weight markers are 
indicated on the right and the positions of the relevant polypeptides on the left. Closed arrowheads indicate full-length 
proteins and open arrowheads indicate cleavage products.
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in the presence of various inhibitors of caspases 
for 1 hour prior to the induction of apoptosis 
by anti-Fas. Four different tetrapeptide caspase 
inhibitors were used, Ac-YVAD-CMK for group 
I caspases (caspase-1-like), Z-DEVD-FMK for 
group II caspases (caspase-3-like), or Z-IETD-
FMK (caspase-8) and Z-LEHD-FMK (caspase-9) 
for group III caspases. Rabbit anti-PM/Scl-75 
antiserum was used to analyze the cleavage of 
PM/Scl-75 in these cells. The cleavage of PM/
Scl-75 was completely inhibited in the presence 
of 2 or 20 µM of Ac-YVAD-CMK, Z-DEVD-
FMK, or Z-IETD-FMK inhibitors (Figure 4, 
lanes 4–9). In the presence of the Z-LEHD-FMK 
inhibitor, PM/Scl-75 cleavage was partially 
inhibited at 2 µM and completely inhibited in 
the presence of a 10-fold higher concentration 
(Figure 4, lanes 10–11). These results suggest that 
caspases, or other proteases activated downstream 
of the caspase-cascade, are involved in the apop-
totic cleavage of PM/Scl-75. 
Cleavage of PM/Scl-75 by different caspases
To determine whether PM/Scl-75 is a 
direct substrate for recombinant caspases and, 
if so, whether the major cleavage product had a 
similar electrophoretic migration behaviour as the 
cleavage product observed in cell extracts, in vitro
translated PM/Scl-75a-α and PM/Scl-75a-β (see 
also Figure 6) were incubated with recombinant 
murine caspases-1, -2, -3, -7, -8 and -11. Caspase-
1 very effi ciently cleaved PM/Scl-75 (Figure 
5A, lanes 2, 9), whereas cleavage, although to a 
lesser extent, was also observed with caspase-8 
Figure 5. Cleavage of PM/Scl-75 by recombinant caspases.
 In vitro translated 35S-labeled PM/Scl-75a-α and PM/Scl-75a-β were incubated with 200 nM of purifi ed murine 
recombinant caspases-1, -2 , -3, -7, -8 or -11 for 1.5 h at 37ºC. The resulting reaction products were analyzed by 10% 
SDS-PAGE, followed by autoradiography (A). In the fi rst lane the mock-incubated protein was loaded. Closed arrowheads 
mark the full-length proteins and open arrowheads mark the cleavage products. Immunoprecipitations were performed 
with anti-VSV-tag antibodies using either C- or N-terminally VSV-tagged PM/Scl-75a-α (lanes 3 and 4), after cleavage of 
the protein with recombinant caspase-1 as in panel A. The input of the respective immunoprecipitation are loaded in lanes 
1 and 2 (B). In each panel, the positions of molecular weight markers are indicated on the right and the positions of the 
relevant polypeptides on the left. Closed arrowheads indicate full-length proteins and open arrowheads indicate cleavage 
products.
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(lanes 6, 13) and caspases-3 and -7 (lanes 4, 5, 11, 
12).  Interestingly, a number of cleavage products 
appeared, displaying small differences in electro-
phoretic mobility, which suggests the presence of 
a number of different cleavage sites. The cleavage 
products observed for PM/Scl-75a-α (Figure 5A, 
lanes 1-7) and PM/Scl-75a-β (lanes 8-14) ap-
peared to be of identical size, suggesting that these 
PM/Scl-75 fragments lack the C-terminal region 
of the protein, because this region contains the se-
quence encoded by the extra exon present in the 
β variant. Since caspase-8 plays a key role in death 
domain receptor mediated apoptosis, it was tested 
whether caspase-8 is essential for the cleavage of 
PM/Scl-75 in apoptotic cells. Therefore, caspase-
8-defi cient Jurkat cells (ATCC CRL-2571) 
were used to analyze the apoptotic processing of 
PM/Scl-75. These cells become apoptotic when 
treated with staurosporin in combination with 
cycloheximide. Despite the absence of caspase-8, 
upon induction of apoptosis the same cleavage 
pattern was observed as in control cells contain-
ing caspase-8 (data not shown). This suggests that, 
in agreement with the in vitro proteolysis results, 
other caspases might be responsible for cleavage 
of PM/Scl-75 in apoptotic cells.
Putative cleavage sites in PM/Scl-75
Using recombinant capase-1, in vitro trans-
lated PM/Scl-75a-α carrying a VSV-G-tag at 
either the N- or the C-terminus of the protein 
was cleaved. Next, immunoprecipitations were 
performed, using an anti-VSV-tag monoclonal 
antibody. As is shown in Figure 5B, the cleavage 
products of PM/Scl-75 could only be immu-
noprecipitated when the VSV-tag was attached 
to the N-terminus of the protein, confi rming 
that the major cleavage products observed by 
SDS-PAGE contain the N-terminal, but not the 
C-terminal part of PM/Scl-75. 
These data for the in vitro cleavage products 
are in agreement with the in vivo cleavage data, 
Figure 6. Amino acid sequence of PM/Scl-75. 
An alignment of both splice variants (α and β) of PM/Scl-75 is shown, in which the RNase PH domain, the NLS and the 
N-terminus of both published sequences for the protein, PM/Scl-75a (8) and PM/Scl-75c (129), are indicated. In addition, 
all aspartic acid residues are highlighted in black if they are putative cleavage sites based on available data, and otherwise in 
gray. Finally, the aspartic acid residues that were mutated in an attempt to fi nd the cleavage site are marked.
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because the major product observed in vivo was 
shown to be associated with the exosome com-
plex (Figure 3) and therefore still contains the N-
terminal part of the protein which encompasses 
the RNase PH domain, which is required for the 
interaction with other exosome subunits. Taken 
together these data indicate that the caspase cleav-
age site(s) in PM/Scl-75 are located in the C-
terminal half of the protein, C-terminal from the 
RNase PH domain and N-terminal from the 
sequence encoded by the PM/Scl-75a-β specifi c 
exon (Figure 6). 
Based on homology with previously 
described caspase-1 and -8 cleavage sites, four 
aspartic acid residues were selected that might 
represent caspase cleavage sites in PM/Scl-75. 
To investigate their involvement in cleavage, the 
aspartic acid residues at position 272 (‘LEND’), 
307 (‘DTSD’), 352 (‘DLED’)  and 381 (‘EVSD’) 
were substituted by alanine and the correspond-
ing in vitro translated mutants of PM/Scl-75 were 
incubated with caspases-1, -3 and -8. In Figure 7, 
it can be seen that all four mutants were still 
cleaved by these caspases, suggesting that at least 
in vitro these aspartic acid residues are not essential 
for caspase mediated cleavage of PM/Scl-75.
Discussion
Although many different autoantibodies 
have been identifi ed in a variety of autoimmune 
diseases, the origin of these autoreactive antibod-
ies is still unknown. During the last decade a sub-
stantial number of autoantigens have been shown 
to be modifi ed during apoptosis and/or necrosis. 
This has led to the hypothesis that intracellular, 
modifi ed autoantigens are exposed to the im-
mune system because of massive cell death and/or 
ineffi cient removal of dying cells, which could 
elicit a primary immune response targeting the 
modifi cation on the autoantigen. Subsequently, in 
a secondary response, involving epitope spread-
ing, also other parts of the autoantigen will be 
targeted by the immune system (124). Patients 
Figure 7. Cleavage of PM/Scl-75 mutants by recombinant caspases.
In vitro translated 35S-labeled PM/Scl-75a-α and mutants of the protein in which the aspartic acid residues at positions 272 
(D272A), 307 (D307A), 352 (D352A) or 381 (D381A) were changed into alanine residues, were incubated with 200 nM 
of purifi ed murine recombinant caspases-1, -3, or -8 for 1.5 h at 37ºC. The resulting reaction products were analyzed by 
10% SDS-PAGE, followed by autoradiography. In the lanes 1-5 the mock-incubated proteins were loaded. The positions 
of molecular weight markers are indicated on the right and the positions of relevant polypeptides on the left. Closed 
arrowheads indicate full-length proteins and open arrowheads indicate cleavage products. 
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with the PM/Scl overlap syndrome often develop 
antibodies against a number of components of the 
human PM/Scl or exosome complex, especially 
PM/Scl-100, PM/Scl-75 and hRrp4p (79). Here, 
we show for the fi rst time that one of the exo-
some subunits, PM/Scl-75, is specifi cally modifi ed 
during apoptosis. PM/Scl-75 is cleaved, probably 
by one or more caspases, in the C-terminal part 
of the protein. The electrophoretic mobility of 
the products observed after cleavage with recom-
binant caspases (at least three individual cleavage 
products of similar size) suggests that the caspase 
cleavage sites in PM/Scl-75 are most likely 
located in the highly charged region between 
aspartic acid 349 and aspartic acid 381 (Figure 6). 
Strikingly, the cleavage products observed in ap-
optotic extracts did not show this heterogeneity, 
suggesting that one of the aspartic acid residues in 
this region serves as the predominant cleavage site 
in vivo. This difference between the in vitro and 
in vivo data might be explained by the association 
of PM/Scl-75 with the exosome in vivo. Four of 
the aspartic acid residues in this region of the 
protein (D272, D307, D352 and D381) did not 
serve as the predominant caspase cleavage sites in 
vitro (Figure 7). The exact position(s) where the 
protein is cleaved, both during apoptosis in vivo
and in vitro using recombinant caspases remain 
to be identifi ed. Although for most caspase 
proteins preferential cleavage sites have been 
identifi ed, for example LE(T/V)D for caspase-8 
and (W/L)EHD for caspase-1 (130), a number 
of autoantigens, including DNA topoisomerase 
1 and Sm-F, have been shown to be cleaved at 
unconventional sites, making it diffi cult to predict 
the exact cleavage site in PM/Scl-75 (128,131).
Consistent with the observation that the 
C-terminal part of the protein is removed during 
apoptosis, leaving the RNase PH domain intact, 
PM/Scl-75 remains associated with the core of 
the exosome complex. Based on interactions 
between exosome components and structural 
similarity with the bacterial protein polynucle-
otide phosphorylase (PNPase), we have recently 
generated a model for the structure of the human 
exosome. In this model the six proteins contain-
ing an RNase PH domain (RPD) form the 
core of the exosome, which adopts a hexameric 
ring structure (106). Interestingly, this structural 
model suggests that the RPD of PM/Scl-75 is 
in tight association with other proteins, whereas 
the C-terminal part of the protein extends from 
the outer surface of the ring, leaving the putative 
cleavage site accessible for caspases. A very similar 
situation has been described for the Sm-F protein, 
which is apoptotically cleaved while associated 
with the heptameric ring of the Sm complex 
(128). Currently, it is not known whether the 
total cellular pool of PM/Scl-75 molecules is 
associated with the exosome complex. The pos-
sibility exists that a certain fraction of it is ‘free’. 
The effi ciency by which PM/Scl-75 is cleaved, 
however, suggests that if both exosome associated 
and ‘free’ pools of the protein exist, both will be 
cleaved in apoptotic cells. 
The results of several experiments indicate 
that the β splice variant is more effi ciently cleaved 
in vivo than the α isoform. This difference is most 
likely due to a better accessibility of the caspase 
cleavage site(s), because the extra sequence of 
PM/Scl-75-β is located near the aspartic acid-
rich region. The β isoform has been implicated 
to be preferentially associated with the nuclear 
exosome complex as compared to the α isoform 
(129).
To assess whether the cleavage of PM/Scl-
75 by caspases leads to the generation of neo-
epitopes on the proteins, the exact cleavage site(s) 
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have to be identifi ed, for example by mutagenesis 
of the aspartic acid residues in the highly charged 
region depicted in Figure 6. Another approach 
would be to investigate whether the B-cell 
repertoire of PM/Scl patients contains antibodies 
that are specifi cally reactive with the cleaved PM/
Scl-75 protein. Autoantibodies only reactive with 
apoptotically modifi ed isoforms of the autoanti-
gen have been suggested to exist for the U1-70K 
protein (132). In addition to the generation of 
autoantigenic epitopes, cleavage of PM/Scl-75 
might also have implications for the function 
of the protein and the function of the exosome 
complex. It has been shown that PM/Scl-75 
contains a nuclear localization signal (NLS) close 
to the C-terminus of the protein, which plays 
a role in the nuclear and nucleolar targeting of 
PM/Scl-75 and possibly the entire exosome 
complex (129). Because cleavage of PM/Scl-75 
in apoptotic cells separates the NLS containing 
part from the protein, the subcellular distribution 
of the protein and the associated complex in these 
cells might change.  It is tempting to speculate that 
this leads to an increased exosome concentration 
in the cytoplasm and/or nucleoplasm, which may 
be required for an enhanced degradation rate of a 
variety of RNA molecules in the cytoplasm. 
Materials and Methods
Cell lines
Jurkat cells (human T-cell leukemia, ATCC 
CRL-2570), Peer cells (human T-cell leukemia) and 
CCRF-CEM cells (human T-cell lymphoblastic leukemia, 
ATCC CCL-119) were grown in RPMI-1640 medium 
(Gibco-BRL) supplemented with 10% heat-inactivated 
fetal calf serum (FCS), 1 mM sodium-pyruvate, penicil-
lin, and streptomycin. Jurkat cells stably transfected with 
Bcl-2 (Jurkat/Bcl-2) or with the empty transfection vector 
(Jurkat/Neo) were cultured in the same medium with the 
addition of 200 µg/ml G418 (Gibco-BRL). 
Induction of cell death
To induce apoptosis, Jurkat cells were treated with 
the agonistic anti-Fas monoclonal antibody 7C11 as de-
scribed previously (127,128). Peer and CCRF-CEM were 
treated with 0.5 µg/ml actinomycin D, 10 µg/ml anisomy-
cin, 100 µg/ml cycloheximide or 400 nM staurosporin. 
CCRF-CEM cells were also treated with the anti-Fas 
antibody. The extent of induced apoptosis was assessed 
by fl ow cytometry using annexin V-FITC and propidium 
iodide (PI) staining as described previously (127). After 
8 h generally more than 90% of the cells were apoptotic. 
After harvesting the dying cells, cells were washed two 
times with PBS and used immediately or stored at -70º C. 
For experiments utilizing the cell-permeable tetrapeptide 
caspase inhibitors (Calbiochem), Jurkat cells were cultured 
for 1 h in the presence of 2 or 20 µM Ac-YVAD-CMK, 
Z-DEVD-FMK, Z-IETD-FMK, or Z-LEHD-FMK 
(irreversible inhibitors of caspases-1, -3/-7, -8, and -9, 
respectively) as described previously (128). The specifi city 
of these inhibitors is based on in vitro assays with purifi ed 
caspases. Their specifi city in a cellular context is diffi cult to 
defi ne. Subsequently, apoptosis was induced by the addition 
of anti-Fas monoclonal antibody followed by harvesting 
the cells after 8 h of incubation.
Western blot analysis
Cells were lysed on ice for 30 min in NP-40 lysis 
buffer (25 mM Tris-HCl, pH 7.5, 1% NP-40, 100 mM 
KCl, 10 mM MgCl
2
, 1 mM dithiothreitol (DTT)), con-
taining a protease inhibitor cocktail (Complete, Roche). 
Cell lysates were centrifuged for 15 min at 4º C (12,000g) 
and the supernatants were used immediately or stored at 
-70º C. Protein extracts of 1x106 cells were analyzed by 
10% SDS-PAGE and western blotting using SLE patient 
serum Ven96 (a patient serum reactive with many exosome 
subunits (88)), an anti-PM/Scl-100 rabbit serum (14) or an 
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anti-PM/Scl-75 rabbit serum (57), followed by detection 
via HRP-conjugated secondary antibodies and visualiza-
tion by chemiluminescence.
Immunoprecipitation
Protein A–agarose beads (20 µl of 50% slurry) were 
coated with 20 µl of Ven96 patient serum, anti-hRrp46p 
rabbit serum(14) or anti-PM/Scl-75 (57) rabbit serum. 
Incubations were performed overnight at 4º C in IPP150 
(150 mM NaCl, 10 mM Tris-HCl, pH 8.0, 0.1% NP-40) by 
end-over-end rotation. After washing the beads three times 
with IPP150, the beads were incubated with 20 µl (2x106
cell equivalents) of Jurkat extract (control or apoptotic) in 
IPP150 by end-over-end rotation for 2 h at 4º C. After 
three wash steps with IPP150, the beads were resuspended 
in protein sample buffer and immunoprecipitated proteins 
analysed by SDS-PAGE and western blotting.
Plasmids
The cDNAs of PM/Scl-75a-α and PM/Scl-75a-β 
(129) were cloned into the EcoRI and XbaI sites of the 
pCI-neo vector, containing an in-frame VSV-G tag at either 
the 5’ or the 3’ end of the cDNAs. Four mutant cDNAs 
of PM/Scl-75a-α were generated, encoding substitution 
mutants in which one of the aspartic acids at positions 272, 
307, 352 and 381 was substituted by alanine. All mutants 
were generated by a  megaprimed PCR-based approach 
using the orginal PM/Scl-75a-α cDNA as a template and 
specifi c primers overlapping the regions that were mutated. 
The resulting PCR products were purifi ed, digested with 
EcoRI and XbaI and inserted into the EcoRI and XbaI 
sites of pCI-neo. The integrity of the mutant constructs 
was confi rmed by DNA sequencing. The resulting cDNAs 
were used as template for transcription/translation of the 
respective proteins.
In vitro cleavage assay
Proteins were generated by in vitro transcription/
translation using the TnT T7-coupled rabbit reticulocyte 
lysate system (Promega) as described by the manufacturer. 
For detection of the translation products, 35S-methionine 
was added to the translation reactions. In vitro translated 
proteins were incubated with 200 nM of the purifi ed 
murine recombinant caspases in a total volume of 25 µl 
CFS buffer (220 nM mannitol, 68 nM sucrose, 2 mM 
NaCl, 2.5 mM KH
2
PO
4
, 10 nM HEPES, pH 7.4, 1 mM 
aprotinin, 1 mM leupeptin, and 1 mM PMSF, supplemented 
with 5 mM DTT) for 1.5 h at 37º C. The resulting cleavage 
products were analyzed by 10% SDS-PAGE, followed by 
autoradiography. 
Immunoprecipitation of in vitro cleaved proteins
In vitro translated PM/Scl-75a-α containing either 
an N- or an C-terminal VSV-G tag was incubated with 
recombinant caspase-1 and subjected to immunopre-
cipitation using protein G–agarose beads coated with anti-
VSV-G mouse monoclonal antibody. Precipitated proteins 
were fractionated on 10% SDS-PAGE and visualized by 
autoradiography. 
PM/Scl-75 is the main autoantigen 
in patients with the polymyositis/
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Introduction
Specifi c autoantibodies in the sera of 
patients with clinical symptoms of polymyositis 
(PM) or dermatomyositis (DM) and scleroderma 
(Scl), called the polymyositis/scleroderma overlap 
syndrome (PM/Scl), capable of precipitating 
antigens from calf thymus extract, were fi rst 
described in 1977. The antigen recognized by 
these autoantibodies was shown to be a nucleolar 
complex, consisting of 11-16 proteins ranging 
from 20-110 kDa (6). These characteristics al-
low the detection of these antibodies in serum 
by indirect immunofl uorescence (IIF) and im-
munoprecipitation assays. After the identifi cation 
of the main autoantigenic proteins, PM/Scl-100 
and PM/Scl-75 (8,9), both of these proteins were 
shown to be homologous to bacterial exoribo-
nuclease proteins (RNase D and RNase PH, 
respectively) (10).
In recent years, the PM/Scl complex was 
shown to be the human equivalent of the yeast 
exosome, a complex consisting of at least ten 
proteins, all displaying characteristics of exoribo-
nucleases, which has been shown to be involved in 
the degradation and processing of many different 
RNA species (106). Besides PM/Scl-75 and PM/
Scl-100 a signifi cant number of other subunits of 
the human exosome have been identifi ed, based 
on their homology with the yeast counterparts or 
by co-purifi cation with known human exosome 
components (14,17). 
Although PM/Scl-100 and PM/Scl-75 
contain the main autoantigenic epitopes of the 
human exosome, also some of the other subunits 
have been shown to be targeted by autoanti-
Objective
To compare the autoantigenicity of the recently described N-terminally elon-
gated PM/Scl-75 protein with that of PM/Scl-100 and the originally defi ned 
PM/Scl-75 polypeptide and to determine its value for analyzing sera from pa-
tients with the polymyositis/scleroderma overlap syndrome. 
Methods
Sera of patients suff ering from PM/Scl overlap syndrome and several other 
diseases were analyzed for the presence of autoantibodies reactive with re-
combinant PM/Scl-100 and PM/Scl-75 (both the original and the longer form) 
proteins in an ELISA assay.
Results
Autoantibodies recognizing the longer PM/Scl-75 protein isoform were detected 
in 28% of the PM/Scl patients, which is slightly higher than PM/Scl-100 (25%) 
and signifi cantly higher than the previously defi ned PM/Scl-75 protein (11%). In 
addition, a signifi cant number of patients was identifi ed that had anti-PM/Scl-
75, but not anti-PM/Scl-100 antibodies, in contrast to what has been reported 
in the past for the shorter version of the PM/Scl-75 protein.
Conclusion
Our data indicate that the use of the long PM/Scl-75 isoform in addition to 
PM/Scl-100 in ELISA signifi cantly increases the number of patients in which 
anti-PM/Scl autoantibodies can be detected.
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bodies. Autoantibodies against the hRrp4p pro-
tein are present in 54% of the sera that are reactive 
with PM/Scl-100, a prevalence similar to that of 
anti-PM/Scl-75 autoantibodies (79). The exo-
some components hRrp40p, hRrp41p, hRrp42p, 
hRrp46p and hCsl4p all are signifi cantly less au-
toantigenic, although autoantibodies recognizing 
these proteins have been described (79).
In general, autoantibodies against the PM/
Scl complex are found in approximately 24% 
of patients with the polymyositis/scleroderma 
overlap syndrome (68), and in only 2% of patients 
suffering from scleroderma alone (68) and 6% of 
patients with myositis (polymyositis or dermato-
myositis) alone (77). Conversely, between 43% 
and 88% of the patients positive for anti-PM/Scl 
antibodies are indeed diagnosed with a myositis/
scleroderma overlap syndrome (68,73).
Only limited information is available 
on the exact epitopes on the PM/Scl-75 and 
PM/Scl-100 proteins that are recognized by the 
patient sera. The PM/Scl-100 protein appears to 
contain two autoantigenic epitopes (aa 229-244 
and aa 775-795), both enriched in positively and 
negatively charged amino acid residues (9). The 
exact autoantigenic epitope on the PM/Scl-75 
protein is not known, although most likely the 
highly charged C-terminal part of the protein is 
recognized by a subset of the autoantibodies (8). 
Recently, we have shown that the major isoform 
of the PM/Scl-75 polypeptide is 84 amino acids 
longer than was believed before, by character-
izing cDNAs encoding an additional N-terminal 
part that is missing in the originally described 
sequence (8), but which is present in the reported 
PM/Scl-75 sequence of Mus musculus. This do-
main was found to be required for the incorpora-
tion of PM/Scl-75 in the core of the exosome 
complex (129). This exosome core consists of a 
ring of 6 proteins, which are all homologous to 
RNase PH (106). A schematic illustration of the 
difference between the original (PM/Scl-75a) 
and the longer (PM/Scl-75c) form of the protein 
is depicted in Figure 1. In this study, we compared 
Figure 1. The difference between PM/Scl-75a and PM/Scl-75c. 
A schematic overview of the difference between the originally published PM/Scl-75 polypeptide (8) and the full-length 
polypeptide that has been described recently (129) is shown in panel A. The full-length PM/Scl-75 protein has 84 
additional amino acids at its N-terminus that are required for the association of this protein with the exosome complex. 
The highly charged C-terminal region of the protein, suggested to be important for its autoantigenicity, is also indicated. 
The numbers refer to amino acid (aa) positions in the respective polypeptides. A third form of the protein, called PM/Scl-
75b (129), which contains only part of the additional N-terminal sequence of PM/Scl-75c, is not included in this study. 
Panel B shows a Coommassie stained gel with His-tagged recombinant PM/Scl-75a and PM/Scl-75c and blots containing 
the same proteins, stained with an anti-PM/Scl-75 positive patient serum and a normal human serum (NHS). Both full-
length recombinant proteins are indicated with an asterix.
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the autoantigenicity of these two forms of PM/
Scl-75 in parallel with that of PM/Scl-100 in 
patients with the PM/Scl overlap syndrome and 
various other diseases in a recombinant protein 
ELISA.
 Results
To assess the reactivity of patient sera with 
PM/Scl-75a (8), PM/Scl-75c (129) and PM/Scl-
100 (9), His-tagged recombinant proteins were 
expressed in E. coli and subsequently purifi ed. 
Figure 1B shows a Coommassie stained gel of 
the recombinant PM/Scl-75 proteins. A reference 
anti-PM/Scl-75 patient serum was reactive with 
both recombinant proteins on western blot (Fig-
ure 1B). Note that the PM/Scl-75a protein runs 
at a similar size compared to PM/Scl-75c due to 
the fusion of a vector-encoded sequence to the 
open reading frame of the former. These proteins 
were used as a substrate in an ELISA to detect 
antibodies reactive with these proteins present in 
the sera of 45 patients with PM, 43 patients with 
DM, 51 patients with Scl and 36 patients with the 
PM/Scl overlap syndrome. In addition, the sera of 
30 patients suffering from malignant melanoma 
were tested in this assay, because hRrp46p, 
another subunit of the PM/Scl complex, was re-
cently shown to be autoantigenic in patients with 
various types of cancer, including melanoma (80). 
Table 1 summarizes the reactivity of patient sera 
with each of the proteins. In total, 8% (16/205) of 
the sera was reactive with PM/Scl-75c, whereas 
only 2% (4/205) was reactive with PM/Scl-75a, 
indicating that the N-terminal part of PM/Scl-75 
indeed plays an important role in the autoanti-
genicity of the protein. The prevalence of the 
anti-PM/Scl-75c antibodies was the highest in 
patients suffering from the PM/Scl overlap syn-
drome (28%, 10/36), but they were also detected 
in some sera of patients with DM (2%, 1/43) or 
Scl (10%, 5/51). No anti-PM/Scl-75c reactivity 
was found in patients with PM or melanoma. 
Notably, anti-PM/Scl-100 autoantibodies were 
detected in only 25% (9/36) of the patients with 
PM/Scl and also in 2% of the patients with either 
PM (1/45), DM (1/43) or Scl (1/51) and in 7% 
(2/30) of the patients with melanoma.
Figure 2A shows the reactivity of patient 
sera with the antigens, compared to a number 
of control sera (the antibody ratio is calculated 
by dividing the observed reactivity by the cut-off 
value). It is evident that patients with the PM/Scl 
overlap syndrome that are positive for PM/Scl-
75c generally have higher titers of these antibod-
ies than patients with scleroderma. 
Several other techniques (including western 
blotting, line immunoassay (LIA) and immuno-
precipitation) were used to analyze the reactivity 
of patient sera with the recombinant PM/Scl-75 
Table 1. Reactivity of patient sera with PM/Scl-75a, PM/Scl-75c and PM/Scl-100.
sera tested PM/Scl-75a (%) PM/Scl-75c (%) PM/Scl-100 (%)
polymyositis (PM) 45 0 (0) 0 (0) 1 (2)
dermatomyositis (DM) 43 0 (0) 1 (2) 1 (2)
scleroderma (Scl) 51 0 (0) 5 (10) 1 (2)
PM/Scl overlap 36 4 (11) 10 (28) 9 (25)
melanoma 30 0 (0) 0 (0) 2 (7)
total 205 4 (2) 16 (8) 14 (7)
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proteins. In part, the ELISA data were confi rmed 
by these experiments. However, some sera that 
were not reactive with PM/Scl-75a in ELISA 
displayed a (weak) reactivity with the PM/Scl-
75a protein in these assays. This is most likely due 
to the presence of relatively low titers of autoanti-
bodies directed to the C-terminal epitopes of the 
protein, which remain undetected in ELISA. On 
the other hand, for some sera no reactivity with 
PM/Scl-75 was detected at all, suggesting that the 
recognition of at least one important epitope of 
the protein is highly conformation-dependent, 
which is in agreement with previous observations 
(15). In conclusion, ELISA appears to be the 
method of choice to compare the reactivity of 
sera with the two isoforms of PM/Scl-75.
The co-occurrence of anti-PM/Scl-75 and 
anti-PM/Scl-100 antibodies in positive patient 
sera is depicted in Figure 2B. In agreement with 
previous observations, all sera that are reactive 
with PM/Scl-75a are also reactive with PM/Scl-
100 (79). No sera were found that are reactive 
with PM/Scl-75a but not with PM/Scl-75c, 
which is not surprising because the complete 
amino acid sequence of PM/Scl-75a is also 
present in PM/Scl-75c. Importantly, both in the 
total group of reactive sera and the subset of PM/
Scl overlap sera, sera that show reactivity with 
only PM/Scl-100 (4/20 of all reactive sera) or 
Figure 2. Reactivity of patient sera with recombinant PM/Scl-75a, PM/Scl-75c and PM/Scl-100. 
Panel A shows the reactivity of patient sera from different patients with the recombinant proteins relative to the reactivity 
of normal human serum (the antibody ratio indicates the titer of the antibodies relative to the control sera). The cutoff used 
for positivity (a ratio of >3) is indicated by the dotted line. In panel B, the co-occurrence of autoantibodies that recognize 
the recombinant proteins is illustrated separately for all the sera analyzed and for the PM/Scl overlap sera.
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only PM/Scl-75c (6/20) were found. Only half 
(50%, 10/20) of the sera reactive with PM/Scl-75 
or PM/Scl-100 contains antibodies directed to 
both proteins, although this number is higher in 
the patients with the PM/Scl overlap syndrome 
(73%, 8/11). Combining the results obtained for 
PM/Scl-75c and PM/Scl-100 shows that 31% 
(11/36) of the PM/Scl patients are positive for 
either PM/Scl-75c or PM/Scl-100. 
Discussion 
The aim of this study was to compare the 
autoantigenicity of the full-length PM/Scl-75 
protein that we have described recently (129) 
with that of the originally defi ned PM/Scl-75 
polypeptide described by Alderuccio et al. (8) 
and the PM/Scl-100 protein (9). The results 
showed that the presence of the newly identifi ed 
N-terminus of PM/Scl-75 dramatically increases 
the frequency by which it is recognized by patient 
sera in ELISA. Moreover, our results suggest that 
autoantibodies directed to PM/Scl-75 might be 
more prevalent in patients with the PM/Scl over-
lap syndrome and related diseases than anti-PM/
Scl-100 autoantibodies, which were considered 
to be most frequently present up to now. 
In the past, the presence of these antibodies 
in serum was generally monitored by IIF with 
HEp-2 cells, immunodiffussion assays with calf 
thymus extract and/or by immunoblotting using 
extractable nuclear antigens. All these techniques 
allow the detection of a wide variety of autoan-
tibodies present in patient serum. The detection 
of anti-PM/Scl antibodies by immunoblotting, 
however, is diffi cult, because the reactivity of the 
antibodies with particularly PM/Scl-75 in cell 
extracts is notoriously weak on immunoblots 
(74), which may be due to the importance of 
conformational epitopes. In recent years especially 
ELISA using a recombinant PM/Scl-100 protein 
has become more common to detect anti-PM/
Scl reactivity, because it can easily be applied in 
an automated setting. In ELISA conformational 
epitopes in recombinant proteins are more readily 
formed than in other assays, allowing more sensi-
tive detection of anti-PM/Scl-75 autoantibodies. 
On the other hand, the use of a stringent cut-off 
value, as is often required to obtain suffi cient spe-
cifi city, makes it diffi cult to detect weak reactivity 
with an antigen, which in the present study is 
particularly true for PM/Scl-75a.
Since anti-PM/Scl-75 reactivity was 
previously only detected in patient sera that 
also contained anti-PM/Scl-100 autoantibodies 
(74,77), this protein is usually not included in 
such assays. In addition to the limitations of the 
applied detection method, our data show that also 
the use of an incomplete recombinant PM/Scl-
75 polypeptide may have led to an underestima-
tion of the diagnostic value of the PM/Scl-75 
antigen. Although more cohorts of PM/Scl, Scl, 
PM and DM sera have to be analyzed with the 
full-length PM/Scl-75 antigen, our data strongly 
suggest that, if only PM/Scl-100 is used in ELISA 
assays, a signifi cant number of patients will test 
negative, because anti-PM/Scl-75 antibod-
ies remain undetected. Some of these would 
test positive with PM/Scl-75a in other assays, 
whereas others might only be detected using 
PM/Scl-75c in ELISA. Taken together, the use of 
both recombinant proteins increases the number 
of patients with the PM/Scl overlap syndrome 
detected by ELISA. Although the prevalence of 
autoantibodies recognizing most other exosome 
subunits relatively low (79), the co-occurrence of 
antibodies targeting different exosome subunits 
in patient sera might be indicative for the overlap 
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syndrome. The co-occurrence of anti-PM/Scl-
100 and anti-PM/Scl-75 seems to be particularly 
associated with the PM/Scl overlap syndrome 
(see Figure 2B), but whether the use of even more 
components of the human exosome will further 
increase the sensitivity of these assays remains to 
be investigated. 
Materials and Methods
Patients
Most patient sera were obtained from the depart-
ments of Surgery, Rheumatology and Neurology from 
the University Medical Centre St. Radboud, Nijmegen. 
Patients were selected that met the established criteria for 
Scl, PM, DM or having malignant melanoma. Many of the 
patients with PM, DM or overlap syndromes of Scl with 
PM or DM (both referred to as PM/Scl in this study) were 
also included in previous studies that assessed the preva-
lence of anti-exosome antibodies in these patients (77,79).
Expression and purifi cation of recombinant proteins
The cDNA encoding PM/Scl-75a (acc. nr. M58460) 
was cloned into the pEx34 expression vector and the 
cDNAs encoding PM/Scl-75c (acc. nr. AJ505989) and 
PM/Scl-100 (acc. nr. X66113) were cloned into pET21a. 
Proteins were expressed in transformed E. coli 537 cells 
(PM/Scl-75a) and BL21(DE3)Star cells (Invitrogen) 
(PM/Scl-75c, PM/Scl-100) and purifi ed by Ni2+-affi nity 
chromatography, followed by preparative SDS-PAGE.
Enzyme linked immunosorbent assay (ELISA)
ELISA assays were essentially performed as de-
scribed before (77). In brief, with 0.2 µg/well of each of 
the proteins, medium binding microtiter plates (Greiner, 
Germany) were coated and antibody screening was 
performed with 200 µl of diluted serum samples (1:100). 
After incubation (30 minutes, 37°C) and washing, plates 
were incubated (30 minutes, 37°C) with 200 µl/well of 
alkaline phosphatase-conjugated Affi niPure Fc-fragment 
specifi c goat anti-human IgG (Jackson Laboratories, USA). 
Bound antibodies were visualized with 38 mM disodium-
paranitrophenyl-phosphate and 50 mM diethanolamine 
pH 9.8. ODs were measured at 405 nm and tests were re-
garded positive at >3 fold ODs compared to the calculated 
cut-off (based on three negative control sera with 99.5% 
confi dence (133)).
General Discussion
Chapter 8
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Structure of the exosome
The composition of both the yeast (21) 
and human (Chapter 3) (106) exosome has been 
largely identifi ed. Both were found to contain six 
proteins homologous to RNase PH, which are 
likely to assemble into a hexameric ring. Attached 
to the outer surface of this ring are three proteins, 
each containing an S1 RNA binding domain. 
This exosome core structure is very similar to 
that of the bacterial protein polynucleotide phos-
phorylase (PNPase) (21,106) (Chapters 2 and 
3). Very recently, also the exosome of Drosophila 
melanogaster was purifi ed (25). Remarkably, only 
4 RNase PH-like proteins were found in this 
complex. Since the structure of the exosome 
core (and the complex formed by the related 
protein PNPase) seems to be highly conserved 
throughout evolution (Chapter 4), this suggests 
that either two RNase PH-like proteins of the 
D. melanogaster exosome remain to be identifi ed, 
or that some of the subunits are present in the 
complex in multiple copies. The relationship of 
a number of other proteins with the exosome 
remains unclear. The human homologue of the 
yeast exosome subunit Rrp44p/Dis3p, hDis3p, 
does not appear to be a component of the human 
exosome (17,106), even though this protein has 
been found in association with the D. melanogaster
exosome (25). Similar to the human situation, 
evidence suggests that the Rrp44p/Dis3p 
homologue of Trypanosoma brucei also functions 
independent of the exosome (23). Homologues 
of the yeast subunit Rrp6, on the contrary, have 
been found in all exosome complexes studied to 
date (11,17,23,25). However, the exact nature of 
the interaction of this protein with the core of the 
exosome complex is still not understood. In yeast, 
the protein has been suggested to be positioned 
on top of the ring structure (23). This interaction 
might require additional proteins, since no direct 
protein-protein interactions between exosome 
subunits and Rrp6p or any of its homologues 
have been found so far. In the case of the human 
exosome, which might exist as a dimeric core 
complex, both rings could be involved in the 
interaction of one or more copies of the Rrp6p 
homologue PM/Scl-100 with the core of the 
exosome complex (see Figure 1)(106).
Quite a number of other proteins have been 
implicated in exosome function (Figure 1 and 
summarized in Chapter 1). Although preliminary 
studies have indicated that some of these proteins 
are able to associate transiently with the exosome, 
the exact nature of these interactions remains to 
be identifi ed. 
Since the identifi cation of the exosome complex, six years ago, a lot of progress 
has been made in the characterization of the exosome from a variety of organ-
isms. Nevertheless, still many questions remain unanswered. What factors are 
responsible for the regulation of the exosome? How and where is the complex 
assembled and are there diff erences in the composition of the nuclear and cy-
toplasmic exosome? Why are some proteins of the exosome autoantigenic in 
patients with a myositis/scleroderma overlap syndrome? In this chapter, some 
of the most prominent questions will be discussed.
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Assembly of the exosome
Only few data are available on the mode 
and subcellular localization of exosome assembly. 
Because the exosome is present in both cytoplasm 
and nucleus, the assembly most occurs in the 
cytoplasm, followed by translocation of a subset 
of the assembled complexes to the nucleoplasm. 
One of the core components, hCsl4p, has been 
shown to require both of its interacting partners 
(hRrp42p and hMtr3p) to be incorporated 
into the complex and to be able to enter the 
nucleolus (Chapter 2 and 3) (88,106). In three 
of the exosome subunits (hRrp41p, PM/Scl-75 
and PM/Scl-100) a putative nuclear localization 
signal (NLS) can be identifi ed (Chapter 5). The 
NLS sequences in PM/Scl-75 and hRrp41p 
appear to be conserved in C. elegans and in addi-
tion the putative NLS of hRrp41p is located in 
a extended loop when this protein is modelled 
according to the crystal structure of an RNase 
PH domain from S. antibioticus PNPase. Although 
the NLS present in PM/Scl-75 was able to target 
a reporter protein to the nucleus, this element 
did not appear to be essential for exosome as-
sociation and nuclear localization of the protein. 
Still, the element might contribute to nuclear 
translocation of the complex in vivo. However, it 
is required for the nucleolar localization of PM/
Scl-75 (129) (Chapter 5). This suggests that PM/
Scl-75 is transported to the nucleus as part of an 
already (partially) assembled exosome complex. 
Figure 1. Model of the human exosome and the interacting proteins. 
A schematic model of the human exosome, based on the protein-protein interactions and proteins known to interact 
transiently with the complex in either yeast or human. In the cytoplasm, a single exosome ring can interact with a number 
of regulatory proteins, whereas the nuclear exosome consists two rings. This dimerisation might be mediated by the 
binding of the nucleus specifi c exosome subunit PM/Scl-100. 
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Combined with the observation that PM/Scl-
100 is only associated with the nuclear and not 
with the cytoplasmic exosome (11), these data 
support a model for the assembly and routing of 
the exosome as shown in Figure 2. Following the 
assembly of the ring structure in the cytoplasm, 
the exosome can be transported to the nucleus, 
possibly via the NLS present in hRrp41p. In 
the nucleus, the ‘NLS’ of PM/Scl-75 directs the 
complex to the nucleolus. The nucleus-specifi c 
exosome protein PM/Scl-100 is imported in-
dependently into the nucleus, where it associates 
with the core of the exosome complex. During 
these processes, fractions of the exosome are 
retained in the cytoplasm and nucleoplasm.  The 
molecular mechanisms underlying the retention 
in cytoplasm and nucleoplasm are unknown.
Regulation of exosome function
The exosome plays a role in a variety of 
processes including the removal of incorrectly 
processed RNA molecules and the maintenance 
of correct levels of mRNA, rRNA and a number 
of small RNA species. Despite the identifi cation 
of several proteins, including RNA helicases 
and GTPase-like proteins, that might perform a 
regulatory role when associated with the exo-
Figure 2. Possible routing of 
the human exosome. 
Model for the assembly and 
routing of the human exosome. 
The exosome core most likely 
is assembled in the cytoplasm 
and a subset of the complexes is 
subsequently transported to the 
nucleoplasm. In the nucleus, the 
exosome core associates with PM/
Scl-100 and accumulates in the 
nucleolus.
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some (Chapter 1), the mechanisms of substrate 
specifi city and up- an down-regulation of exo-
some levels are still a mystery. An important factor 
in determining a particular exosome function is 
the subcellular localization of the complex. It has 
been shown that distinct proteins associate with 
the core of the complex in the cytoplasm and 
nucleus. In the cytoplasm, the exosome core can 
interact with the Ski-complex in yeast and several 
AU binding proteins in human cells, all known 
to be involved in the degradation of mRNA 
(17,29). Similarly, the nuclear exosome is able 
to associate with a number of proteins known 
to be involved in rRNA processing, RNA tran-
scription, pre-mRNA quality control and other 
processes involving nuclear RNA (25,27,46). 
Since the exosome core itself does not appear to 
have any sequence specifi city, recognition of the 
substrate RNA molecules most likely involves 
these associated proteins, after which the RNA is 
handed-over to the core complex for degradation 
or processing.
Origin of the exosome
The theory of the ‘RNA world’, in which 
RNA molecules were the fi rst biomolecules 
capable of catalyzing enzymatic reactions and 
self-replication, suggests that early proteins would 
be able interact somehow with RNA. It is there-
fore not surprising that the exosome, as one of 
the key players in the cellular regulation of RNA 
metabolism, belongs to a family of structurally 
highly conserved complexes present in the vast 
majority of all known organisms (Chapter 4). 
The strong conservation of these enzymes in all 
three kingdoms of life (archaebacteria, eubacteria 
and eukaryotes) not only suggests that this RNA 
degrading machinery appeared very early in 
evolution, but it also stresses the importance of 
maintaining correct RNA levels for any organ-
ism. Although other enzymes performing similar 
functions are present in many organisms, none of 
these are as widely distributed as the exosome. 
The observation that many organisms do not 
seem to require such additional RNA degrading 
proteins, underscores the effi ciency and universal 
functionality of the exosome/PNPase. 
Autoantigenicity of the exosome
One of the major molecular characteristics 
of autoimmune diseases is that the patients 
produce autoantibodies recognizing certain 
self-proteins. In many cases the targeted autoan-
tigen is strongly correlated with the disease and 
determination of the specifi city of the autoanti-
bodies can therefore facilitate the diagnosis. In 
rheumatoid arthritis, for example, the majority 
of the patients produce autoantibodies recogni-
zing epitopes containing the non-standard amino 
acid citrulline, whereas autoantibodies with this 
specifi city are not found in healthy individuals or 
in patients with other autoimmune diseases (134). 
Although it is hypothesized that the generation 
of autoantibodies could be linked to cell death 
following cell damage or infl ammation (125), the 
remarkable relation between a disease and the 
specifi city of the antibodies associated with that 
disease is still not understood. Many autoantigens 
have been shown to be modifi ed or cleaved dur-
ing either apoptosis or necrosis, thereby possibly 
triggering the immune system. But how a modi-
fi ed autoantigen is capable of inducing a specifi c 
autoimmunedisease remains a unclear, although 
the genetic background (especially the HLA 
genes) of an individual might be of great impor-
tance. 
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Autoantibodies recognizing the exosome, 
and in particular the PM/Scl-75 and PM/Scl-
100 subunits, are found in approximately 25% of 
all patients suffering from the overlap syndrome 
of two autoimmune diseases, myositis and scle-
roderma (Chapter 7) and the presence of these 
antibodies often correlates with a HLA-DR3 
genotype (78). Since the exosome most likely 
is present inside all cells, its subunits can only 
be exposed to the immune system following 
cell damage. Interestingely, at least one of the 
exosome components, PM/Scl-75, appears to be 
modifi ed during apoptosis (Chapter 6). Although 
this could provide a clue towards understanding 
the development of the disease and the occur-
rence of anti-exosome autoantibodies, many 
additional studies will be required to understand 
the phenomenon of autoimmunity.
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Summary
The human exosome is a multi-protein 
complex present in all eukaryotic cells, which is 
involved in the processing and degradation of a 
large variety of RNA molecules. It plays a central 
role in the regulation and maintenance of correct 
levels of messenger RNA, ribosomal RNA and 
other RNA species.
In patients suffering from an overlap syn-
drome of the autoimmune diseases polymyositis 
(PM) and scleroderma (Scl), autoantibodies are 
found that are reactive with protein subunits of 
this complex. These antibodies are referred to as 
anti-PM/Scl antibodies.
The goal of this study was to characterize 
in more detail the composition and structure of 
the human exosome and to gain more insight in 
the reason why this complex is targeted by auto-
antibodies in patients with the PM/Scl overlap 
syndrome.
Chapter 1 gives an overview of our cur-
rent knowledge on the composition, structure 
and the various  functions of the exosome. 
Although the exosome of yeast has been studied 
most extensively, more information has recently 
become available regarding the exosome in other 
organisms, including men.
The interactions between three of the 
components of the human exosome, hCsl4p, 
hRrp42p and hRrp46p, are described in detail 
in Chapter 2. The hCsl4p protein was shown 
to interact directly with both other proteins in 
vitro and using deletion mutants of the protein 
the regions responsible for this interaction were 
determined. A systematic analysis of interactions 
between human exosome subunits is presented 
in Chapter 3, together with an interesting ho-
mology between the exosome and the bacte-
rial protein polyribonucleotide phosphorylase 
(PNPase). The combination of these data allowed 
the construction of a model for the exosome 
complex, the main feature of which is a ring 
structure composed of the six exosome subunits 
that contain an RNase PH domain.
A human homologue of the bacterial 
PNPase protein is described in Chapter 4. This 
protein is localized in the mitochondria and is an 
active ribonuclease, both in vivo and in vitro. Fur-
thermore, the evolutionary relationships between 
the exosome complex and both prokaryotic and 
eukaryotic PNPases are discussed.
Chapter 5 deals specifi cally with one of 
the exosome subunits, PM/Scl-75, which is a 
signifi cantly longer protein than was believed un-
til recently. The additional N-terminal sequence 
was shown to be important for the nucleolar 
localization of this protein as well as for the in-
teraction between PM/Scl-75 and the rest of the 
exosome complex. PM/Scl-75 is also a substrate 
for caspase-mediated cleavage in apoptotic cells 
(Chapter 6), suggesting a role for the protein 
in the generation of patient autoantibodies that 
recognize the exosome complex. PM/Scl-75 is 
most likely cleaved in its C-terminal region, and 
the cleavage can probably occur when the protein 
is associated with the complex.
In Chapter 7 it is shown that autoantibodies 
from patients with the PM/Scl overlap syndrome 
are mainly targeted to the longer form of the 
PM/Scl-75 protein, whereas until now another 
exosome subunit, PM/Scl-100, was believed to 
be the main autoantigen of the complex.
The results obtained in this project and 
the questions that remain to be answered are 
discussed in Chapter 8.
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Samenvatting
Het menselijke exosoom is een complex 
bestaande uit een tiental eiwitten dat aanwezig is 
in alle eukaryotische cellen. Het is betrokken bij 
het “op maat snijden” en het volledig afbreken van 
allerlei RNA moleculen en speelt een belangrijke 
rol bij het in stand houden van de correcte hoeveel-
heden messenger RNA, ribosomaal RNA en andere 
soorten RNA.
Bij patiënten die lijden aan het overlapsyn-
droom van de auto-immuunziekten polymyositis 
(PM) and sclerodermie (Scl) worden autoantilicha-
men gevonden die gericht zijn tegen eiwitten van 
dit complex. Daarom worden deze antilichamen 
ook wel anti-PM/Scl antilichamen genoemd. Het 
doel van het onderzoek was om de samenstelling 
en structuur van het humane exosoom te bepalen 
en om meer inzicht te krijgen in de vraag waarom 
er in patiënten met het PM/Scl overlapsyndroom 
autoantilichamen gericht tegen dit complex gepro-
duceerd worden.
Hoofdstuk 1 beschrijft de huidige kennis 
op het gebied van de samenstelling, structuur en 
de verschillende functies van het exosoom. Hoewel 
het exosoom vooral in gist bestudeerd is, werd er re-
centelijk ook steeds meer bekend over de structuur 
en functie van het exosoom in andere organismen, 
waaronder dat van de mens.
De interacties tussen drie van de eiwitten 
van het humane exosoom, hCsl4p, hRrp42p en 
hRrp46p, worden beschreven in Hoofdstuk 2. Het 
hCsl4p eiwit gaat in vitro een directe interactie aan 
met de twee andere eiwitten, en met behulp van 
deletiemutanten van het eiwit is bepaald welke 
gebieden van het eiwit voor deze interactie verant-
woordelijk zijn. Een systematische analyse van alle 
interacties tussen exosoom eiwitten is beschreven 
in Hoofdstuk 3. Ook wordt in dit hoofdstuk een 
verrassende overeenkomst tussen het exosoom en 
het bacteriële eiwit polyribonucleotide phosphory-
lase (PNPase) beschreven. Deze laatste ontdekking 
maakte het mogelijk een model voor de structuur 
van het exosoom te ontwerpen, waarbij de zes exo-
soom eiwitten met een RNase PH domein een 
ringstructuur vormen die de kern van het complex 
vormt.
Een humane homoloog van het bacteriële 
PNPase eiwit wordt beschreven in Hoofdstuk 4. 
Dit eiwit is aanwezig in de mitochondria en is een 
actief exoribonuclease, zowel in vitro als in vivo. In dit 
hoofdstuk wordt ook de evolutionaire relatie tussen 
het exosoom en het PNPase van zowel prokaryoten 
als eukaryoten behandeld.
Hoofdstuk 5 concentreert zich op één van 
de exosoomeiwitten, PM/Scl-75, waarvan wordt 
aangetoond dat het een aanzienlijk groter eiwit is 
dan tot nu toe werd aangenomen. De extra sequen-
tie aan de N-terminus van het eiwit blijkt belangrijk 
te zijn voor zowel de accumulatie van het eiwit in 
de nucleoli als voor de interactie van PM/Scl-75 
met de rest van het complex. PM/Scl-75 is ook 
een substraat voor klieving door caspase enzymen in 
apoptotische cellen (Hoofdstuk 6), wat suggereert 
dat het eiwit betrokken zou kunnen zijn bij het 
ontstaan van autoantilichamen gericht tegen het 
exosoom. Het eiwit wordt waarschijnlijk in de C-
terminale regio gekliefd, vermoedelijk terwijl het 
onderdeel uitmaakt van het exosoom complex.
In Hoofdstuk 7 wordt beschreven dat de 
autoantilichamen in patiënten met het PM/Scl 
overlap syndroom met name gericht zijn tegen de 
langere vorm van PM/Scl-75. Tot nu toe werd aang-
enomen dat een ander exosoom eiwit, PM/Scl-100, 
het belangrijkste autoantigen van het complex was.
Tot slot worden de resultaten uit dit proef-
schrift en de nog onbeantwoorde vragen bedis-
cussieerd in Hoofdstuk 8.
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Het was in 2003 precies 50 jaar geleden dat 
James Watson en Francis Crick hun inmiddels 
wereldberoemde helixstructuur voor het erfelijke 
materiaal DNA publiceerden. Tot dat moment 
was grotendeels onduidelijk hoe erfelijke in-
formatie in het DNA wordt opgeslagen en hoe 
erfelijke informatie van ouders op nakomelingen 
wordt overgedragen. Sinds de ontdekking van de 
DNA structuur is veel vooruitgang geboekt bij de 
beantwoording van deze belangrijke vragen. Zo 
weten we nu dat de informatie die in het DNA 
opgeslagen is (de ‘genen’) gekopieerd wordt in 
een vergelijkbaar molecuul, genaamd RNA, dat 
op zijn beurt weer vertaald wordt in een eiwit. 
Het zijn de eiwitten die de meeste belangrijke 
functies in onze cellen uitvoeren.
In dit proefschrift staan enkele van deze 
eiwitten centraal. De door mij bestudeerde eiwit-
ten (exosoom eiwitten) hebben als belangrijkste 
functie het RNA af te breken wanneer dat nodig 
is, en kunnen op die manier de overdracht van 
informatie van DNA naar eiwit beïnvloeden. 
De exosoom eiwitten zijn ook in medisch 
opzicht interessant. In patiënten die lijden aan de 
ziekten polymyositis en sclerodermie is het im-
muunsysteem dikwijls zodanig ontregeld dat het 
lichaam antistoffen tegen deze exosoom eiwitten 
maakt. Normaal gesproken is het immuunsysteem 
alleen gericht tegen lichaamsvreemde stoffen 
(bijvoorbeeld afkomstig van infecties door bac-
teriën of virussen) en zal het geen lichaamseigen 
eiwitten aangrijpen. Bij auto-immuunziekten 
gebeurt dit wel, en valt het immuunsysteem onze 
eigen eiwitten en cellen aan. Welke eiwitten, 
cellen of weefsels worden aangevallen hangt af 
van de auto-immuunziekte waar de patiënt aan 
lijdt. Bij myositis worden de spieren aangetast; bij 
sclerodermie is dat de huid en het onderliggende 
bindweefsel. Bij het polymyositis/sclerodermie 
overlap syndroom uit zich dat, naast de schade aan 
spier- en bindweefsel, blijkbaar in de vorming van 
antistoffen die gericht zijn tegen het exosoom.
Van de eiwitten die in dit proefschrift 
bestudeerd zijn was aan het begin van het project 
al bekend dat ze onderdeel uitmaakten van een 
groter complex van tenminste tien eiwitten dat 
het exosoom werd genoemd (Hoofdstuk 1). 
Het was echter niet bekend hoe dit complex 
of de verschillende onderdelen ervan er precies 
uit zagen en waarom sommige patiënten er antist-
offen tegen maken.
In de Hoofdstukken 2 en 3 hebben we 
bepaald wat de vermoedelijke vorm van dit 
complex zou kunnen zijn. Het lijkt er op dat 
het exosoom een ringvorm aanneemt, die uit zes 
eiwitten bestaat, met nog drie eiwitten die aan de 
buitenkant op deze ring geplakt zitten. Voor één 
van de tien eiwitten kon nog geen plekje in dit 
model gevonden worden. De hier voorgestelde 
ringvorm lijkt heel erg op de structuur van een 
ander eiwit, genaamd PNPase, waarvan oorspron-
kelijk werd gedacht dat het alleen in bacteriën 
en planten voorkwam. Dit eiwit blijkt ook in de 
mens aanwezig te zijn, zoals beschreven is in de 
Hoofdstukken 3 en 4.
De laatste drie hoofdstukken gaan over een 
van de meest interessante componenten van het 
exosoom, het eiwit PM/Scl-75. Het is een van 
de eiwitten waartegen antistoffen voorkomen in 
de al eerder genoemde auto-immuun patiënten. 
Hoofdstuk 5 beschrijft de verschillende vor-
men die van dit eiwit gevonden zijn en toont 
ook aan dat het eiwit in werkelijkheid groter 
is dan tot nu toe werd aangenomen. Dat deze 
langere vorm van PM/Scl-75 ook inderdaad een 
rol speelt bij de auto-immuniteit van patiënten 
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staat beschreven in Hoofdstuk 7. Bij patiënten 
met zowel myositis als sclerodermie blijken de 
aanwezige autoantistoffen voornamelijk gericht 
te zijn tegen deze langere vorm van PM/Scl-75, 
een aanwijzing is dat dit eiwit misschien een rol 
speelt bij het ontstaan van de autoantistoffen. Een 
mogelijk mechanisme daarvoor wordt in Hoofd-
stuk 6 gesuggereerd. We beschrijven daar dat een 
deel van het eiwit PM/Scl-75 wordt afgeknipt 
tijdens het doodgaan van cellen (een proces dat 
veel voorkomt bij de ontstekingen in auto-im-
muunziekten). Het kan zijn dat het verkorte eiwit 
door het immuunsysteem als “vreemd” wordt 
herkend waardoor er antistoffen tegen gemaakt 
worden. Of dit inderdaad het mechanisme is dat 
leidt tot de vorming van deze antistoffen zal nog 
meer onderzoek vergen. Wel kan het bepalen of 
autoantistoffen tegen PM/Scl-75 aanwezig zijn 
in patiënten in de toekomst bijdragen aan het 
diagnosticeren van patiënten met het PM/Scl 
overlap syndroom. 
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klimmers. Ook ons werk is regelmatig onderwerp 
van discussie en mede daarom vind ik het erg leuk 
dat je me nu ook bij  de promotieplechtigheid komt 
‘zekeren’.
Ook alle andere vrienden, scouts en studie-
genoten wil ik bedanken voor de interesse die jullie 
hebben getoond. En een aantal van jullie natuurlijk 
succes gewenst met jullie eigen promotie!
En ik moet natuurlijk niet Flip, Spoekie, Zowie, 
Dink, Flynn, Tuzi en Toki vergeten, die (bijna) altijd 
bereid waren zich te laten knuffelen, als ik weer eens 
balend van de mislukte proeven thuiskwam.
Zonder jullie, Connie en Huub, was dit boekje 
er waarschijnlijk nooit gekomen. Doordat jullie bei-
den ook in de biochemie werkzaam zijn (geweest), 
is mijn interesse voor dit onderzoek er al heel vroeg 
in geslopen. Het is daarom ook een beetje jullie 
boekje en ik wil jullie bedanken voor al jullie steun 
en interesse tijdens deze promotietijd.
En tot slot wil ik jou natuurlijk ook bedanken, 
Floor. Je hebt me in de afgelopen jaren altijd ge-
steund tijdens mijn onderzoek, ook als dat betekende 
dat we op een zondag weer eens ‘even’ langs het lab 
moesten gaan. Vooral ook bedankt dat je me, als het 
weer eens tegenzat, er op wist te wijzen dat er zoveel 
meer belangrijke dingen in het leven zijn.
Reinout
Dankwoord
En nu, beste lezer, bent u aan het einde be-
land van dit proefschrift. Het doet mij goed dat u, 
geboeid door de wetenschappelijke verhandelingen 
beschreven in de voorgaande hoofdstukken, dit 
boekwerk tot het einde heeft weten uit te lezen. 
Daar wil ik u dan ook van harte voor bedanken, net 
als de vele mensen die hebben bijgedragen aan het 
tot stand komen van dit proefschrift.
Om te beginnen wil ik natuurlijk mijn 
begeleiders Walther en Ger bedanken, dat zij het 
voor mij mogelijk maakten om in hun lab mijn 
promotieonderzoek uit te voeren. Ik heb van jullie 
allebei erg veel geleerd en kan gelukkig in mijn 
huidige baan ook over jullie wilde ideeën en grote 
expertise beschikken.
Wilma, ondanks het feit dat je nooit offi cieel 
voor me hebt gewerkt, sta je bij vijf hoofdstukken 
in dit proefschrift als coauteur vermeld. Ik ben je 
erg dankbaar voor al het werk dat je mij uit handen 
hebt genomen en ik ben daarom blij dat we nu onze 
samenwerking kunnen voortzetten.
Ook mijn studenten, Yvet, Sonja en Léon, wil 
ik graag bedanken voor hun inzet tijdens de stage. 
Het is erg leuk om te zien dat jullie alledrie verder 
gaan in de biochemie. Ik hoop dat jullie net zoveel 
van jullie stages hebben geleerd als ik en wens jullie 
veel succes met jullie biochemische carrière.
En dan zijn er natuurlijk een aantal generaties 
VRT te bedanken, aangezien ik eigenlijk al veel te 
lang op dit lab rondloop. Ik wil iedereen van de VRT 
graag bedanken voor alle hulp bij de experimenten, 
discussies, werkbesprekingen, (fl auwe) grappen, uit-
stapjes, het verzinnen van Google opdrachten, hulp 
bij het voorbereiden van de promotie en dit boekje 
en natuurlijk voor alle gezelligheid op de labs in het 
Trigon (1.89) en het NCMLS (2.55).
Vanzelfsprekend wil ik ook de andere collega’s 
van de afdelingen eiwitbiochemie en reumatologie 
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